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Abstract 
Diets induced obesity and Type 2 diabetes affect an alarming number of people in the 
world. Patients exhibit a number of associated co-morbidities that require treatment 
and reduce life expectancy. The development of Type 2 diabetes results from a 
chronic disruption of glucose homeostasis as a consequence of environmental and 
genetic factors. The regulation of hypothalamic metabolic signalling is understood to 
be critical to the dynamic and long-term maintenance of glucose homeostasis by 
virtue of its influence on peripheral effectors (pancreas, liver, muscle and fat). 
Prolonged periods of inflammation observed in the development of diet-induced 
obesity and diabetes and accumulating evidence suggests this may negatively affect 
the maintenance of these neuroendocrine networks.  
Interleukin 6 (IL-6) is a pleiotropic cytokine involved in the acute, as well as the 
resolving and adaptive phase of inflammatory responses. The IL-6 receptor has 
recently been shown to exhibit extensive localization in key regions of the human and 
rodent hypothalamus involved in glucose and energy homeostasis regulation. Recent 
work at Prof. Rory McCrimmon's lab investigating the role of IL-6 in the 
development of hypoglycaemia unawareness in Type 1 Diabetes identified the 
development of a glucose-sensing defect in hypothalamic glucose-sensing mouse 
cultures (GT1-7) in response to antecedent IL-6. These studies provided preliminary 
evidence to suggest that inflammatory cytokines such as IL-6 could directly modulate 
hypothalamic glucose sensing neurons and therefore might influence whole body 
glucose and energy homeostasis. 
The body of work contained in this thesis sets out to examine the hypothesis that 
down-regulation of central IL-6 signaling would disturb the ability of mammals to 
regulate energy homeostasis, and would exacerbate defects in glucose clearance, 
insulin sensitivity and body composition typically observed in during the 
development of Type 2 Diabetes through chronic energy excess. To test this 
hypothesis cre-lox technology was used to generate a CRE-mediated nervous-system 
specific NesCreIL-6Rα knock-down (KD) mouse. Chronic administration of high-fat 
diet (>40% fat) in mice is commonly used to model the effects of diet-induced obesity 
and the progression to type 2 diabetes in humans. To examine the effects of this 
intervention in the development of diet induced obesity and diabetes, age (8-10 weeks 
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old) and sex-matched KD and control animals on standard chow (SC -15% fat) and 
high fat diet (HFD - 60% fat) were characterized using an array of in vivo metabolic 
phenotyping tests over a period of 20 weeks.  
To generate a brain-specific IL-6Rα KD, heterozygous B6.Cg-Tg (Nes-cre) 1Kln/J 
mice were crossed with B6 (SJL)-Il6ratm.1.1Drew/J animals (IL-6Rαflox/flox). The Nestin 
promoter exhibits brain-specific expression, while the IL-6Rα gene is flanked by 2 
loxP sites in IL-6Rαflox/flox mice that would theoretically allow for brain-specific 
disruption of the receptor gene in offspring of this cross.  Incorporation of the CRE 
gene in NesCre+ mice, and the presence of loxP sites in the genome of IL-6Rαflox/flox 
colony were confirmed by standard PCR (Figures 1.1, 1.2). Offspring of the cross 
bearing the CRE gene were classified as KD, while the rest were considered wild-type 
littermates. Disruption of the IL-6Rα gene was confirmed at the mRNA level using 
real-time PCR (Figure 1.3.2), with KD mice exhibiting down-regulation of the gene 
at the hypothalamus (~50%) and hippocampus (~35%). The effects of the NesCre-
mediated down-regulation of the IL-6Rα were also examined using in vivo and ex 
vivo approaches, in relation to the induction of the STAT3 phosphorylation typically 
observed in response to IL-6. Administration of IL-6 in the periphery failed to induce 
STAT3 phosphorylation in the hypothalamus and hippocampus of KD mice, even 
though similar responses to control animals were observed in peripheral organs 
(Figures 1.4, 1.5). Furthermore, examination of IL-6Rα protein expression by 
immunohistochemistry, confirmed decreases in the number of IL-6Rα-positive 
neuronal cells in NesCreIL-6Rα KDs compared to control mice (Figures 1.7.1-4). 
Brain-specific IL-6Rα down-regulation in NesCreIL-6Rα KDs was associated with a 
dramatic suppression of in vivo GSIS (Figure 2.5.4), but was of little consequence to 
the blood glucose response to insulin (Figures 2.4.1-3). Examination of insulin and 
glucagon immunohistochemistry and ex vivo hormone release, KD and control islets 
were found to produce and release similar levels of the hormones in isolation, 
implicating a central component in the effect observed in vivo (Figures 2.8.1-3). 
Body weight was closely matched between KD and control animals on SC diet, while 
dramatic increases observed in control animals on HFD were mirrored in HF-fed KDs 
(Figure 2.1). Paradoxically, KD SC mice were significantly leaner than control mice, 
despite being hyperphagic (Figures 2.2.1-5, 2.3, 2.9.1), hypoactive and 
hypothermogenic (Figure 2.6.2-4). Hyperphagia and suppression of energy 
9 
 
expenditure was also observed in the HF-fed KDs, but in this case the leaner 
phenotype was progressively reversed through the course of 20 weeks of diet 
(Figures 2.2.1-5, 2.6.2-4). Examination of a separate cohort of SC mice indicated that 
increases in food intake and body fat in response to chronic diet, were not a 
consequence of differences in leptin sensitivity between KD and control animals 
(Figures 2.9.1-2).  
Collectively, data presented in this thesis suggest central IL-6 to play a fundamental 
role in the ability of the body to release insulin and regulate glycaemia in response to 
a glucose challenge. KD mice exhibited increased food intake and decreased energy 
expenditure and activity, that were only associated with increased body fat following 
chronic HF-feeding. This would suggest that increases in peripheral IL-6 observed in 
obese patients are part of a protective response to chronic energy excess, acting 
centrally to promote energy expenditure at least in part through increases in 
circulating insulin and thermogenic fat oxidation.   
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Chapter 1:  Introduction 
Diet Induced Obesity and Diabetes: A Modern Epidemic 
Obesity is a medical condition characterized by excess body fat, leading to decreased 
life expectancy through the accumulation of a range of pathologies in patients 
(Haslam & James, 2005; WHO, 2000). It is among the leading causes of preventable 
death (Yoon, et al., 2014), as it is associated with type 2 diabetes, hypertension and 
hyperlipidaemia - major precursors to cardiovascular disease (Eckel, 1997; Poirier & 
Eckel, 2002). Obesity is most frequently the consequence of a combination of 
environmental factors (excess food intake, lack of physical activity) and genetic 
susceptibility (Lau, et al., 2007). In rare cases, obesity is caused by genetic mutations, 
endocrine disorders, medications or psychiatric illness (Barness, et al., 2007). Body 
mass index (BMI) is currently the primary focus in obesity treatment 
recommendations, in relation to obesity-related comorbidities such as hypertension 
and hyperlipidaemia (WHO, 2000). Patients are generally characterized as individuals 
with a BMI above 30kg/m2, with the normal range being around 25kg/m2. 
Figure 1.1: The Body Mass Index Scale 
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Obesity and its associated pathology was described as early as 500BC (Haslam & 
James, 2005; Dwivedi & Dwivedi, 2007); however historically, mankind has faced 
extended periods of food scarcity and obesity was rarely observed (Balke & Nocito, 
1994). Changes in diet and exercise were recommended by early physicians, yet 
during the Middle Ages in particular, obesity was indicative of social status 
(Bloomgarden, 2003). The industrial revolution of the 19th century and the array of 
socioeconomic changes that followed, promoted increases in body weight and height 
in the developed world  (Caballero, 2007). Increases in the Body Mass Index of the 
population resulted in improved survival and productivity, driving the establishment 
of early industrialized societies.  
During the 20th century however, as the genetic height potential of populations was 
reached, body weight increases were maintained through the advent of technology 
and the adoption of a more sedentary life style. Alarming increases in cardiovascular 
disease were reported in the US during 1960s and 70s (US Department of Health, 
1966), but it wasn’t until 1995 that World Health Organization (WHO) first stated 
diet-induced obesity (DIO) prevalence to be of epidemic proportions  (WHO, 1995). 
At that time, 200 million were thought to be obese. Current estimates indicate a 
tripling of this figure, while with the increased prevalence in the developing world, 
approx. 2 billion people in the world are thought to be overweight (WHO, 2014). 
Excess body weight accumulation in obesity is naturally the consequence of positive 
energy balance. Energy intake in obese patients far exceeds energy expenditure over 
prolonged periods of time. The relative contribution of increased energy intake and 
decreased energy expenditure to the obesity epidemic is still a matter of debate. 
Epidemiological data with regards to the US where obesity is leading among the 
causes of preventable death (Danaei, et al., 2009), implicate a combination of factors. 
A 200kcal/day increase in daily food intake was observed during 1980-2000 (Popkin, 
et al., 2002), while current figures suggest consumption to exceed recommendations 
by approx. 50% (FAO, 2008). This can be partly attributed to increases in the 
consumption of sweetened beverages over fruit and vegetable, accounting to nearly 
25% of daily intake (Rajeshwari, et al., 2005; Striegel-Moore, et al., 2006; US 
Department of Health and Human Services, 2005).  The increased availability of low 
cost energy-dense foods and the preference to ready-meals is particularly detrimental, 
especially when considering low-income areas (Drewnowki & Specter, 2004). The 
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lack of physical activity within the US population was an issue of concern since the 
1950s; however current figures suggest a mere 20% of adults currently meet the 
recommended physical activity guidelines (Carlson, et al., 2015). 
Figure 1.2: Global Adult Obesity Prevalence 2008 
Scotland was second only to the US in terms of prevalence in a survey among the 
members of the Organization for Economic Co-operation and Development (Arah, et 
al., 2006). The total (direct and indirect) cost of obesity to Scottish society was 
estimated around £2 billion and thus tackling obesity is a key priority for government 
and public health professionals. In 2013 the Scottish Health Survey, estimated over a 
quarter (27.1%) of the adult population to be obese while a daunting two thirds were 
thought to be overweight (Bromley, et al., 2013). Prevalence was higher among 
women (29.3% compared to 24.9%), even though men appear more likely to be 
overweight (68.3% compared to 61%). Age was strongly correlated with disease 
prevalence (~75% of adults aged 45-74, >75% of adults aged 55-74), yet an alarming 
28.8% of children aged 2-15 are also at risk of overweight or obesity. Collectively a 
10% increase in obesity prevalence in people aged 16-64 since 1995 was noted, 
despite the efforts made such as the publication of the Revised Dietary Goals for 
Scotland in 1996.  A recent estimation of food intake in Scotland (Barton & Wrieden, 
2015), suggested that little progress was made towards those goals over 2001-2012. 
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On the other hand data in the years between 1998 and 2011 indicate that only a 30% 
of the adult population met the recommended physical activity guidelines (Bromley, 
et al., 2013).  
Figure 1.3: Obesity Prevalence Scotland 
      Adapted from Bromley C. et al. (2013) 
Prolonged exposure to positive energy balance in obesity not only increases BMI and 
adiposity, but also the risk of development of the most common form of metabolic 
disease,  Type 2 Diabetes mellitus (Lewis, et al., 2002). Earlier clinical studies 
indicated obesity to be strongly associated with diabetes in men (Chan, et al., 1994), 
while a 28-fold greater risk of developing the disease was reported in obese women  
(Colditz, et al., 1995). The International Diabetes Federation estimates the world 
diabetic population to approach 400million of whom at least 80% are overweight or 
obese (IDF, 2014). Type 2 diabetes (T2D) accounts for approx. 90% of the diabetic 
population and is characterized by hyperglycaemia and the development of insulin 
resistance  (Kahn, 1998). Prior to the discovery of insulin in 1920 by Dr Frederick 
Banting and the subsequent establishment of insulin replacement therapy as treatment, 
diabetic disease was a synonym to death (Anon., 1966; Best, 1942). Insulin therapy is 
targeted towards lowering glucose levels to desired norms, as sustained 
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hyperglycemia is also associated with severe micro- and macro-vascular disease 
(Pickup, 2004; Venieratos, et al., 2010) 
Despite being the subject of extensive research in the past century, diabetes remains 
the 4th commonest cause of death in the developed world (IDF, 2014). The current 
diabetic population of the UK is around 4 million, and is expected to reach 5 million 
by 2025. The estimated the cost of diabetes treatment in the UK in 2012 was around 
14.5billion GBP, with the annual cost of treatment per patient around £1,800-2,500 
GBP (Kanavos, et al., 2012). The projected annual cost of diabetes to the NHS is 
expected to increase to £17billion in the next 25 years. In Scotland - a nation of 
5million, the diabetic population is believed to be close to 250,000 patients and is 
currently increasing by 13,000/year (Diabetes UK, 2015).  The aforementioned high 
prevalence of obesity in the adult Scottish population though a combination of 
socioeconomic factors, is an obvious precursor to this statistic. 
Figure 1.4: Type 2 Diabetes in Scotland 
 Adapted from Bromley C. et al. (2013) 
Various initiatives directed towards improving public awareness have thus far been 
ineffective in decreasing disease prevalence and the population of obese and diabetic 
patients is still on the rise. The combined annual cost of diabetes to Scottish society is 
currently around £2 billion and the disquieting increases in obesity prevalence can 
only be expected to drive further increases to this figure. This figure relates to a 
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number of disease-associated pathologies (e.g. retinopathy, neuropathy, nephropathy, 
stroke and cardiovascular events) that require medical attention due to their direct 
impact on patient life quality and expectancy (Barness, et al., 2007). Research in the 
pathophysiology of disease development is still ongoing as the precise molecular 
mechanisms underlying this are still somewhat elusive. Diet induced obesity and 
diabetes comprise a serious threat to public health, and advancements in the 
understanding of disease development that could provide the basis for improved 
treatment would be of significant socioeconomic value. 
Figure 1.5: Type 2 Diabetes Disease-associated Pathology 
Adapted from Saltiel & Olefsky (2001) 
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Type 2 Diabetes Pathology 
Type 2 diabetes is characterised by relative insulin deficiency and reduced insulin 
sensitivity in insulin target tissues (e.g. muscle, liver and adipose tissue) that promotes 
the dysregulation of glucose homeostasis. Patients experience impaired insulin-
stimulated glucose uptake in muscle (Cusi, et al., 2000) and adipose tissue (Yki-
Jarvinen, 2002), while the inhibition of glucose output from the liver is also disrupted 
(Nakatani, et al., 2004) as a consequence. Traditionally, chronic exposure to high fat 
diet alone is considered to lead to insulin resistance and the development of T2D 
(Reaven, et al., 1988; Walker, et al., 1966).  
The secretion of insulin from pancreatic β cells is a highly regulated process targeted 
to account for the hyperglycaemia observed following food intake. Glucose up-take 
from muscle and fat is stimulated; liver gluconeogenesis is inhibited, while free fatty 
acid levels are decreased through the inhibition lipolysis and increases in lipogenesis 
(Kahn & Flier, 2000). The action of insulin and the induction of hypoglycaemia are 
countered by the release of glucagon from pancreatic α cells and catecholamines from 
the adrenals (Taborsky, et al., 1998). Glucagon release from pancreatic α cells 
promotes gluconeogenesis at the liver and inhibits β cell secretions. Maintenance of 
glucose homeostasis is physiologically achieved through the rigorous and dynamic 
maintenance of these relationships  (Cannon, 1929; Stumvoll, 2004; Boner-Vier, 
2000). 
Figure 1.6: Physiological Regulation of Glucose Homeostasis in Humans 
 
 
 
 
 
 
 
 
 
Adapted from Taborsky G.J. et al. (1998) 
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A reduced ability of insulin to stimulate intracellular signal transduction pathways for 
peripheral glucose uptake and hepatic glucose production inhibition (insulin 
resistance); leads to increases in circulating plasma insulin levels in most patients 
with Type 2 Diabetes.  Glucose up-take in response to insulin is primarily driven by 
the hormone acting on muscle (and to a lesser extent fat) to promote glucose-
transporter-4 (GLUT-4) translocation to the membrane, following recruitment of 
insulin receptor substrate-1 (IRS-1) and activation of tyrosine kinase activity (Klip & 
Paquet, 1990; Stolic, et al., 2002). Insulin resistant states are characterized by down-
regulation of GLUT-4 in both muscle and adipose tissue while increases in 
intracellular lipid intermediates promote serine/threonine kinase activity; inhibit the 
action of insulin via receptor substrate-1 (IRS-1) and disrupting glucose-uptake (Yu & 
al., 2002; Pickersgil, et al., 2007; Lee & al., 2006).   
Adipose tissue on the other hand is responsible for the uptake free fatty acids in 
circulation (Jensen, 2002; Shadid, et al., 2007), while the ability of fat to expand in 
response to metabolic challenges is instrumental to homeostasis maintenance (Gray & 
Vidal-Puig, 2007). Insulin regulates genes in adipocytes that promote fatty acid 
synthesis and lipogenesis, while the oxidation of fatty acids is inhibited (Kahn & 
Flier, 2000).  High fat diets lead to the accumulation of free fatty acids in plasma and 
tissue, due to disruption of the inhibitory effects of insulin on hormone-sensitive 
lipase (HSL) and reduction in the activity of the lipogenic receptor PPARγ 
(Guilherme, et al., 2008) in adipocytes and in hepatocytes.  
Figure 1.7: Insulin Resistance in Type 2 Diabetes 
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In the liver, the primary regulated step that determines glucose uptake is glucose 
phosphorylation by glucokinase, and not glucose transport. Approximately a third of 
dietary glucose is stored by the liver as glycogen and released in the post-absorptive 
state through the activation of glycogenolysis (Pagliassotti & Cherrington, 1992). 
However the chronic exposure to hyperglycaemia and dietary carbohydrates typical of 
DIO, results in the accumulation of metabolic intermediates that initially impair and 
progressively suppress the activity of glucokinase driving insulin resistance (Torres, 
et al., 2011; Torres, et al., 2009).  
The establishment of insulin resistance in target tissues promotes sustained increases 
in insulin release from the β cell, to counter hyperglycaemia. However, Β cells have 
very low anti-oxidative enzymes and are under considerable endoplasmic reticulum 
(ER) stress, even under physiological conditions (Donath, et al., 1999; Robertson, et 
al., 2004). The maintenance of hyperinsulinaemia observed in DIO and T2D, 
increases oxidative and endoplasmic reticulum stress in pancreatic β cells further 
promoting their dysfunction (Donath, et al., 2005; Robertson, 2007). The number and 
mass of β-cells is reduced, while the pulsatility of insulin release is disturbed 
(Schofield & Sutherland, 2012; Song, et al., 2000; Porksen, et al., 1996; Butler, et al., 
2003); leading to a vicious cycle of disordered secretory function of the β cell that is 
inadequate to overcome the establishment of insulin resistance at target tissues and 
drive glucose uptake. 
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Neuroendocrine Regulation of Glucose Homeostasis and Energy 
Expenditure 
Disruption of glucose homeostasis regulation is a fundamental aspect of DIO and the 
progression to T2D. The brain is a particularly energy demanding organ and accounts 
for approximately 25% of the total body glucose utilization in mammals (Ebert, et al., 
2003), but its role in metabolic disease was overlooked for decades. Traditionally, 
brain glucose up-take was viewed to take place independently of insulin and the 
hormone itself was falsely considered to be too large to cross the blood brain barrier 
(Baskin, et al., 1987). During the past 20 years significant progress has been made in 
the role of the brain in metabolic disease. The neuronal pathways that link the central 
nervous system with autonomic innervation of the pancreas were delineated, while the 
role of the hypothalamus in controlling food intake and energy homeostasis is being 
increasingly acknowledged. 
Figure 1.8: Neuroendocrine Regulation of Glucose Homeostasis 
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Pancreatic β cells have been demonstrated to be subject to regulation by neuronal and 
hormonal stimuli. This is thought to be largely a feature of the array of G-protein 
coupled receptors (GPCRs) expressed at these cells. Expression of GPCRs acting via 
the heterotrimeric Gq protein (e.g. muscarinic acetylcholine receptor - m3AChR) 
allows for parasympathetic stimulation of glucose-stimulated insulin secretion (GSIS)  
(Gilon & Henquin, 2001). Sympathetic innervation on the other hand, inhibits β cell 
GSIS through activation of α2 adrenoceptors coupled to Gi by agents such as 
noradrenaline and epinephrine from the adrenals (Ahren, 2000). Conversely, 
catecholamines stimulate glucagon release from α cells via β2 adrenoceptors.  
The appearance of glucose in the oral cavity induces the cephalic phase of insulin 
secretion that is dependent on neuronal connections from taste buds project to the 
brainstem to activate the parasympathetic vagus nerve and stimulate GSIS from the β 
cell (Berthoud & Jeanrenaud, 1982; Berthoud & Powley, 1990). Parasympathetic 
innervation of the β cell and its stimulating effects on GSIS has been documented by 
a number of early studies using rodents, and researchers speculated the presence of 
central glucose-sensing populations (Kaneto, et al., 1975; Berthoud, et al., 1980; 
Lundquist, 1982; N'Guyen, et al., 1994). Studies during the late 70s first suggested the 
hindbrain and hypothalamus to act in concert to detect changes in nutrient availability 
and to calibrate autonomic tone by independently adjusting the function of the 
pancreas. Regulation of glucagon secretion by distinct sites within the hindbrain was 
initially demonstrated using administration of the glucose anti-metabolic 5-
thioglucose (Ritter, et al., 1981; Ritter, et al., 2000), while lesions of the ventromedial 
nucleus in anesthetized rats induced hyperinsulinaemia that was suppressed by 
vagotomy (Berthoud & Jeanrenaud, 1979). In support of these early studies, extra-
carotid injection of glucose in rats was shown to induce a transient increase in insulin 
secretion that was accompanied by the activation of neurons of the paraventricular 
and arcuate hypothalamus (Guillod-Maximin, et al., 2004; Jansen, et al., 1997).  
Changes in circulating blood glucose are paralleled in the brain, inducing changes in 
the activity of neurons in the dorsal vagal complex at the hind brain (nucleus tractus 
solitarius, area postrema and dorsal motor nucleus of the vagus) as well as neurons in 
the ventromedial, arcuate, paraventricular and lateral hypothalamus, receiving input 
from vagal afferents (Mizuno & Oomura, 1984; Ritter, et al., 2000; Hudson & Ritter, 
2004; Dallaporta, et al., 1999; Berthoud & Powley, 1990; Yang, et al., 2004). 
Glycaemic signals detected at the brainstem are directly or indirectly transmitted to 
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the hypothalamus via the basolateral medulla or the parabranchial nucleus (Yuan & 
Yang, 2002), where they are thought to be integrated to determine autonomic output 
(Thorens, 2011). These specialised cells resemble the function of pancreatic β cells, 
even though the precise molecular mechanisms of glucose-sensing are still being 
intensively studied (Marty, et al., 2007; Steinbusch, et al., 2015). 
The ventromedial hypothalamus (VMH) is an important centre of integration of 
glucose-sensing signals and a regulator of sympathetic output to the pancreas 
(Burdakov, et al., 2005; Thorens, 2011). Direct administration of the glucoprivic 
agent 2-deoxy-D-Glucose (2-DG) into the VMH on the one hand induces glucagon 
secretion  (Borg, et al., 1995), while the infusion of glucose into the nucleus 
suppresses glucagon secretions in response to systemic hypoglycaemia  (Borg, et al., 
1997). Lesions of the nucleus causes dramatic increases in insulin release, that were 
demonstrated to be the consequence of increases in parasympathetic output to the 
pancreas, increasing β cell proliferation and mass (Kiba, 2004; Kiba, et al., 1996). By 
integrating input from the hepatoportal vein and motivational cues from the medial 
amygdala (Zhou, et al., 2010); the VMH acts as the orchestrator of autonomic output 
from the dorsomedial, paraventricular and lateral nuclei to modulate pancreatic 
function (McCrimmon, et al., 2006). 
In addition to regulating the release of pancreatic hormones, the hypothalamus is 
involved in appetite control, and mediates the action of adipostatic hormonal and 
neuronal mediators, such as leptin (Friedman & Halaas, 1988). A product of the ob 
gene, leptin is derived primarily from white- and to a certain extent brown adipose 
tissue  (Moinat, et al., 1995; Tsuro, et al., 1996). Leptin acts in the brain (Satoh, et al., 
1997), even though a variety of other tissues also express the hormone (Hoggard, et 
al., 1997; Hoggard, et al., 1997; Spicer & Francisco, 1997; Bado, et al., 1998; Wang, 
et al., 1998). Circulating leptin levels correlate with body weight and adiposity 
(Ahima, et al., 2000; Barsh, et al., 2000; Schwartz, et al., 2000; Maffei, et al., 1995), 
that are regulated by satiety and energy expenditure stimulating effects of the 
hormone (Berglund, et al., 2012; Baver S.B., et al., 2014; Williams, et al., 2001).  
The arcuate nucleus (ARC), is situated at the base of the third ventricle, and the lack 
of tight junctions in the capillaries of the median eminence allows the ARC to be 
more directly exposed to circulating nutrients (e.g. glucose) and endocrine factors 
(e.g. insulin, leptin, ghrelin and incretins) than other brain regions  (Broadwell & 
Brightman, 1976; Elmquist, et al., 1998). Specialized neuronal populations within the 
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ARC sense glucose and stimulate the release of pancreatic hormones (Claret, et al., 
2007), while dense discrete populations of leptin and insulin receptor positive 
neuropeptide-secreting neurons allow for the regulation of energy balance in relation 
to body status  (Plum, et al., 2006). Characteristically, direct injection of insulin (van 
Dijk, et al., 1997), leptin (Cowley & al., 2001) or glucose (Ahmed & Lauterio, 1993) 
in the ARC is sufficient to acutely reduce food intake and energy expenditure (Dunbar 
& Lu, 1999).  
Figure 1.9: Neuroendocrine Regulation of Energy Expenditure 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Adapted from Vetter M.L. et al. (2010) 
The ARC contains orexigenic neuropeptide Y (NPY) and Agouti-related peptide 
(AgRP); and anorexigenic pro-opiomelanocortin (POMC) and cocaine and 
amphetamine-regulated transcript (CART) neurons (Broberge, et al., 1998B; Wilson, 
et al., 1999; Elias, et al., 1998). Neurons in the ARC (and NTS) are the primary 
source of anorexigenic cleavage product of POMC, α-melanocortin stimulating 
hormone (α-MSH), acting at the melanocortin-4 receptor in the PVN and LH, where 
the balance of orexigenic and anorexigenic activity is thought to be integrated and 
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propagated onto autonomic preganglionic neurons of the medulla and spinal cord 
(Swanson & Sawchenko, 1983; Elmquist, et al., 1998). Through the induction of 
separate yet synergistic signaling events, insulin and leptin act to promote the 
expression of products of POMC, inhibiting the activity NPY/AgRP expressing 
neurons (Plum, et al., 2006; Belgardt, et al., 2009; Ersnt, et al., 2009). 
NPY/AgRP neurons of the hypothalamus are fundamental in stimulating feeding 
behaviour through the gut-brain axis (Luquet, et al., 2005). Stomach emptying in the 
context of fasting promotes increases in circulating ghrelin from the gastrointestinal 
tract promoting orexigenic activity in the brain (Wren, et al., 2000). This is paralleled 
by decreases in circulating leptin and insulin, and decreases in anorexigenic α-MSH 
and CART activity in the hypothalamus  (Ahima, et al., 2000; Myers, et al., 2008). 
Other gut hormones such glucagon-like peptide-1 (GLP-1) and peptide tyrosine 
tyrosine (PYY) are also secreted from the gut, to limit meal size  (Small & Bloom, 
2004) by paracrine stimulation of pancreatic secretions (Smeets, et al., 2008; 
Ellingsgaard, et al., 2011), as well as directly or indirectly promoting the activity of 
anorexigenic neurons of the hypothalamus (De Silva & Bloom, 2012; Shirazi, et al., 
2013). 
Progressive increases in circulating leptin during feeding inhibit food intake and 
increase sympathetic outflow and energy expenditure by suppressing NPY/AgRP and 
increasing POMC activity in the ARC (Elias, et al., 1999). Chronic high-fat feeding, 
promotes down-regulation of anorexic α-MSH and CART in the ARC, while lack of 
POMC (Tung, et al., 2006; Diane, et al., 2014) or functional melanocortin receptors 
(Tarnow, et al., 2003; Butler, et al., 2000) causes hyperphagia and obesity. Mimicking 
the effects of DIO chronic intra-cerebroventricular administration of NPY in the 
ARC, promotes body weight gain, hyperphagia, hyperinsulinaemia, hyperlipidaemia 
and hyperleptinaemia  (Sainsbury, et al., 1997; Zarjevski, et al., 1993).  
Increases in sympathetic activity in response to the action of anorexigenic hormones 
such as leptin in the hypothalamus, enhance energy expenditure (Jequier, 2002; 
Konturek, et al., 2005; Valassi, et al., 2008). This involves stimulation of lipolysis, 
thermogenesis in muscle and fat and secondary increases in heat loss through the skin 
by vasoconstriction and dilation (Cannon & Nedergaard, 2004; Whittle, et al., 2011; 
Contreras, et al., 2014). Retrograde labelling studies have identified white adipose 
tissue to be innervated by neurons tracing to the brainstem (noradrenergic neurons of 
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the LC), the hypothalamic nuclei (ARC, DMH, LHA, and VMH) and the forebrain 
(Bamshad, et al., 1998; Shi & Bartness, 2001; van Baak, 2001).  
Sympathetic activation of lipolysis in WAT is regulated by orexin neurons of the LH 
that modulate β3-adrenergic receptor output to the tissue. The activity of anorexigenic 
and orexigenic neuronal populations of the ARC modulates activity in the LH, and 
indeed a number of studies have demonstrated that stimulation of the melanocortin 
system promotes increased catecholamine release and lipolysis. Innervation of BAT 
has also been demonstrated to be synaptically connected with a number of 
hypothalamic neuronal populations including the VMH, PVN, ARC and 
suprachiasmatic nucleus (Elmquist, 2002; Bamshad, et al., 1999; Oldfield, et al., 
2002). The VMH is particularly important in the thermoregulatory role of the BAT 
and electrical stimulation of the nucleus induces β-adrenergic-dependent increases in 
tissue temperature (Perkins, et al., 1981; Yoshida & Bray, 1984; Holt, et al., 1987). 
Steroidogenic factor 1-expressing neurons are expressed in the VMH, and project to 
autonomic centres and other hypothalamic regions involved in sympathetic outflow 
such as the ARC and PVN (Lindberg, et al., 2013). A number of studies have 
indicated these neurons to be particularly important in promoting thermogenesis and 
weight loss induced by increases in sympathetic output in response to leptin (Tanida, 
et al., 2013; Kim, et al., 2011). 
Finally, energy expenditure and satiety are known to be influenced by mood and 
arousal states that commonly override homeostatic signals (Saller & Stricker, 1976; 
Breisch, et al., 1976). Neuronal networks stimulating arousal such as serotoninergic 
neurons in the dorsal & median raphe nuclei, the noradrenergic networks in the locus 
coeruleus and histaminergic tuberomammilary nucleus, modulate the activity of 
satiety-regulating neurons of the hypothalamus (Burke & Heisler, 2015). These 
neurons are thought to regulate motivated feeding behaviour and increase energy 
expenditure through positive modulation of the melanocortin system; stimulating 
POMC and inhibiting direct- and indirect effects of NPY/AgRP neurons. Peripheral 
effects of serotonin (5-HT) agonists were shown to be associated with an array of side 
effects during the 1990s, but in recent years the effects of activation of specific 
receptor subtypes within the hypothalamus were outlined (Xu, et al., 2010). This led 
to the development of 5-HT2CR agonists that have been shown to display efficacious 
in promoting energy homeostasis, including glucose homeostasis and insulin 
sensitivity (Joo & Lee, 2014).   
32 
 
Hypothalamic nuclei, thus play a fundamental role in the detection of changes nutrient 
availability and act to modulate the balance between food intake, energy storage and 
energy expenditure. Specialized neuronal populations within the hypothalamus are 
involved in glucose-sensing, while distinct populations of orexigenic and 
anorexigenic neurons express leptin and insulin receptors. By integrating input from 
the autonomic nervous system and hindbrain, the activity of distinct neurons of the 
hypothalamus orchestrates short- and long-term management of changes in nutrient 
availability through promoting appropriate neuroendocrine and behavioural 
responses. Maintenance of the dynamic regulation of signaling cascades and 
excitability within neuronal networks of the hypothalamus, represent fundamental 
aspects of the ability of the body to manage perturbations of energy homeostasis. The 
effects of circulating factors such as pancreatic hormones and the multifunctional 
protein leptin in the maintenance of homeostasis, are dependent on the balance of 
activity within these networks. However, much is still unknown and research in the 
molecular mechanisms that lead to the dysfunction of these neuroendocrine networks 
in DIO and T2D are still being heavily investigated. 
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Metabolic Dysregulation in Type 2 Diabetes: The role of Inflammation 
The initial step leading to the development of T2D remains somewhat elusive. More 
recent research efforts have discovered an important role for chronic inflammation in 
the impairment of insulin signaling via systemic and local effects. Metabolic 
inflammation in this context is unlike that of the response to infection or injury in that 
it lacks the classical symptomatology observed (tissue swelling, heat and pain) but is 
discernible at the molecular levels (Gregor & Hotamisligil, 2011; Cai, 2009). Obese 
patients are understood to experience chronic low-grade inflammation, as suggested 
by increases in plasma levels of C-reactive protein, inflammatory cytokines 
(Kalofoutis, et al., 2006) and the multifunctional proteins leptin (Friedman & Halaas, 
1988) and osteopontin (Kiefer, et al., 2008).  
Figure 1.1.1: Cytokines and Chronic Inflammation 
 
Inflammatory cytokines such as TNF-α, IL-1β and IL-6 are products of NF-κΒ 
activity (Brasier, 2006). NF-κΒ is a protein complex expressed in all animal cell types 
that acts in the regulation of DNA transcription in the response to various stress 
stimuli and promotes cell survival (Gilmore, 2006; Perkins, 2007). Cytokines are 
secreted in response to stimuli such as oxidative stress (Pereda, et al., 2006), infection 
(Cooper, et al., 2011; Gee, et al., 2009) and UV radiation. Cytokine signaling is often 
observed to act in a feed-forward manner, culminating in activation of IKKβ-NF-κB 
and the c-jun kinase (JNK) arm of the mitogen-activated protein kinase (MAPK). 
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Similarly, hyperinsulinaemia and the accumulation of free fatty acids and glucose that 
takes place in response to DIO and T2D induces increases in circulating cytokines via 
these pathways (Milanski, et al., 2009; Hirosumi, et al., 2002).  
Earlier work indicated recruitment of tissue macrophages to visceral adipose tissue in 
obesity to induce the appearance of TNF-α and to aggravate insulin resistance 
(Hotamisligil, et al., 1993; Visser, et al., 1999; Kim & al., 2005). TNF-α was found to 
be over-expressed in muscle and adipose tissue of obese humans, while its exogenous 
administration led to insulin resistance (Hotamisligil, et al., 1995; Krogh-Madsen, et 
al., 2006). In other experiments using human ex vivo pancreatic β cells, exposure to 
high glucose increased expression of Interleukin-1β (IL-1β) via NF-κΒ activity which 
was also observed in islets from obese, but not control subjects. Ex vivo data indicated 
increased NF-κB activity to promote insulin resistance in patients by disrupting β cell 
secretory function and increasing vulnerability to the hyperglycaemia observed in 
DIO (Maedler, et al., 2002).  
In the brain, increases in NF-κB activity are known to be detrimental to the survival to 
acute and prolonged ischemia (Stephenson, et al., 2000; Wang, et al., 2010). 
However, more recently it has been suggested that NF-κΒ activation during transient 
middle cerebral artery occlusion, is associated decreases in infarct size, while its 
suppression following hypoxia produced exacerbation of neural deficits over time 
(Teoh, et al., 2003; Van Den Tweel, et al., 2006; Pires, et al., 2014). Forebrain-
specific neuronal inhibition of NF-κB rendered neurons more susceptible to 
neurotoxic insults (Fridmacher, et al., 2003), while accumulating evidence indicate 
NF-κΒ activity in hippocampal neurones to be a positive modulator learning and 
memory (Meffert, et al., 2003; Kaltschmidt & Kaltschmidt, 2009). In the 
hypothalamus, promotion of serine kinase activity via NF-κΒ signaling cascades has 
recently emerged as a harbinger of metabolic dysregulation.  
The frequent and sustained increases in circulating free fatty acids observed in DIO 
rodents were demonstrated to directly promote hypothalamic metabolic inflammation 
and coincided with up-regulation of sympathetic output (Barnes, et al., 2003; 
Chsnokova & Mlmed, 2002) and down-regulation of the parasympathetic pathway 
(Mashaly & Provencio, 2008). A combination of receptor independent as well as toll-
like-receptor dependent effects of cytokines and chemokines are activated in response 
to increases in endoplasmic reticulum (ER) and oxidative stress in response to chronic 
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HFD.  These changes possibly take place as adaptive responses to DIO-associated 
insults, however their persistent engagement is suggested to contribute to 
dysregulation of pulsatile relationships between neuroendocrine centers associated 
with metabolic regulation (Zhang, et al., 2013; Chsnokova & Mlmed, 2002; Berglund, 
et al., 2012; Xu, et al., 2010).  
Characteristically, chronic administration of low dose TNF-α in the rodent brain was 
shown to induce insulin insensitivity and reduced thermogenesis (Romanatto, et al., 
2007; Arruda, et al., 2011). Increases in IKKβ activity in the ARC in particular were 
suggested to be particularly detrimental, and down-regulation of IKKβ  (Zhang, et al., 
2008) and JNK (Belgardt, et al., 2010) using the nervous system-specific Nes-Cre 
promoter were protective against obesity and glucose intolerance. Indicative of a 
broader role in metabolic dysregulation, accumulation of NF-κΒ gene products in 
POMC neurons in earlier studies, promoted the cachectic effects of sickness response 
(Jang, et al., 2010; Challis, et al., 2004). Additionally, DIO-induced activation of the 
IKK-β-NF-κΒ signaling pathway was associated with depletion of hypothalamic stem 
cell population, suggesting that perhaps the dysfunction observed in DIO and T2D is 
a form of accelerated aging (McNay, et al., 2012; Mihaylova, et al., 2014).  
Inflammatory signaling cascades are driven by the tissue- and context-specific 
expression of cytokines involved in both the initiation and resolution of the response 
in relation to the insult. DIO is suggested to promote the institution of a pro-
inflammatory state and down-regulation of anti-inflammatory cytokines that promote 
its resolution. For example, the deficiency of the main anti-inflammatory cytokine 
Interleukin-10 in mice, exacerbates brain inflammatory responses to ischaemia 
without preventing lesion resolution (Perez-de Puig, et al., 2013). Cytokines exhibit 
particular pleiotropy and redundancy which relates to the expression of cytokine 
adaptor molecules in multiple cell lineages, as well as the shared signaling pathways 
by virtue of similarities between cytokine receptor motifs (Ozaki & Leonard, 2002). 
The precise contributions of cellular and molecular factors that participate in the 
hypothalamic cytokine signaling networks in the metabolic response to HFD could 
provide novel avenues for pharmacological treatment of metabolic disorders.  
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IL-6; a pleiotropic JAK/STAT of all trades 
Interleukin-6 (MW=21-28kDa) is a cytokine of pleiotropic character involved in the 
regulation a milieu of immune, hematopoietic and metabolic processes. Initially 
characterized as B-cell stimulatory factor-2 in the 1960s, IL-6 is a glycosylated four-
helical protein that was first successfully cloned in 1986 and described by Kishimoto 
and others (Kishimoto, 1987; Sehgal, et al., 1987). Work at the beginning of the 
1990s identified the cytokine to be central in the mounting of the acute phase 
response of inflammation (Heinrich, et al., 1990), while the involvement of IL-6 in 
the transition from innate to acquired immunity, and protection against septic shock 
was also confirmed (Kopf, et al., 1994; Van Snick, 1990; Vink, et al., 1990).  
A number of regulatory sequences have been shown to promote IL-6 production and 
secretion by through the IL-6 gene. Supershift analysis indicated the functional role of 
NF-κΒ, cAMP response element-binding protein (CREB), the nuclear factor for IL-6 
(NF-IL-6) and the activator protein-1 (AP-1) in regulating IL-6 expression (Castell, et 
al., 1988; Wang, et al., 1995; Grassl, et al., 1999), while more recently a role for 
circadian gene products was also demonstrated (Sato, et al., 2014). Under resting 
conditions, NF-κΒ is found in the cytosol as a dimer of the p65 and p50 transcription 
factors, in association with IκΒ (Baeuerle & Baltimore, 1988).  Stress and infection 
induce the phosphorylation of IκΒα and ΙκΒβ by IKKinase (Huxford, et al., 1998; 
Verma, et al., 1995), prompting their ubiquitination and degradation by proteasome 
26S (Karin, 2000). Increased phosphorylation of the p65 NF-κΒ subunit allows for 
the dimer to move into the nucleus (Phelps, et al., 2000), where interactions with the 
p300/CREB-binding protein (Tang, et al., 2007), allow for binding at NF-κΒ sites 
resulting in the production of IL-6.   
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IL-6 Binding and Signaling 
IL-6 mediates its signaling via binding with nanomolar affinity to its receptor (IL-
6Rα), a four-helical protein of 184 amino acids. Three distinct binding sites allow the 
IL-6 receptor to propagate its specific signaling pathway via recruitment of the 
cytokine and binding to a gp130 dimer. Site 1, formed by the C-terminal residues of 
helix D and the C-terminus of the AB-loop determine the receptor’s IL-6 specificity. 
Site 2 consists of intermediate portions of helices A and C, while site 3 consists of N-
terminal residues of the AB loop and C-terminal residues in the D helix. (Fiers, et al., 
1987; Rose-John, et al., 1990) 
Binding of IL-6 to IL-6Rα does not directly lead to signaling. It is rather the 
formation of an IL-6/IL-6Rα complex that allows for association with gp130 protein, 
which dimerizes on binding and mediates intracellular signaling via JAK/STAT. This 
results in recruitment of JAK (Janus-activated Kinases) at proline-rich domains. 
Gp130-associated JAK kinases tyrosine-phosphorylate their cytoplasmic domains to 
enable phosphorylation-activation of STAT3 and STAT1 (less) (Hemmann, et al., 
1996; Heinrich, et al., 1998). Activation of SH2 domain-containing tyrosine 
phosphatase allows for the induction of Mitogen-Activated Protein Kinase (MAPKs) 
(Muller, et al., 2001) and Phosphatidylinositide 3-Kinase (PI3K) pathways, an event 
of particular importance in both cancer (Birkenkamp, et al., 2000; Hideshima, et al., 
2001) and cardiac physiology (Kodama, et al., 2000).  
The STAT family of transcription factors encompasses 7 mammalian members (1-4, 
5a, 5b, 6), but IL-6 cytokines have been shown to induce specific activation of 
STAT3 and to a lesser extent STAT1 through gp130.STAT3 binds to phosphorylated 
YxxQ motifs, while STAT1 requires phosphorylation of YXPQ receptor motifs 
(Garhatz, et al., 1996). Subsequently, STATs are phosphorylated on a single tyrosine 
residue (Y701 for STAT1, Y705 for STAT3), leading to the formation of active 
STAT dimer association at SH2 domains.  Interestingly, in separate studies (Kim, et 
al., 2004) have also indicated the existence of non-phosphorylated as well as IL-6 
activated-phosphorylated STAT3 and STAT3 pools in plasma membrane rafts. 
Tyrosine phosphorylation of the gp130 receptor in the context of IL-6 signaling, has 
been also shown to recruit the mitogen-activated protein kinase (MAPK) and 
phosphatidylinositol 3-kinase (PI3-K)  pathways via the JAK-mediated 
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phosphorylation of SHP2 (SH2-domain-containing tyrosine phosphatase) site Tyr759 
(Stahl, et al., 1995; Zhang, et al., 2002). The subsequent SHP2-dependent activation is 
the consequence of interactions of the SHP2 Tyr542 and Tyr580 C-terminal domains 
with the Grb2-SOS (growth factor-receptor-bound protein/Son of Sevenless) complex 
(Schaper, et al., 1998). Further complexity is provided to this mode of signaling by 
the tyrosine phosphorylation of Gab1, a scaffolding protein that is targeted via 
pleckstrin-homology (PH) to the plasma membrane (Takahashi-Tezuka, et al., 1998). 
Gab1 contains binding sites for Grb2, SHP2, PI-3K, Crk, phospholipase Cγ and the c-
Met receptor (Schaeper, et al., 2000).  
IL-6 signaling is associated with cell survival and proliferation via the combination of 
the mitogenic effects of the ERK/MAPK pathway and the anti-apoptotic effects of 
STAT3 phosphorylation (Takahashi-Tezuka, et al., 1998; Fukada, et al., 1996). Up-
regulation of Bcl-2 via Stat3 and the inhibition of cell cycle inhibitor p27 via 
ERK1/MAPK signaling, are recognized as instrumental to ischaemia/reperfusion 
injury consolidation in cardiac myocytes (Stephanou, 2004) and more recently 
demonstrated neuroprotective effects of IL-6 to NDMA-induced excitotoxicity 
(Wang, et al., 2009).  The effects of IL-6 signaling on the MAPK signaling cascade 
are not limited to survival, but extend to stress-activated JNK and p38 MAPK activity 
(Bode, et al., 2001; Zauberman, et al., 1999), promoting elements of cytokine 
signaling feedback inhibition.  
Activation of gp130 and more specifically the recruitment of PI3-K pathway via the 
hydrophobic core of the SH2 domain Tyr657, has been suggested to regulate cardiac 
myocyte survival in doxorubicin-induced apoptosis through facilitating the function 
of Bcl-xL (Negoro, et al., 2001). Interestingly, more recent work has suggested 
phosphorylation of PKB via SHP2 in the context of classical IL-6 signal transduction 
to be sufficient to induce cardioprotection in rat myocytes, in the absence of 
JAK/STAT activation (Fahmi, et al., 2013). Earlier work suggested Hyper-IL-6 
signaling (described in subsequent section) to promote liver regeneration (Peters, et 
al., 2000), while more recently IL-6/STAT3-mediated proliferation and PI-3K-
mediated cell growth, have been described as pivotal in the treatment of liver 
dysfunction and disease (Fujiyoshi & Ozaki, 2011; Nechemia-Arbely, et al., 2011).  
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Figure 1.1.2: Schematic representation of the molecular pathway involved in IL-6 
signal transduction:  
 
On the other hand IL-6/PI3-K signaling is particularly prominent in certain forms of 
cancer, and was demonstrated to be crucially involved in up-regulation of anti-
apoptotic Mcl-1 in basal cell carcinoma cells (Kuo, et al., 2001). Interactions of the 
PI3-K arm of IL-6 signaling in particular with androgen signaling has been suggested 
to be detrimental to the advancement of prostate cancer (Xie, et al., 2004) and to 
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regulate cancer growth (Culig, et al., 2002; Culig, et al., 2005) and survival (Wegiel, 
et al., 2008).  
IL-6 has been also observed to transiently phosphorylate AMP-activated Kinase 
(AMPK), a signaling event first speculated by experiments investigating the activity 
of AMPK in the context of exercise-induced IL-6 release (MacDonald, et al., 1987); 
and was later underlined by the effects of IL-6 KO on exercise in mice (Kelly, et al., 
2004). A recent review of IL-6 signaling pathways, suggested AMPK 
phosphorylation to occur via STAT3 (Sarvas, et al., 2013), while the current dogma 
suggests IL-6 mediated increases in cAMP and the AMP: ATP ratio to underlie 
AMPK phosphorylation (Kelly, et al., 2004). 
SOCS-3 is the primary direct negative feedback regulator of IL-6 signaling (Niemand, 
et al., 2003; Alexander & Hilton, 2004). It is a member of the suppressor of cytokine 
signaling family of 8 related proteins (CIS and SOCS-1 to 7), induced in response to 
activation of STAT proteins, but is known to be most potently induced by IL-10 
independently of STAT (Cassatella, et al., 1999). SOCS-3 has been extensively 
characterized to specifically act towards termination of gp130 and Ob-Rb signaling in 
a variety of tissue (Croker, et al., 2003; Mori, et al., 2004; Yasukawa, et al., 2003). 
More recent in vivo mouse studies where the SOCS-3 gene was conditionally deleted 
(Croker, et al., 2012); confirmed the role of the protein in IL-6 response regulation as 
well as its requirement for survival during inflammatory responses.  
Glucagon was demonstrated to act independently of de novo protein synthesis to 
inhibit IL-6 mediated gene expression in a pituitary adrenocorticotropic hormone 
(ACTH)-secreting cell line (Bousquet, et al., 2000), as well as more recently, in 
hepatocytes (Khouri, et al., 2011). Increases in activated adenylyl cyclase-induced 
calcium flux (and/or potentially PKC) (Tian & Laychock, 2001), can thus act to 
promote the induction of SOCS-3 as an additional means of cytokine signaling 
regulation.  
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Soluble and Membrane-bound IL-6 Signaling 
As mentioned, the ubiquitously expressed gp130 protein has no measurable affinity 
for IL-6 or its receptor outside the spectrum of their complex (IL-6Rα/IL-6) (Taga, et 
al., 1989). A soluble form of the receptor exists, catalyzed by ADAM (A Desintegrin 
and Metalloprotease) 10 & 17-mediated proteomic cleavage in mice and by both 
proteomic cleave and/or alternative mRNA splicing in humans (Croucher, et al., 
1999).  
Figure 1.1.3: Schematic representation of Classical and Trans-signaling 
mechanism  
 
Rapid cleavage and generation of the sIL-6Rα have been associated with the 
activation and proteomic cleavage by ADAM17 in response to TNF-α, IL-1β and 
certain bacterial toxins. On the other hand ADAM10 has been found to participate in 
the constitutive, slow shedding of the receptor under basal or un-stimulated 
conditions.  (Marin, et al., 2002; Matthews, et al., 2003). The soluble form of the 
receptor binds to gp130 with similar affinity to the membrane bound isoform. The 
ubiquitous expression of gp130 renders all cell moieties IL-6-responsive and allows, 
in part, for the endocrine, paracrine and autocrine function of the cytokine (Jones, et 
al., 2001). 
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The influence of IL-6 on major body processes and the 
neuroendocrine regulation of metabolism 
IL-6 signaling has been recognized to modulate a vast array of events in different 
target tissues. The ubiquitous expression of the gp130 adaptor molecule; the release of 
the soluble form of the receptor from immune cells and of IL-6 from key homeostatic 
regulators, provide the framework through which IL-6 signaling co-ordinates activity 
in a spectrum of settings and cell types. Release of inflammatory mediators such as 
IL-6 from adipose tissue in the face of DIO contributes to the emergence of pathology 
however the mechanisms through which adipose inflammation contributes to 
disorders of glucose homeostasis remain incompletely understood (Galic, et al., 2010; 
Virtue & Vidal-Puig, 2010; Lontchi-Yimagou, et al., 2013; Richardson, et al., 2013). 
Exposure to hyperinsulinaemia in humans increases IL-6 expression (Kroqu-Madsen, 
et al., 2004) and release from tissue (Mohamed-Ali, et al., 1997). More recently, 
metabolic inflammation at level of the hypothalamus, has been suggested to be key to 
the development of DIO and the progression to T2D and the role of individual 
components of cytokine signaling is still being heavily investigated (Zhang, et al., 
2008; Wang, et al., 2010).  
In early studies in mice over-expressing interleukin-6 and the soluble receptor gene, a 
dramatic increase in hematopoietic progenitor cells at the liver and spleen was 
observed (Peters, et al., 1997). However, other aspects of the phenotype included 
visibly absent fat pads and significantly smaller stature, an effect that albeit not 
apparent in the single transgenic over-expressing sIL-6Rα mice spurred considerable 
interest on the metabolic implications of IL-6 signaling. In accord with other studies 
by Hotamisligil et al. who first reported a role for adipose-derived TNF-α in the 
development of DIO and T2D, these early studies encouraged speculation of the role 
of IL-6 in metabolism (Ling, et al., 2004; Bastard, et al., 2000).  
In the absence of inflammation, the cytokine exhibits a prominent role in 
hematopoiesis (Otsuka, et al., 1994; Laharrague, et al., 2000) and is released from 
adipocytes (Coppak, 2001), myocytes (Loppnow & Libby, 1990; Neumann, et al., 
1995; Pedersen, et al., 1998) as well as endothelia (Hedges, et al., 1992; Kishikawa, et 
al., 2002) in various concentrations in response to an array of stimuli. The growing 
interest in the role of the cytokine in metabolism resulted a number of studies that 
benefited from the use IL-6 deficient mice, and further supported the role of the 
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cytokine in promoting the action of insulin (Wunderlich, et al., 2010; Matthews, et al., 
2010). More recent evidence suggests the action of IL-6 in the hypothalamus to 
mediate decreases in food intake and body weight as well as increases in leptin and 
insulin sensitivity (Flores, et al., 2006; Ropelle, et al., 2010; Shirazi, et al., 2013; 
Schele, et al., 2013). 
The hypothalamus is a brain region that acts as the interface between the nervous and 
endocrine systems, orchestrating the activation of the hypothalamic-pituitary-adrenal 
and –thyroid axis, which act towards the maintenance of homeostasis in physiology 
and disease (Tsigos & Chrousos, 2002; Engelmann, et al., 2004). Distinct 
hypothalamic nuclei have been found to play integral role in the regulation of feeding 
behavior, satiety and energy expenditure  (Williams, et al., 2001). The Jansson group 
(University of Gothenburg) recently published studies where IL-6 receptor 
localization in the human and mouse hypothalamus was characterized using 
fluorescent immunohistochemistry, indicating the medial hypothalamus to be the 
region exhibiting the highest expression (Schele, et al., 2012). IL-6Rα-positive 
neurons were identified in several areas of the mouse hypothalamus involved in the 
regulation of homeostasis regulation, body composition and energy expenditure. 
Receptor immunoreactivity was identified in the ARC, VMH, PVN, DMN and LH in 
close proximity to NPY positive fibres.  
IL-6 is thought as an important dynamic regulator of physiology and disease, through 
local and systemic effects that have not been fully characterized in vivo (Mauer, et al., 
2014; Wolf, et al., 2014). We were thus encouraged to examine role of central IL-6 
signaling in the development of metabolic dysregulation in response to DIO and 
towards this, a tissue-specific IL-6Rα knock-down transgenic was generated. 
Interpretation of the phenotype observed during these studies using this transgenic 
could only be attempted in the context of the wide range of biological activity 
displayed by IL-6, which we summarize in this section. 
  
44 
 
Hematopoiesis 
In mammalian systems, hematopoietic stem cells in bone marrow, give rise to all 
lineages of blood as well as immune cells. Bone marrow is found in the medullary 
cavities of skeletal bones, and is home to a dense network of medullary vascular 
sinuses. Hematopoietic stem cells and their progenitors are packed in the 
microenvironment (or niches) within bone marrow, and regulate bone formation. 
Early work indicated IL-6 to contribute to the proliferative capacity of bone-forming 
osteoblasts in vitro (Taichman & Emerson, 1994), as well as the formation of multi-
lineage blast cell colonies and stem cells (Bernad, et al., 1994). Consistent with this, 
over-expression of the cytokine in rodents, augments the hematopoietic potential of 
animals, increasing progenitors in various tissues (Peters, et al., 1997). 
The fate of stem cells of the hematopoietic system are known to be influenced by 
specialized inflammatory micro-environments and was initially thought to be 
regulated by parathyroid hormone (PTH) thought activation of Notch signaling  
(Calvi, et al., 2003). The critical role of IL-6 signaling in promoting PTH-mediated 
increases in osteoblasts were initially demonstrated in culture, while increases in 
hematopoietic progenitor cells observed in PTH-treated control animals were 
abolished in IL-6-deficient animals (Pirih, et al., 2010).  
More recently, the interdependence of IL-6 and PTH mediated hematopoietic cell 
expansion was shown to involve the combined effects of classical and trans-signaling 
(Cho, et al., 2013). Absence of PTH-mediated hematopoietic cell expansion observed 
in IL-6-/- marrow cultures, was found to be restored by sIL-6Rα treatment. sIL-6Rα 
treatment did not induce any increases in osteoblast proliferation or differentiation in 
vitro, but was found to contribute to the anabolic actions of PTH by supporting 
CD11b+Gr-1+ cells and macrophages (F4/80+) of the hematopoietic system. In other 
studies involving the use of IL-6 and IL-6 receptor deficient mice, the modulatory 
role of IL-6 signaling in wound healing, which is a measure of the ability of the 
hematopoietic system to generate new stem cells was demonstrated (McFarland-
Mancini, et al., 2010).  
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Immune Regulation 
Cytokines such as IL-6 are produced in response to perturbations of homeostasis, such 
as endotoxaemia, endotoxic lung, trauma as well as acute infections (Kishimoto, et 
al., 1992; Zitnik & Elias, 1993). IL-6 release from monocytes was first described to 
stimulate thymocytes and T lymphocytes almost 30 years ago now (Lotz, et al., 1988), 
an event that is dependent on monocyte depletion, indicative of the regulatory role of 
the cytokine in cell immunity. Up-regulation of TNF-α, IL-1β and IL-6 are required 
for the induction of the acute phase response, which includes fever, corticosterone 
release, and hepatic production of acute phase proteins (Baumann & Gauldie, 1993). 
Macrophages and lymphocytes, as well as endothelia activate NFκB signaling 
cascades culminating in the release cytokines such as IL-6 into circulation in response 
to exogenous stimuli and/or stress (Nguyen & Benveniste, 2002). This subsequently 
promotes the production of pro-inflammatory Th17 cells and eventually the mounting 
of the acute phase response (Castell, et al., 1988; Mackiewicz & Kushner, 1989; 
Wang, et al., 1995).  
Lipopolysaccharide (LPS) is a vital component of bacterial cell membranes and 
known to induce the synthesis of pro-inflammatory cytokines IL-1, IL-6 and TNFα in 
both the periphery, as well as various parts of the brain in the presence of a stressor or 
infection (Besendovsky & Del Rey, 1996; Romero, et al., 1993). P38 MAPK was first 
recognized to be involved in regulation of pro-inflammatory cytokine biosynthesis in 
response to various stress stimuli (Lee, et al., 1994; Beyaert, et al., 1996); but is also 
believed to be involved in the feed-forward action of cytokines. In accordance with 
the early idea of overlapping cytokine networks (Akira, et al., 1990), Patil et al. 
(2004) have shown that inhibition of p38 activity by SB203580 reduces IL-1β-
induced increases in IL-6 synthesis and mRNA stability. In further support, 
SB203580 treatment in mice and rats was found to reduce circulating IL-6 and TNFα 
in the context of both acute and chronic inflammation (Badger, et al., 1996; Zhou, et 
al., 2014). 
IL-6 thus participates in the network of cytokines involved in mounting of the acute 
phase response, a system that exhibits particular redundancy in its relationships (Koj, 
1985). However, IL-6 signaling is a requirement at the level of the liver in particular, 
and effective response to trauma or infection is thought to be dependent on the 
presence of IL-6 (Kopf, et al., 1994). This was re-emphasized in more recent work 
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using mouse models of bacterial infection, where IL-6-/- mice experienced increased 
neutrophilia on the one hand, but more importantly reduced bacterial clearance. Re-
constitution of the sIL-6R system in IL-6-/- mice, improved mortality rate though 
ameliorating these effects (Onogawa, 2005) in agreement with the protective role of 
the cytokine in the development of septic shock (Diao & Kohanawa, 2005; Barton & 
Jackson, 1993).  
Acute-phase induced apoptosis promotes IL-6Rα shedding through caspase-
dependent but PKC-, MAPK- and ROS- independent mechanisms (Chalaris, et al., 
2007). Rapid cleavage and generation of the sIL-6Rα are regulated by the proteomic 
cleavage action of ADAM10 and ADAM17. TNFα and IL-1β, as well as certain 
bacterial toxins, are known inducers of ADAM17 metalloproteinase activity (Marin, 
et al., 2002; Matthews, et al., 2003). Inhibition of ADAM17 during apoptosis by small 
pharmacological molecules or the expression of dominant negative ADAM17 variant 
resulted in inhibition of shedding from the neutrophils of mice subjected to the air 
pouch model of acute inflammation (Koenen, et al., 2009). sIL-6Rα/IL-6 complexes 
formed during apoptosis are biologically active and found to trans-signal in non-
apoptotic cells examined (Rose-John, 2012; Rose-John, et al., 2007).  
Shedding of the IL-6Ra during acute phase-mediated neutrophil apoptosis, directs IL-
6 trans-signaling on endothelia. Although this event is acutely detrimental to 
endothelia, it primes the secretion of chemokines, it was found to be a requirement for 
the recruitment of monocellular phagocytic cells towards inflammation resolution 
(Rose-John, 2012; Rose-John, et al., 2006).  Blockade of sIL-6Rα binding onto IL-6 
by a soluble-gp130 analogue (sgp130Fc) resulted in normalization of the neutrophil 
influx observed upon stimulation, however the subsequent recruitment of monocytes 
was severely impaired (Rose-John, 2012; Rose-John, et al., 2007).  
Monocytes are primary immune regulators of the acute phase of inflammation  (Lotz, 
et al., 1988). They replace T cells in the 24-48hour period following initial 
infiltration, in order to protect tissue from local over-accumulation of neutrophils. 
Using IL-6 deficient mice, early studies were able to demonstrate that circulating IL-6 
participates in the regulation of cytokine levels during this event in vivo. Transgenic 
mice experienced augmented pro-inflammatory responses to endotoxaemia, 
underlining the anti-inflammatory nature of IL-6 (Xing, et al., 1998), independently of 
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the main anti-inflammatory mediator IL-10 (de Vries, 1995). Monocytes are currently 
understood to utilize the combined action of IL-6 and TGF-β, which inhibits the 
conversion of nTregs to Th17 as part of negative feedback mechanisms to the initial 
pro-inflammatory response (Gao, et al., 2012). Their synergy along with a down-
regulation of the IL-6Rα, underlie the production of not only helper cells 
characterized by the production of IL-17, TNF-α and IL-6 itself, but also the 
induction FOXP3+ and the differentiation of iTregs, responsible for the transition to 
inflammation resolution (Gao, et al., 2012).  
In acquired immunity development, the successful transition from the acute to the 
resolving phase, is accompanied by leukocyte recruitment (Hoebe, et al., 1995). This 
involves an initial influx of neutrophils, which is followed by their replacement with 
more sustained mononuclear cell populations (McLoughlin, et al., 2003; Topley, et 
al., 1996). IL-6 cytokine governs T-cell activity and defines not only the pattern of 
monocyte differentiation, but also the direction of dendritic cell maturation (Jones, 
2005). During the resolving phase, IL-6 suppresses CXCL1, CX3CL1 and CXCL8, 
while it promotes CXCL5 and CXCL6 release among other monocyte-attracting 
chemokines. The action of IL-6 and the expression IL-1 (Gabay, et al., 1997) and 
TNF-α receptor antagonists result in the induction of neutrophil apoptosis and 
leukocyte transmigration (Romano, et al., 1997; Hurst, et al., 2001; Kaplanski, et al., 
2003). The interaction of IL-6 signaling and trans-signaling along with other cytokine 
cascades are central to determining aspects of both the immediate response to stress 
and constitutes a priming event to a similar future insult (Gao, et al., 2012; Scheller, et 
al., 2011). Collectively, it appears that in the experience of a non-specific stress 
insults; the induction of trans-signaling in the presence of the stimulus acts to 
promote the action of classical signaling and the expression of anti-apoptotic genes in 
the recovery period.  
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Liver Acute Phase Response and Metabolism 
Acute Phase Response: 
The role of IL-6 in the induction of the acute phase response at the liver have been the 
subject of considerable research. Serum IL-6 increases proportionately to systemic 
inflammation under regulation of a cytokine network involving TNF-α, IL-1 and IL-6 
(Fournier, et al., 2000). For example, chronic hepatitis B virus (HBV) infection, is 
associated with up-regulation of IL-6 expression through NFκΒ by the hepatitis B 
virus X-protein in particular, which induces CRP and other acute-phase proteins from 
the liver in humans (Lee, et al., 1998; Zhu & Paddock, 1999; Schaper, et al., 1997). 
Chronic liver disease was demonstrated to be associated with increases in serum IL-6 
and sIL-6Rα that drive increases in the major acute phase protein α1-Acid 
glycoprotein (AG) (Heinrich, et al., 1998; Hirano, 1998).  
On the other hand, the naturally occurring negative feedback regulator of IL-6 trans-
signaling, sgp130 was found to be significantly elevated in cirrhosis patients and 
exhibited correlation with various important biomarkers of the disease (Migita, et al., 
2006). Serum IL-6 and soluble receptor levels are thus important regulators of both 
liver function and degree of impairment in chronic liver disease. In other studies 
where hepatectomy was used to evaluate the role of IL-6 signaling in liver function, 
IL-6 deficient mice showed impaired regeneration compared to controls 
(Blindenbacher, et al., 2003; Ling, et al., 2002). In line with the above, experiments 
with IL-6 transgenic and IL-6/sIL-6Rα double transgenic mice, signified the need for 
the combination of classical IL-6 and trans-signaling, for efficient hepatocellular 
proliferation following injury. The use of the inhibitor of trans-signaling sgp130Fc 
inhibited hepatocellular proliferation following chemically induced damage and 
specific blockade of classical signaling reduced concavalin A-induced liver damage 
(Scheller J. et al. 2011). The cytokine is thus central to the induction of the acute 
phase response at the liver and instrumental to the beneficial effects of inflammation 
in the recovery period. 
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Metabolic regulation: 
High fat feeding is associated with increases in adipose-derived IL-6, and was 
demonstrated to promote liver insulin resistance through inhibition of the insulin 
receptor substrate IRS-1 (Sabio, et al., 2008), by promoting increases in pJNK and 
SOCS-3, as well as NF-κB-IKK-β  (Cai, et al., 2005). However, hepatocyte-specific 
disruption of the IL-6Rα was shown to induce hepatic inflammation and glucose 
intolerance (Wunderlich, et al., 2010; Ouchi, et al., 2011). Thorough studies in IL-6 
deficient mice indicated enhanced weight gain and the development of hepatic 
inflammation and steatosis upon genetic disruption of the cytokine (Matthews, et al., 
2010). It is currently thought that adipose-derived IL-6 contributes to insulin 
resistance, whereas muscle-derived IL-6 is thought to promote it through the 
inhibition of gluconeogenic pathways. 
Insulin resistance and dyslipidaemia observed in DIO and diabetes, induce a 
pathophysiological increase in glucagon release  (Vons, et al., 1991; Reaven, et al., 
1987; Larsson & Ahren, 2000). Elevated glucagon to insulin ratio at the liver both 
drives the persistence of insulin resistance and leads to hyperglycaemia (Eledrisi, et 
al., 2006).  
Glucose-6-Phosphatase (G6Pase) is a metabolic enzyme involved in the final step of 
the gluconeogenic pathway, converting Fructose-6-phosphate to glucose. Liver IL-6 
signaling has been suggested to inhibit gluconeogenesis through reduction of Glucose 
6-Phosphatase (G6Pase) and glycogen levels (Metzger, et al., 1997), and more 
recently, the anti-gluconeogenic effects of IL-6 through inhibition of G6Pase was 
demonstrated in primary hepatocytes (Christ, et al., 2000; Inoue & al, 2004) and 
corroborated in vivo. Phosphorylation of liver STAT3 during euglycaemic-
hyperinsulinaemic clamps was shown to promote insulin sensitivity by inhibiting liver 
Glycogen Synthase Kinase-3 (GSK-3) protein and mRNA (Inoue, et al., 2006; Moh, 
et al., 2008).  In conjunction with previous studies using neuronal-specific insulin 
receptor KO mice (Bruning, et al., 2000), the role for IL-6 in the brain-liver axis being 
heavily investigated, however it is still not clear whether the cytokine is the primary 
driver of the induction of pSTAT3 in vivo (Mauer, et al., 2014).  
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Exercise and the Working Muscle 
It is now widely understood that upon exercise-mediated muscle contraction, the 
stimulation of cytokine production is also induced, as a means of enhancing the 
delivery of substrate to the working tissue (Pedersen & Hojman, 2012). Northoff and 
Berg (1991) first reported IL-6 to be acutely up-regulated in human plasma in 
response to exercise, while Bruunsgaard et al. (1997) initially speculated the 
production of the cytokine to involve the action of leukocytes in response to exercise-
induced local damage at the level of the working muscle (Northoff & Berg, 1991; 
Bruunsgaard, et al., 1997).  
Eccentric exercise was shown to be a strong inducer of IL-6 release from muscle 
(Smith, 1991) and Ostrowski et al. (1998) concluded this to be dependent on duration 
and intensity of exercise activity. However the precise origins of IL-6 were not 
demonstrated and initial evidence suggested found both prolonged running and 2 
hours of concentric exercise to be unable to induce IL-6 release from blood 
monocytes (Starkie, et al., 2000). Around the same time, (Pedersen, et al., 2001) had 
suggested IL-6 as a myokine whose concentrations in plasma increase dramatically in 
response to intense exercise (e.g. rowing), in many cases much higher than in obesity 
and diabetes.  Increases observed, though significant compared to lean subjects (2-
3fold) are nowhere near proportional to the levels previously reported in the context 
of exercise, where IL-6 increases up to 100-fold depending on the duration and 
intensity of exercise (Ostrowski, et al., 1998).  
Along those lines, IL-6 infusion during exercise, was shown to increase the ability of 
the system to dispose glucose, while the appearance of IL-1 receptor antagonist and 
IL-10 in circulation prompted to anti-inflammatory signaling cascade activation; 
further confirming the existence of cytokine cascades (Febbraio & Pedersen, 2002). 
Shortly after, (Petersen & Pedersen, 2005) showed that IL-6 is the first cytokine to 
appear in circulation following the post-exercise period, increasing 100-fold from 
baseline levels, revealing that skeletal muscle harbors IL-6 gene and protein 
expression.  
Contrasting the findings by Starkie et al. (2000) recent work by Reihmane, et al., 
suggests that maximal exercise induces the release of myeoloperoxidase which 
correlates with IL-6 increases in serum (Reihmane, et al., 2013). This was also 
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verified by the Starkie group, that concluded exercise-induced IL-6 release can only 
be partly attributed to neutrophils; (Starkie, et al., 2003; Starkie, et al., 2001) as 
eccentric and concentric muscle exercise normalized for individual lactate thresholds, 
was found to elicit similar IL-6 plasma responses. It is thus now understood that 
eccentric and maximal (Chaar, et al., 2011) exercise-induced plasma increases in IL-6 
are not accompanied by increases in adhesion molecules that would implicate 
leukocytes.   
The precise intracellular mechanisms underlying contraction-induced IL-6 release 
from myocytes was also the subject of considerable research. Individual values of 
activated AMPK correlated with IL-6 release after 60 minutes of cycling exercise in 
the glycogen-depleted state, suggestive of a link between AMPK activity, plasma IL-6 
release and carbohydrate availability (MacDonald, et al., 1987). Some 20 years later, 
IL-6 has been suggested to activate AMPK in skeletal muscle by increasing 
intracellular cAMP and the AMP: ATP ratio (Kelly, et al., 2004), while AMPK-
dependent pathways (Glund & Krook, 2008) have been confirmed to influence IL-6 
release from isolated oxidative skeletal muscle.  
Research work failed to identify an association either between carbohydrate ingestion 
and skeletal muscle AMPK signaling (Lee-Young & al, 2006); or glycogen levels and 
IL-6Rα gene expression (Keller, et al., 2005a) even though IL-6 release appeared to 
be affected by carbohydrate bioavailability. Despite this, IL-6-/- mice were indeed 
found to experience significantly diminished AMPK activity in both muscle (-75%) 
and adipose (-50%) tissue, an effect that was accompanied by dyslipidaemia, insulin 
& leptin resistance, glucose intolerance and mature-onset obesity (Wallenius, et al., 
2002). Activation of AMPK by IL-6 signaling appears to contribute to the 
maintenance of the required kinase activity for effective management of metabolism 
over time, a notion that was further supported by Kelly M. et al. (2004) using IL-6 
KO mouse, that displayed diminished AMPK activity even at rest, in both muscle and 
adipose tissue.  
Interestingly it was recently demonstrated that exercise has ATP-sensitizing effects on 
muscle, that allow for Ca2+ dependent IL-6 release and the establishment of a cytokine 
autocrine loop through activation of JNK and p38 MAPK signaling (Fernandez-
Verdejo, et al., 2014; Bustamante, et al., 2014; Spangenburg, et al., 2006). This would 
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explain the lack of direct correlation to carbohydrate bioavailability, in agreement 
with the regulatory role of the purinergic system on cytokine signaling (Gabel, 2007; 
Noma, et al., 2013). The release of IL-6 from muscle tissue, would appear to 
contribute the insulin-sensitizing effects of exercise at the level of the liver 
(Matthews, et al., 2010; Kraakman, et al., 2013), possibly through the expression of 
protective chemokines (Pedersen, et al., 2011). 
 
Effects on the Pancreatic Islet Cells and Insulin Secretion 
Dysregulation of the insulin signaling is one of the characteristic features of DIO and 
T2D. Chronic exposure to hyperglycaemia, hyperlipidaemia, ER and oxidative stress 
directly contribute to β cell dysfunction and promote insulin resistance (Unger, 1995; 
Kahn & Flier, 2000; Maedler, et al., 2002). T2D patients experience impaired insulin-
stimulated glucose uptake in muscle (Cusi, et al., 2000) and adipose tissue (Yki-
Jarvinen, 2002), while the inhibition of glucose output from the liver is also disrupted 
(Nakatani, et al., 2004). Under physiological conditions, hyperglycaemia promotes 
rapid release of insulin from the β cell, followed by a more moderate KATP channel-
independent release that follows.  
Beta cell insulin release into portal circulation in response to glucose is done under 
the maintenance of an intrinsic rhythm of intracellular Ca2+ and K+ oscillations (Del 
Prato, et al., 2002; Menge, et al., 2011). Upon successful binding to the insulin 
receptor and appropriate recruitment of Insulin Receptor Substrate-1 (IRS-1), rapid 
tyrosine phosphorylation of insulin receptor complexes as well as downstream 
mediators of insulin signaling, culminate in activation of Protein Kinase B (Akt), 
pSTAT3, Forkhead box O1 (FoXO1) protein is achieved in target tissues (Alessi, et 
al., 1997; Alessi, 2001; Brazil & Hemmings, 2001; Matsuzaki, et al., 2003; Campos, 
et al., 1996). Insulin receptor activation in muscle and fat promotes glucose up-take 
through the recruitment of GLUT4 transporters to the membrane via the activation of 
small GTP-binding protein TC10 (Saltiel & Kahn, 2001; Chiang, et al., 2001). This is 
thought to involve pPKB-mediate inhibition of Rab-GDP interactions, promoting 
GLUT4 translocation to the membrane (Miinea, et al., 2005; Elmendorf & Pessin, 
1999; Zeigerer, et al., 2004). 
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Islets, are indeed able to release insulin in isolation, however the integration of the 
influence of diffusible factors and cell-to-cell interactions is required for pancreatic 
insulin release in vivo (Schofield & Sutherland, 2012; Song, et al., 2000; Porksen, et 
al., 1996; Butler, et al., 2003). In type 2 diabetes, the number and mass of β-cells is 
reduced, while and the pulsatility of insulin release in disrupted (Hellman, 2009). This 
results in elevated secretion of insulin at baseline, which contributes to the 
development of hepatic insulin resistance. Research work during the 1990s yielded 
conflicting results with regards to the effect of IL-6 on pancreatic β cell insulin 
secretion. Some studies suggested IL-6 to suppress β cell GSIS  (Sandler, et al., 1990; 
Southern, et al., 1990) and others towards the end of the decade suggested enhanced 
GSIS (Shimizou, et al., 2000). In subsequent work where freshly isolated islets were 
pre-incubated with IL-6, significant increases in β cell viability were observed in 
response to pro-apoptotic insults (IL-1β, TNF-α, IFN-γ), while impairment of insulin 
secretion was suppressed (Choi, et al., 2004).  The sensitizing effects of IL-6 on β cell 
insulin secretion were then corroborated in transgenic mice over-expressing IL-6 in 
muscle cells (Franckhauser, et al., 2008). Chronic elevations in IL-6 promoted 
hyperinsulinaemia and reduced body weight, even though glucose-stimulated insulin 
secretion was disrupted and liver inflammation was markedly increased.  
More recently, evidence presented by the Donath group (University Hospital Basel) in 
particular ,confirmed expression of the IL-6Rα in pancreatic islets and demonstrated 
IL-6 to stimulate β cell insulin secretion and increase pancreatic α cell mass 
(Ellingsgaard, et al., 2011; Ellingsgaard, et al., 2008). The beneficial effects of 
exercise-induced contracting muscle-derived IL-6, were intriguingly suggested to be 
the consequence of increases in GLP-1 secretion from L cells in the intestine and α-
cells in the pancreas.  
Glucagon-like peptide 1 (GLP-1) is produced in the intestine and brain in during 
prandial periods as well as in response to exercise (Donath & Burcellin, 2013). It is 
known to stimulate exercise anorexia and insulin secretion from the pancreas (Donath 
& Burcellin, 2013). GLP-1 receptor agonists that have currently been proven 
beneficial towards food intake and body weight regulation. Central IL-6 signaling was 
recently demonstrated to play a role in mediating the effects of such agonists (Shirazi, 
et al., 2013). IL-6 was found to be massively (11x) up-regulated in the hypothalamus 
in response to GLP-1 receptor agonism, while inhibition of IL-6 biological activity 
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resulted in attenuation of the effects of the analogue on food intake. IL-6 would thus 
appear to promote the action of insulin via its effects involving both the brain as well 
as the periphery.  
 
Effects on Adipose Tissue 
The role adipose tissue as an endocrine organ (Zhang, et al., 1994) and the 
accumulation of inflammatory signaling at this site in the development of diabetic 
disease have been extensively studied in the past 20 years (Aguilar-Valles, et al., 
2015; Trayhurn & Wood, 2004; Guilherme, et al., 2008; Hotamisligil, et al., 1993; 
Kern, et al., 2001). In the absence of an immune response, IL-6 is largely derived 
from white adipose tissue and circulating cytokine levels have indeed been shown to 
correlate with adipose tissue mass as well as long- and short-term changes to food 
intake (Bastard, et al., 2000; Orban, et al., 1999), and serum IL-6 is increased in obese 
individuals and decreases with weight loss (Kopp, et al., 2003).  
Infusion of recombinant human IL-6 into healthy humans was initially shown to 
increase lipolysis  (Van Hall, et al., 2003) through pSTAT3, but not pAMPK-
mediated effects  (Wolsk, et al., 2010). However its central administration in 
experimental mice, was demonstrated to induce acute increases in energy expenditure, 
suppress food intake acutely, and to reduce fat mass more effectively than peripheral 
administration (Rothwell, et al., 1991; Plata-Salaman, 1996; Wallenius, et al., 2002). 
Furthermore, IL-6 over-expression in the brain potentiated the action of leptin in 
promoting energy expenditure through fat oxidation (Lnczowski, et al., 1999; 
Spiegelman & Flier, 2001). 
Up-regulation of IL-6 in adipose tissue can thus be viewed a component of the 
physiological response to counter exposure to HFD, acting towards increasing energy 
expenditure and reducing food intake (Cao, 2014). Increased macrophage infiltration 
into adipose tissue in the context of DIO and diabetes, was previously suggested to be 
concomitant with hypothalamic inflammation, preceding dramatic increases in 
adiposity and promoting the establishment of insulin resistance (Xu, 2003; Wellen, 
2003). White adipose tissue (WAT) - infiltrating macrophages are characterized by 
increased expression of TNF-α, IL-6 and iNOS, glycolytic metabolism and dendritic-
like morphology; effectively shifting form an anti-inflammatory towards a pro-
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inflammatory phenotype (Murray & Wynn, 2011). Alternatively activated, M2 
macrophages on the other hand promote tissue homeostasis through the release of IL-
10 and TGF-β and their reliance on β-oxidation as opposed to glycolysis (Lang, et al., 
2002; Murray & Wynn, 2011). Classification of M1 and M2 macrophages relates to 
their activation cascade. IFN-γ, IL-1β (Th1-cytokines) and microbial products 
polarize M1 macrophages, while IL-4 and IL-13 (Th2-cytokines) polarize anti-
inflammatory M2 macrophages (Gordon & F.O., 2010). Given the prominent role of 
IL-6 trans-signaling in promoting M1 polarization, the effect of its specific blockade 
was evaluated in mice. Unfortunately, blocking trans-signaling does prevent 
macrophage infiltration in adipose tissue, but failed to inhibit the establishment of 
insulin resistance in HF-fed animals (Kraakman, et al., 2015).  
This phenotype might again, relate to the multifaceted nature of IL-6 signaling. 
Besides its de facto pro-inflammatory role in WAT, IL-6 has been suggested to act 
alike IL-10 to induce IL-4 Receptor α chain (IL-4Rα) expression in macrophages, 
polarizing the IL-4/STAT6 anti-inflammatory axis (Herbert, et al., 2004; Vats, et al., 
2006). It was recently demonstrated that in mice bearing myeloid-specific IL-6Rα 
inactivation, experience increased inflammation and a shift in macrophage 
polarization towards M1, resistance to IL-4 mediated alternative polarization and 
enhanced insulin resistance (Mauer, et al., 2014). The sensitizing effect of IL-6 on this 
axis, might be particularly important in the context of obesity where anti-
inflammatory processes are disrupted (Wu, et al., 2011) and might explain the 
phenotype observed in studies by Kraakman et al.  
Earlier work suggested IL-6 to act in the brain and to drive increases in energy 
expenditure and thermogenesis (Lnczowski, et al., 1999; Spiegelman & Flier, 2001). 
Chronic central administration of recombinant IL-6 in rats was shown to induce 
thermogenesis in innervated brown adipose tissue (BAT) through the induction of 
Uncoupling protein 1 (UCP1) (Li, et al., 2002). UCP1 expression involves the action 
of transcription factors (Kelly, et al., 1998; Puiserver, et al., 1998) such as peroxisome 
proliferator activated receptor γ (PPARγ) and the PPARγ co-activator-1α (PGC-1α) in 
response to sympathetic nervous system activation (Sydoux & Giradrier, 1978). More 
recently, the ability of exercise training, as well as cold exposure to induce UCP1 up-
regulation (Ringholm, et al., 2013) and inguinal (but not epididymal) WAT browning 
(Bostrom, et al., 2012), have been shown to be driven by IL-6 (Knudsen, et al., 2014). 
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In other intricate studies, BAT transplantation in mice was found to be sufficient 
towards the improvement of glucose homeostasis in DIO mice, but interestingly not 
from IL-6 deficient mice (Stanford, et al., 2013).  
IL-6 is thus an important regulator of the ability of the body to drive increases in 
thermogenesis and counter increases in body weight and adiposity. Interestingly, it 
was recently demonstrated the local presence of M2 macrophages, is instrumental to 
the up-regulation of energy dissipation through BAT in the context of cold or excess 
feeding (Nguyen, et al., 2011), which was corroborated by the deletion of the IL-4 
receptor in myeloid cells disrupting the function of BAT. When considering the 
priming effects of IL-6 in the shift to the M2 phenotype via IL-4Rα/STAT6 in 
conjunction with the role in BAT-mediated thermogenesis, increases in circulating IL-
6 in obesity might be more indicative of resistance to the beneficial effects of the 
cytokine through their prolonged engagement.  
Figure 1.1.4: The Pleiotropic Role of Central and Peripheral IL-6 
signaling in Physiology and Disease 
 
Adapted from Mauer J. et al. (2014) 
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Hypothesis and Experimental Approach 
The initial and progressive accumulation of low-grade inflammation is increasingly 
understood to be of significance in the pathology of DIO and the progression to T2D. 
Cytokines are adipose-derived mediators involved in the acute phase as well as the 
resolving phase of inflammation. Increases in circulating cytokines such as IL-6 have 
been found to correlate with diabetic disease progression in obese patients (Kopp, et 
al., 2003; Ofstad, et al., 2013). The majority of published work investigating the role 
of IL-6 in metabolic disease, has been focused on its role in the periphery, benefiting 
from the use of whole body- or liver-specific knock-out or IL-6 deficient animals. A 
number of more recent studies have highlighted the importance of hypothalamic 
inflammation in metabolic disease (Fukuda, et al., 2011; Mori, et al., 2004; 
Yasukawa, et al., 2003; Zhang, et al., 2008).  
Interleukin-6 drives metabolic inflammation in adipose tissue in response to HFD 
(Kraakman, et al., 2015), but has been also shown to act in the brain to promote 
energy expenditure through thermogenesis and fat oxidation (Wallenius, et al., 2002). 
Furthermore, activation of the IL-6Rα in the brain has been shown to promote the 
action of insulin and leptin (Shirazi, et al., 2013; Mori, et al., 2004; Ropelle, et al., 
2010). In separate studies conducted at the McCrimmon lab, in a neuronal glucose-
sensing hypothalamic cell line (GT1-7), repeated exposure to IL-6 was found to 
induce a glucose-sensing defect (G.T. Denwood data not shown).  
The majority of published work investigating the role of IL-6 in metabolic disease so 
far, has been benefited from the use of whole body- or liver-specific knock-out or IL-
6 deficient animals (Matthews, et al., 2010; Wunderlich, et al., 2010). Given the 
complex role exhibited by the cytokine in diabetic disease development, we were 
encouraged to examine the hypothesis that down-regulation of central IL-6 signaling 
would induce a defect in the metabolic response to HFD. To test this experimentally, 
we crossed NesCre1 (Dahlstrand, et al., 1995) and IL-6Rαflox/flox (MacFarland-
Mancini, et al., 2010) mice which resulted in the nervous-system specific down-
regulation of the IL-6Rα. Down-regulation of the receptor was validated in the novel 
transgenic, and mice on SC and HFD were studied and characterized over a period of 
20 weeks using an array of metabolic phenotyping tests.  
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Chapter 2:  Materials and Methods 
List of Reagents, ELISA Kits, Antibodies and mRNA probes Used 
Reagents 
Acrylamide – Acrylamide/Bis-acrylamide, 30% solution A3574 Sigma-Aldrich® 
Adenine – A2786 Sigma-Aldrich® 
Agarose – A9539 Sigma-Aldrich® 
Ammonium Persulphate – APS- A3678 Sigma-Aldrich® 
Ascorbic Acid - L-Ascorbic acid A5960 Sigma-Aldrich® 
Benzamidine – Benzamidine hydrochloride 99% 434760 Sigma-Aldrich® 
Beta-mercaptoethanol – 2-Mercaptoethanol M6250 Sigma-Aldrich® 
Blue/Orange Loading Dye, 6X – G1881 Promega® 
Bradford Reagent – B6916 Sigma-Aldrich® 
Bromophenol Blue – B0126 Sigma-Aldrich® 
BSA - Bovine Serum Albumin A2153 Sigma-Aldrich® 
CaCl2 – Calcium Chloride C1016 Sigma-Aldrich® 
Citric acid – 251275 Sigma-Aldrich® 
Collagenase (Liberase TL – Roche 5401020001)  
D-Mannitol – M4125 Sigma-Aldrich® 
dNTP Mix – U1511 Promega ® 
Dulbecco’s Modified Eagle Medium (DMEM) – 21063-029 Life Technologies ® 
EDTA – Ethylenediaminetetraacetic acid – E9884 Sigma-Aldrich® 
EGTA – Ethylene glycol-bis (2-aminoethylether)–N, N, N’, N’-tetracetic acid - 
E3889 Sigma-Aldrich® 
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Ethanol – 459844 Sigma-Aldrich® 
Ethidium Bromide – E7637 Sigma-Aldrich® 
Extraction Buffer – E7526 Sigma-Aldrich®  
Foetal calf serum – 10270-106 Life Technologies ® 
Glucose – D-Glucose - G8270 Sigma-Aldrich® 
Glycine – G8898 Sigma-Aldrich® 
GoTaq Buffer – M7911 Promega ® 
GoTaq Hot Start Polymerase – M5001 Promega® 
Hank’s Buffered Salt Solution - HBSS 14025092 Life technologies®  
HCl – 435570 Sigma-Aldrich® 
Histoclear – HS200 National Diagnostics ® 
Insulin - Actrapid®, Novo Nordisk 
Interleukin-6 from mouse – II9646 Sigma-Aldrich® 
KCl – P9541 Sigma-Aldrich® 
Leptin – Recombinant Mouse Leptin CF – 498-OB-05M R&D Systems 
Methanol – 320390 Sigma-Aldrich® 
MgCl2 – Magnesium Chloride - M8266 Sigma-Aldrich® 
MgCl2x6H2O – Magnesium Hexahydrate - M9272 Sigma-Aldrich® 
Na3VO4 – Sodium Orthovanadate – S6508 Sigma-Aldrich® 
NaCl – Sodium Chloride – S7653 Sigma-Aldrich® 
NaF – Sodium Fluoride – 201154 Sigma-Aldrich® 
NaH2PO4X2H2O – Sodium phosphate dibasic dehydrate – 71662 Sigma-Aldrich® 
NaHCO3 – Sodium bicarbonate – S6014 Sigma-Aldrich® 
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Neutralization Buffer B – N3910 Sigma-Aldrich® 
Nuclease-free Water (not DEPC-treated) – Thermo Fisher Scientific® AM9932 
Paraformaldehyde – 158127 - Sigma-Aldrich® 
Penicillin/streptomycin – PEN/STREP - 15140-122 Life Technologies® 
PMSF – 36978 – ThermoFisher Scientific® 
Ponceau S Solution – P7170 Sigma-Aldrich® 
Ribose – R7500 Sigma-Aldrich® 
Sodium Dodecyl Sulphate – SDS- 436143 Sigma-Aldrich®  
Sodium Pyruvate – P5280 Sigma-Aldrich® 
Sucrose – S0389 Sigma-Aldrich® 
TEMED (N, N, N’, N’-Tetramethylethylenediamine) – 411019 Sigma-Aldrich® 
Tissue Preparation Solution – TPS - T3073 Sigma-Aldrich® 
TRITON X-100 – X100 Sigma-Aldrich® 
Trizma Buffer – T4661 Sigma-Aldrich® 
Trizol® Reagent – 15596-026 ThermoFisher Scientific 
Tween-20 – P2287 Sigma-Aldrich® 
Vectashield anti-fade mounting medium with DAPI – H-1000 Vector Laboratories® 
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ELISA Kits Used 
- Mouse IL-6 Quantikine ELISA M6000B (R&D Systems®) 
- Mouse/Rat Insulin, Glucagon Kit K15145C-1 (MSD®) 
- Mouse/Rat Leptin Quantikine ELISA Kit MOB00 (R&D Systems®) 
- SuperScript™ II Reverse Transcriptase – Invitrogen® 
- Ultra-sensitive Rat Insulin ELISA kit 90060 (CrystalChem®) 
 
Antibodies Used for Western Blotting 
Anti-GAPDH Primary Antibody:  GAPDH (D16H11) XP® Rabbit mAb #5174 – Cell 
Signaling Technology® 
Anti-Mouse Fluorescent secondary antibody: IRDye® 680LT anti-mouse IgG – 
Licor® 
Anti-Phospho-STAT3: Phospho-Stat3 (Tyr705) (D3A7) XP® Rabbit mAb #9145 – 
Cell Signaling Technology® 
Anti-Rabbit Fluorescent secondary antibody: IRDye® 680LT anti-Rabbit IgG – 
Licor® 
 
Antibodies Used for Immunohistochemistry 
Anti-Insulin antibody produced in Guinea Pig ab7842– Abcam®  
Anti-Glucagon antibody produced in Rabbit SAB451137 - Sigma Aldrich ® 
Alexa Fluor® 488 AffiniPure Goat Anti-Rabbit IgG 11-545-144 - Jackson 
ImmunoResearch® 
Alexa Fluor® 647 AffiniPure Fragment Donkey Anti-Chicken IgY 703-606-155 - 
Jackson ImmunoResearch® 
Anti-IL-6R antibody (ALEXA Fluor 488) produced in rabbit ABIN902559 - 
antibodies-online®  
Anti-NeuN antibody produced in Guinea Pig ABN90 - Millipore®  
Anti-GFAP antibody produced in Chicken ab4674- Abcam® 
Cy ™3 AffiniPure Donkey Anti-Guinea Pig IgG 706-165-148 - Jackson 
ImmunoResearch® 
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Mouse Colonies and Breeding Strategy 
All mice used for the purposes of these studies were housed in the local Animal 
Resource Unit with water and chow pellet available ad libitum, under a 12-hour 
dark/light cycle. All procedures were approved under license in accordance to the 
Animal (Scientific Procedures) under Project License 60/4120. C57Bl/6 mice were 
used as a wild-type model and represent the most widely used inbred strain and the 
first to have its genome completely sequenced. Importantly, C57Bl/6 mice fed a high-
fat diet develop mild to moderate hyperglycaemia and hyperinsulinaemia as well as 
obesity (Winzell & Ahren, 2004; Schreyer, et al., 1998). C57Bl/6 were used as the 
background strain for both the IL6Raflox/flox and NesCre1 models utilized to generate 
NesCreIL-6R KD mice in this study.   
B6 (SJL)-Il6ratm.1.1Drew/J animals (IL-6Rαflox/flox) were obtained from Jackson 
Laboratories. The target endogenous gene (in this case Il-6ra), is modified by 
homologous targeting in embryonic stem cells. A loxP site was inserted upstream of 
exon 4 and an frt-flanked neomycin resistance (neo) cassette followed by a second 
loxP site downstream of exon 6 of the Il6ra gene. Flp mediated recombination 
removed the neo cassette leaving exons 4 through 6 floxed (Sauer, 1998). These mice 
were generated at the University of Cincinnati through work lead by Prof. Angela 
Drew, and provide the framework for tissue specific deletion of the IL-6Rα gene, by 
crossing with strains bearing recombinase activity (McFarland-Mancini, et al., 2010).  
Primers for the IL-6Rα lox-P sites were obtained from Sigma Aldrich towards 
identification of IL-6Rαflox/flox homozygote colony founders (2 male, 2 female). 
NesCre1 (B6.Cg-Tg (Nes-cre) 1Kln/J) mice were obtained from Dr. Simon Arthur’s 
group at the MRC Protein phosphorylation unit, University of Dundee (Graus-Porta, 
et al., 2001) and maintained in a C57Bl/6 background. These mice were first 
generated by work lead by Prof. Rudiger J. Klein, at the Max Planck Institute of 
Neurobiology. Nestin is an intermediate filament protein that was initially identified 
in rat neuroepithelial precursor cells (Dubois, et al., 2006; Lendahl, et al., 1990; 
Graus-Porta, et al., 2001). A modified Cre gene was placed in between the 5.8kb rat 
Nestin promoter and the rat Nestin intron 2, which contains at least 2 enhancer 
elements. The Nestin Cre mouse was chosen as it offers the potential to generate 
primarily central nervous system deletion of the floxed gene, in this case the IL-6 
receptor (IL-6Rα) under the control of the promoter and enhancer (Troche, et al., 
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1999). However, homozygous NesCre-positive mice are embryonically lethal. 
Hemizygous NesCre-positive males were identified by standard PCR and 
subsequently crossed with IL-6Rαflox/flox mice, to generate NesCre1IL-6Rα knock-
down (NesCreIL-6Rα KD) and wild type littermates. Mice used exhibited no gross 
abnormalities, or differences in body weight, length and behavior. 
Figure 2.1: Schematic Representation of Breeding Strategy  
 
Genotyping of Nes-Cre and IL-6Raflox/flox mice by Standard PCR 
Founders for the IL-6Rαflox/flox colony (2 female, 2 male) were ordered in directly 
from Jackson Laboratories®, while founders for the NesCre1 (CRE) colony obtained 
from Simon Arthur’s lab (University of Dundee). The CRE colony was maintained by 
crossing founders with in-house bred C57Bl/6 wild type (WT) animals. The IL-
6Rαflox/flox colony was maintained initially by crossing offspring of the founder mice. 
This was done to ensure that only homozygous IL-6Rαflox/flox animals were crossed 
with CRE. Later on in the study, new IL-6Rαflox/flox founders were introduced to 
improve breeding and avoid genetic drift (Casellas, 2011). Animals were ear-notched 
within the first 4 weeks of their lives and samples were stored at -20OC until 
processing.  
DNA Extraction 
Ear-notch samples were suspended in suitable eppendorfs containing mixture of 100µl 
of extraction buffer (Sigma Aldrich®) and 25µl tissue preparation solution (TPS – 
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Sigma Aldrich®) at room temperature. The mixture was then briefly centrifuged to 
collect tissue and solution at the bottom of the tube and allowed 10 minutes at room 
temperature. This was followed by heating at 950C for 3 minutes, while the reaction 
was stopped by quickly removing from heat and adding 100µl of Neutralization 
buffer (Sigma Aldrich®). Samples were subsequently mixed and placed on ice. The 
resulting sample was deemed ready to be used to provide DNA for PCR amplification 
using and subsequent analysis by agarose gel electrophoresis. 
Primers 
Primers to confirm the presence of Cre activity were obtained from Sigma Aldrich® 
as advised by the Jackson® Laboratory website. 
FORWARD (5’) CRE PRIMER SEQUENCE: 
AAATGGTTTCCCGCAGACC 
REVERSE (3’) CRE PRIMER SEQUENCE: 
TAGCTGGCTGGTGGCAGATG 
 
The presence of IL-6Rα loxP sites was confirmed by using primers obtained from 
Sigma Aldrich® in accordance to directions provided by Jackson Laboratories®: 
FORWARD (5’) IL-6Rαflox/flox PRIMER SEQUENCE: 
GAAGGAGGAGCTTGACCTTGG 
REVERSE (3’) IL-6Rαflox/flox PRIMER SEQUENCE: 
AACCATGCCTATCATCCTTTGG 
The success of the PCR reaction was confirmed by means of a positive control primer 
pair obtained from Sigma Aldrich® in accordance to directions provided by Jackson 
Laboratories®: 
FORWARD (5’) oIMR 8744 PRIMER SEQUENCE: 
CAA ATG TTG CTT GTC TGG TG  
REVERSE (3’) oIMR 8745 PRIMER SEQUENCE: 
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GTC AGT CGA GTG CAC AGT TT 
Polymerase Chain Reaction Amplification 
DNA amplification by PCR was carried out using the GoTaq® Polymerase system 
(Promega®). The following mixture was prepared per sample: 
• 5x Go Taq Buffer – 5µl 
• 2mM dNTP mix – 2.5µl 
• Go Taq DNA Polymerase – 0.125µl 
• Forward and reverse primers were loaded from a 10mM stock for a final 
concentration of 0.5µM:  
[Cre or IL-6Raflox 5’ Forward Primer 10µM stock – 1.25µl] 
[Cre or IL-6Raflox 3’ Reverse Primer 10µM stock – 1.25µl] 
[Positive Control Forward Primer oIMR 8744 10µM stock – 1.25µl] 
[Positive Control Reverse Primer oIMR 8745 10µM stock – 1.25µl] 
• DNA – 2µl 
• PCR-grade water was used to make up a final volume of 25µl/sample 
Samples were then briefly centrifuged and placed in appropriate slots in the Applied 
Biosystems® Veriti® Thermal cycler. The following cycle was tailored by trial and 
error and was found to reproducibly allow for amplification of sample DNA. The 
PCR reaction was complete after 50 minutes and samples were held at 4OC until 
recovery. 
Figure 2.2: PCR Program used for DNA amplification 
 
 
 
 
 
 
 
• 95OC for 3 minutes 
• 94OC for 20 seconds 
• 64OC for 30 seconds  
• 72OC for 35 seconds 
• 94OC for 20 seconds 
• 58 OC for 30 seconds  
• 72OC for 35 seconds 
• 72OC for 35 seconds 
• 4OC HOLD 
X 12 
X 25 
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Agarose Electrophoresis 
Resulting amplified samples were then mixed with 5µl of appropriate Blue/Orange 
6X dye (Promega®) and briefly allowed to stand at room temperature. Products were 
then loaded in a 1% Agarose gel (2µl Ethidium Bromide/100ml) and ran at 120V for 
40 minutes, along with an appropriate marker; 100bp DNA ladder® (Life 
Technologies®).   Intact gels were then photographed using a UV camera and film 
was analyzed to identify and differentiate transgenic animals.  
Where CRE Primers were used for the PCR reaction, the presence of the CRE 
sequence within the genome of transgenic animals was confirmed by the appearance 
of a 600bp. Successful identification of CRE sequences from ear notch samples was 
used as an indicator incorporation of the Nestin promoter. Similarly, in samples 
incubated with primers the IL-6Rαflox sequence, the incorporation of loxP sequences 
flanking the IL-6Rα gene was confirmed by the appearance of a band at 671bp. 
Success of the PCR reaction was assessed by the appearance of the positive control 
band at 200bp (oIMR). NesCreIL-6Rα KD were essentially CRE-positive offspring of 
the NesCre+ x homozygote IL-6Rαflox/flox cross, while CRE-negative offspring were 
similarly identified by PCR as wild-type littermates.  
 
mRNA quantification by Real Time PCR analysis 
Wild-type (WT), NesCre+ (CRE) and NesCreIL-6Rαflox/flox (KD) male mice (>8 
weeks old, n=7), previously confirmed by PCR were euthanized by cervical 
dislocation and brains were isolated and dissected. Brain tissue was divided into 
Frontal Cortex, Hippocampal, Hypothalamic and Cerebellar regions by anatomical 
identification using an appropriate mouse brain atlas (Paxinos G & Franklin KBJ 
2001).  
Tissue was homogenized in 1ml of Trizol® reagent (Invitrogen®) and 0.2ml of 
chloroform was added and vigorously mixed by shaking. Samples were then left at 
room temperature for 15 minutes before being centrifuged at 12,000g for 15 minutes 
at 4OC. This allowed for phase separation, and the aqueous phase was transferred in a 
fresh tube where 0.5ml of isopropanol was added and mixed. The mixture was again 
left at room temperature for 10 minutes before being spun at 12,000g for 10minutes at 
4OC. The resulting supernatant was discarded and the RNA pellet was washed by the 
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addition of 1ml of 75% Ethanol. Washed samples were subsequently briefly mixed 
and centrifuged at 7,500g for 5 minutes at 4OC. The ethanol supernatant was then 
removed and the pellet was allowed to briefly dry for 15 minutes under a fume hood. 
Any remaining supernatant was carefully removed using a 2µl micropipette before 
dissolving the pellet in 30µl of PCR grade water. To facilitate dissolution, samples 
were transferred for 15 minutes at 60OC and mixed by pipetting.  
Following successful RNA isolation the purity and concentration of samples was 
examined using a nano-drop spectrophotometer in combination with the ND 8000® 
software. First-strand cDNA synthesis was carried out using SuperScript™ II RT. 1µg 
of RNA from each sample was suspended in 12µl of PCR grade water along with 50-
250ng random primers (Life Technologies®) and 1µl of dNTP mix (10mM each) and 
heated to 65OC for 5 minutes. Contents were collected at the bottom of the tube using 
brief centrifugation and quickly placed on ice. 4µl of 5x first-strand buffer 
(Invitrogen®) and 2µl of 0.1M DTT was loaded and mixed with the products and left 
to stand at room temperature for 5minutes. 200 units of SuperScript™ II RT were 
then thoroughly mixed with the products before letting them to stand at room 
temperature for 15 minutes. Samples were then incubated at 42OC for 50 minutes 
before inactivating the reaction by heating at 70OC for 15 minutes. 
Real time-PCR amplification was carried out with primers of the Il-6ra gene and 
Cyclophillin A as an internal control, using 6-carboxyfluorescein (FAM) as the 
fluorophore (Life Technologies®). Degradation of the primer probes releases the 
fluorophore from the quencher attached and allows for fluorescence to be detected in 
the quantitative PCR thermal cycler. More abundant genes produce lower values, as 
less thermal cycling is required for effective release of the fluorophore. Data obtained 
was analyzed according to the 2-∆CT method (Schmittgen & Livak, 2008). 
 
Brain Immunohistochemistry 
Adult male mice (>8weeks, n=2) were sacrificed using an appropriate CO2 chamber 
and brain was dissected and fixed in 4% paraformaldehyde in phosphate buffer 
solution (PBS) for 24 hours at 4°C. Tissue was embedded in paraffin and cut into 
20µm sections using a microtome, to be subsequently collected  in PBS. Slices 
collected in PBS were matched to Bregma coordinates using an appropriate mouse 
brain atlas (Franklin & Paxinos, 1997). Antigen retrieval was carried out by 
68 
 
Bregma -1.64 
Hypothalamus 
incubating slides in 10mM citric acid pH6.0 at 100°C for 30minutes. Upon cooling to 
room temperature in the citric acid for 20 minutes, sections were permeabilised in 
PBST (PBS + 0.5% Triton X-100) for one hour.  
Sections were treated for non-specific binding using 5% BSA in PBST for 1 hour at 
room temperature and transferred in humidified chamber. This was then used to 
incubate sections in 5% BSA in PBST containing primary antibody (Rabbit Anti-IL-
6R 1:100 (antibodies-online®); Guinea-pig Anti-NeuN 1:100 (Millipore®) and 
Chicken Anti-GFAP 1:100 (Abcam®)) overnight at 4°C. On the following day, 
primary solution was removed and sections were washed in PBST (3x10min) at room 
temperature for 30 minutes. Following the final wash, sections were incubated in 
appropriate secondary antibodies in PBST (Anti-rabbit Alexa Fluor® 488 1:1000; 
Anti-guinea pig-Cy™3 1:500; Anti-chicken Alexa Fluor® 647 1:500 (Jackson 
ImmunoResearch®)) for 1 hour at room temperature.  
Figure 2.3: Brain Slice Regions Used for Immunohistochemistry 
   
 
 
 
 
 
 
 
 
Secondary antibody was removed for a final wash in PBS (3x 10minutes) and distilled 
water (1x 10 minutes). Prior to mounting onto coverslips, sections were successively 
dehydrated in 70% ethanol for 2 minutes, 90% ethanol for 2 minutes and 100% 
ethanol (2x 5 minutes) and air dried for 30 minutes at room temperature. Coverslips 
were placed over sections along with Vectashield anti-fade mounting medium with 
 
Bregma 1.98 
Frontal Cortex 
Bregma -1.28 
Hippocampus 
Adapted from Paxinos G & Franklin 1997 (www.mbl.org) 
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DAPI (Vector Laboratories®) sealed with nail varnish and stored at 4°C until imaged. 
Fluorescent images were acquired using a confocal laser scanning microscope 
(Leica® TCS SP5 II) with x100 oil-objective lens. 
Cell counting was performed in region- and tissue area-matched (0.13mm2) images 
from frontal cortex, hippocampal and hypothalamic brain slice tissue from each 
mouse to confirm IL-6Rα down-regulation, as previously described (Bologna-Molina, 
et al., 2011). Furthermore, images acquired were used to conduct co-localization 
analysis of target proteins using the Volocity ® Image Analysis Software  (Barlow, et 
al., 2010).  
 
Examination of peripheral and central responses to Intra-peritoneal IL-6 
(50µg/kg) 
To examine the ability of transgenic and control animals to respond to exogenous IL-
6, adult (>8weeks old) KD, CRE and WT mice (n=2) were fasted for 4 hours and then 
received an IP injection of IL-6 (50mg/kg) prior to harvesting. Schedule 1 was carried 
out by cervical dislocation 30minutes following the injection. Central and peripheral 
tissue was harvested and snap-frozen using liquid nitrogen and stored in -80OC.   
 
Ex Vivo Brain Slicing Protocol for Rodent brains 
To examine the ability of the mediobasal hypothalamus of KD and control animals to 
respond to IL-6, adult female (>8weeks old) KD, CRE and WT mice (n=7) were 
fasted for 4 hours prior to brain harvesting and subsequent slicing and treatment. All 
glassware and surgical equipment used was autoclaved daily and care was taken 
towards ensuring sterility of the work surfaces used. 
Slicing solution: 50µM Adenine (daily), 1mM Ascorbic Acid (daily), 0.5mM CaCl2, 
7mM D-Glucose, 2.5mM KCl, 7mM MgCl2x6H2O, 28mM NaHCO3, 1.25mM 
NaH2PO4X2H2O, 1mM Ribose (daily), 235mM Sucrose (daily), 3mM Sodium 
Pyruvate (daily). 
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On experimental day, 200ml aliquots of slicing solution per brain were prepared and 
frozen for 2-3 hours. Each solution was thawed on ice into an “ice slurry” constitution 
and oxygenated (100% O2) for 20-30minutes before use.  
Incubation Solution: 50µM Adenine (daily), 1mM Ascorbic Acid (daily), 2mM CaCl2, 
10mM D-Glucose, 15mM D-Mannitol, 1mM MgCl2x6H2O, 125mM NaCl, 25mM 
NaHCO3, 1.25mM NaH2PO4X2H2O, 1mM Ribose (daily), 110mM Sodium Pyruvate 
(daily). 
On experimental day, 175ml aliquots of incubation solution/brain were prepared and 
oxygenated (95% Ο2/5% CO2) for 20-30minutes before and continuously during use.  
4.5mM Glucose Treatment Solution: 50µM Adenine (daily), 1mM Ascorbic Acid 
(daily), 2mM CaCl2, 4.5mM D-Glucose, 20.5mM D-Mannitol 1mM MgCl2x6H2O, 
125mM NaCl, 25mM NaHCO3, 1.25mM NaH2PO4X2H2O, 1mM Ribose (daily), 
110mM Sodium Pyruvate (daily) 
Brain Tissue Harvest: Schedule 1 was carried out using cervical dislocation prior to 
decapitation. All instruments were autoclaved during the 4 hour fasting period before 
use. This method was used in order to minimize stress to the animal and 
contamination of the brain from the CO2 gas chamber. Upon decapitation, the head 
was transferred into a petri dish of ice slurry of slicing solution with filter paper at the 
bottom. Damage to the cerebellum was to be expected. The brain was removed intact 
from the skull within 2 minutes. Skin and hair are removed from the scalp using a 
small pair of scissors. Using the same instrument a careful incision along the midline 
of the scalp was made, cutting from back to front, pushing upwards to avoid damage 
to the underlying soft tissue. While still in solution, brains were carefully removed 
from the skull by breaking the zygomatic and lightly pushing the brain upward from 
the frontal end, using the underside a small spatula. 
Individual intact brains were transferred into a petri dish containing the slicing 
solution ice slurry, and rested upside down on a small piece of filter paper. Using a 
blade, the cerebellum and a small proportion of the frontal cortex were dissected and 
discarded. The remaining brain was scooped using a small spatula or appropriate 
instrument and excess fluid was removed using filter paper. Superglue was used to 
attach the brain, frontal side-up onto the stage of the vibratome. The stage was 
attached to Vibratome and briefly left to stand to allow the brain to dry. The slicing 
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stage was then filled with slicing solution. The surrounding exterior bathing space 
was filled with ice and cold water, to minimise any unwanted tissue temperature 
increases during slicing.   
Figure 2.4: Ex Vivo Brain Slicing Protocol Representative photographs 
 
Brain slicing and slice treatment: 
Slices were chosen by anatomical identification of hypothalamic regions as 
demonstrated (Paxinos G & Franklin KBJ 2001) to contain regions of interest such as 
the glucosensing arcuate hypothalamic nucleus. Three 350µm slices were collected 
starting at approximately Bregma -1.05mm, with appearance of the arcuate 
hypothalamic area, up to approximately Bregma -2.05mm. Using a slice tip (cut and 
inverted 1ml pipette tip attached to appropriate sucker) desired slices were transferred 
into a petri dish. A sterile surgical blade was used to dissect out hypothalamic wedges 
from this region, using the third ventricle as an indicator. This would include the 
arcuate nucleus and aspects of the ventromedial, paraventricular and dorsomedial 
hypothalamus. 
Using a similar tip slices were transferred into a previously oxygenated (95% Ο2/5% 
CO2) incubation solution 175ml aliquot and kept at room temperature (22°C) for 15-
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20 minutes in appropriately constructed receptacles. Tissue was subsequently 
transferred to a 15ml flacon tube containing 5ml of incubation solution in a 34°C 
water bath. Slices were kept in the incubation solution with a constant supply of 
oxygen (95% Ο2/5% CO2), for 2 hours before being transferred into treatment 
solutions (4.5mM Glucose), with or without a stimulus (i.e. 20ng/ml IL-6) for 
30minutes.  At the end of the treatment, hypothalamic slices were transferred to an 
appropriate glass tube to be homogenized. Treatment solution was quickly removed 
and tissue was homogenized in 200µL of lysis buffer and stored at -80°C. 
Figure 2.5: Schematic Representation of Ex vivo Slice Regions Used 
 
 
 
 
 
 
 
 
 
 
Western Blotting  
Sample preparation 
Lysis Buffer: 100mM NaCl, 10mM NaF, 25mM Tris/HCl (pH 7.4), 10mM NaPPi, 
5mM EGTA, 1mM EDTA, 1mM Na3VO4, 1mM Benzamidine, 0.1 mM PMSF, 0.1% 
(v/v) β-mercaptoethanol, 1% (v/v) Triton X-100, 92mg/ml Sucrose 
Sample Buffer (4x): 4ml Glycerol (99.5%), 2.5mM Tris/HCl pH 6.8, 2mM Sodium 
Dodecyl Sulphate (SDS), a pinch of Bromophenol blue (Sigma®) and 10% (v/v) β-
mercaptoethanol added on the day of preparation. 
Adapted from Paxinos G & Franklin 1997 (www.mbl.org) 
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Ex Vivo Brain Slice sample preparation: On completion of the treatment procedure, 
hypothalamic arcuate nuclei wedges were homogenized in 200µL of lysis buffer and 
stored at -80°C. On the following day, samples were centrifuged at 13200 rotations 
per minute for 30 minutes to separate the soluble and insoluble components of the 
lysate. The supernatant was removed, mixed and analysed for protein concentration 
using the Bradford Micro-Assay (0-10µg/ml protein). Appropriate lysate volumes 
were then suspended in (4x) sample buffer to constitute a 40µg stock. 
Peripheral and Central Tissue sample preparation: Peripheral and central tissue 
harvested from the long-term and the short-term leptin sensitivity assessment studies 
was snap-frozen in liquid nitrogen and stored in -80°C. On the following day, tissue 
was homogenised in appropriate volumes (500µL for central and 1000µL for 
peripheral tissue) of lysis buffer, over dry ice to ensure no thawing of the tissue and 
denaturing of any resident protein. Muscle, white and brown adipose tissue was first 
pulverized into a thin powder by direct application of liquid nitrogen use of a mortar 
and a pestle over dry ice. Resulting homogenates were then briefly sonicated and 
centrifuged at 13200 rounds per minute (rpm) for 30minutes to separate the soluble 
and insoluble protein content. The supernatant was removed, mixed and analysed for 
protein concentration using the Bradford Micro-Assay (0-10µg/ml protein). Where 
lysates obtained exceeded the range of detection, diluents were prepared in distilled 
water. Appropriate lysate volumes were then suspended in (4x) sample buffer to 
constitute a 40µg stock. 
Buffers 
10x Tris-Glycine Running buffer: 121.1g Trizma base, 576g Glycine, 200ml of 20% 
SDS made up to 4L using distilled water. 
20x TBS & TBST: 193.6g Trizma base and 640g NaCl were dissolved and made up 
to 3.2 L with ddH2O. The pH of the solution was adjusted to 7.4 with concentrated 
HCl and volume made up to 4 L using ddH2O. 2 ml of Tween-20 were added to 
100ml of 20x TBS and made up to 2 L with ddH2O, resulting in TBST (1x). 
Transfer Buffer: 11.62g Trizma base, 5.86g Glycine, 1600ml dH2O made up to 2L 
using 400ml Methanol (ACS grade).  
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Lower Gel Buffer - Tis-HCl pH 8.8: 1.5M Tris; 36.5g pH to 8.8 with concentrated 
HCl  
Upper Gel Buffer – Tris-HCl pH 6.8: 0.5M Tris; 6.06g pH to 6.8 with concentrated 
HCl 
 
SDS-PAGE  
Table 1: Reagent Volumes Used for Polyacrylamide Gel Preparation 
Lower Gel (10%) 3 Gels 4 Gels 6 Gels  
dH20 6.2ml 8.3µl 12.4ml 
Tis-HCl pH 8.8 4.7ml 6.3µl 9.3ml 
30% Acrylamide 5.6ml 7.5µl 11.3ml 
10% SDS 165µl 220µl 330µl 
TEMED 16.5µl 22µl 33µl 
20% APS 83µl 110.7µl 166µl 
Upper Gel (4%) 3 Gels 4 Gels 6 Gels 
dH20 4.2ml 5.6ml 8.4ml 
Tis-HCl pH 6.8  1.9ml 2.5ml 3.8ml 
30% Acrylamide 1.25ml 1.7ml 2.5ml 
10% SDS 75µl 100µl 150µl 
TEMED 8µl 10.7µl 16µl 
20% APS 75µl 100µl 150µl 
SDS-Poly-Acrylamide Gel Electrophoresis (SDS-PAGE) was utilized in order to 
examine the effects of experimental treatments at the protein level. Successfully 
casted gels were transferred to the running apparatus (Bio-Rad®) and the tank was 
filled with running buffer. Running buffer was prepared in a 10x stock and 2L of 1x 
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were prepared daily. Tris-Glycine Running buffer (1x) was used to completely fill the 
tanks, ensuring the space between gel plates to be completely filled. Wells were 
washed with running buffer using a syringe and 5µl of appropriate protein marker 
(Seeblue Plus2 Invitrogen ®) were loaded in the first well. 10µg of protein was 
loaded in each well, according to the calculations made during the Bradford assay. 
Upon successful loading, gels were run at 150V for approximately 1hour 45min (or 
until the blue dye ran out of the gels).  
Proteins were separated by electrophoresis, to be transferred to a suitable membrane 
to be detected by using antibodies specific to target proteins of interest. Electro-
blotting, uses an electric current which pulls proteins from the gel into nitrocellulose 
membranes used, maintaining the organization they had within the gel.  A transfer 
cassette (BioRad®) was prepared, in which the membrane was placed on top of the 
gel with a stack of filter paper on either side. The entire stack was placed in 
appropriate transfer buffer, to allow for movement of proteins from the gel to the 
membrane in the presence of electric current. Transfer buffer was prepared fresh on 
the day of running. An ice pack was added to the tank or the whole tank was placed in 
an ice bucket before initiating transfer, as increases in temperature would disturb 
effective transfer. The tank was filled with appropriate volume of transfer buffer to 
fill the tank and gels transferred at 100V for 1 hour. 
Protein Detection 
Transfer cassettes were carefully disassembled and membranes removed from the 
arrangement using a forceps, to be placed in a square petri dish containing 5-10ml of 
Ponceau S dye (Sigma Aldrich ®) to confirm effective protein transfer. Membranes 
were then briefly washed in Tris-buffered saline with Tween-20 (TBST), ensuring 
that the membrane was free of any staining. To account for any non-specific protein 
binding membranes were blocked for an hour at room temperature using 10 ml of 
10% non-fat milk/TBST per membrane. Membranes were then briefly (3x20minutes) 
washed in TBST before being treated with 10ml of primary antibody at appropriate 
recommended dilution overnight at 40C. Primary antibodies were prepared in 5% 
bovine serum albumin (BSA)/TBST at 1:1,000 dilution apart from GAPDH that was 
prepared at 1:2,000. Primary antibodies for GAPDH (GAPDH (D16H11) XP® Rabbit 
mAb #5174) and pSTAT3 (Phospho-Stat3 (Tyr705) (D3A7) XP® Rabbit mAb 
#9145) were purchased from Cell Signaling Technology ®. 
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On the following day, membranes were again washed (3x20minutes) in TBST at 
room temperature and incubated in 10ml of anti-rabbit (IRDye® 680LT anti-Rabbit 
IgG) or anti-mouse (IRDye® 680LT anti-mouse IgG) fluorescent secondary antibody 
in 5% BSA/TBST at 1:10,000. Membranes were then washed in TBST to account for 
any background staining (3x20minutes). This allowed protein detection and 
densitometry to be carried out using a Licor® chemiluminescence scanner and 
appropriate Licor® Odyssey software.   
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Study Plan for Evaluation of the role of central IL-6Rα signaling in the 
metabolic response to high fat diet 
Male adult offspring (>8weeks) resulting from crosses of NesCre+ and IL-6Rαflox/flox 
mice genotyped and identified as NesCreIL-6Rα Knock-Down (KD) or wild-type 
littermate (WT) were placed on a 20-week study plan towards evaluation of the role 
of the receptor system in diabetic disease. Similarly, adult male NesCre+ (CRE) 
animals were also examined to be used as a control. For each genotype (WT, CRE 
and KD); 2 groups of 8-11 animals were examined for a period of 20 weeks in a 12-
hour light/12-hour dark cycle. During the study groups from each genotype were 
assigned to be supplied either standard chow (SC; CRE n=9, KD n=9) or a 60% high-
fat diet (HFD; CRE n=7, KD n=11) and water at libitum. Where a HFD was supplied, 
animals were allowed 3 weeks of habituating themselves to the diet, and a 50:50 
mixture of HF and SC diet was provided in the first 2 weeks. In a recent report 
possible metabolic pitfalls of Nes-Cre mediated recombination were outlined, (Harno, 
et al., 2013) which arise as a consequence of differences in lean body mass and body 
length and absolute body weight compared to C57B/l6 mice. This was also observed 
in comparing CRE mice to WT mice and towards this, the CRE mice were used as a 
control group. 
Table 2: Study Plan towards Metabolic Phenotyping of in KD and Control 
animals on SC and HFD  
PROCEDURE STUDY WEEK 
Weighing 1-20 
EchoMRI Body Composition Evaluation 3,7,12,14,20 
Oral Glucose Tolerance Test 10,15,19 
Intra-peritoneal Insulin Tolerance Test 6,12,14 
Food Intake 9 
Oral Glucose Stimulated Insulin 
Secretion 
19 
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Body Composition Evaluation by echo MRI™ 
The echo MRI™ system was set-up and the appropriate checks were carried out using 
the supplier-provided software briefly before the start of the procedure. Animals were 
weighted briefly before entering the machine, where their body composition was 
recorded (fat vs. muscle mass) in triplicate. Water content was not measured. Mean 
body composition was calculated for each animal and means were extracted for 
statistical analysis. 
 
Oral Glucose (50µg) Tolerance Test  
Experimental animals were fasted 4 hours prior to the start of the procedure. At Time 
0 basal blood glucose levels were measured using a Contour® Glucose meter by 
drawing blood from the tail vain of animals. Subsequently, mice were administered an 
oral dose of 50mg glucose by means of a gavage needle and allowed to move freely. 
Blood glucose levels were measured using tail vain sampling from freely moving 
animals 15, 30, 45, 60, 90 and 120 minutes following administration. On completion 
and upon inspection, animals were supplied with food according to their diet.  
Figure 2.6: Schematic Representation of Oral Glucose Tolerance Protocol 
  
Time 
-4hours         0  15min 30min 45min 60min 90min 120min  
Fasting 
Glucose Measurement 
GLUCOSE  
79 
 
Intra-peritoneal Insulin (1U/100g) Tolerance Test  
On experimental day, animals were fasted for at least 4 hours prior to the start of the 
procedure and baseline (Time0) glycaemia was recorded using a Contour® Glucose 
meter by drawing blood from the tail vain of animals. Mice were then administered an 
intra-peritoneal (IP) injection of 1U of insulin/kg weight and allowed to move freely. 
Following administration, glycaemic levels were measured using tail vain sampling 
from freely moving animals 15, 30, 45, 60 and 90 minutes. On completion and upon 
inspection, animals were supplied with food according to their diet.  In cases where 
hypoglycaemic bouts were encountered animals were administered an intra-peritoneal 
dose of 50mg glucose, allowed to recover and excluded from the remainder of the 
experiment. 
Figure 2.7: Schematic Representation of Intra-peritoneal Insulin Tolerance Protocol 
 
Oral Glucose Stimulated Insulin Secretion 
Similarly to the oral glucose-tolerance tests, mice were fasted for 4 hours prior to 
measurement of baseline glycaemia (Time 0) using tail vain blood. Larger samples of 
blood were collected at each time point (approx. 30µl) for evaluation of the 
endogenous secretion of insulin by means of an ultra-sensitive enzyme-linked 
immunoabsorbent assay (ELISA) provided by CrystalChem ®. Similarly, mice were 
administered an oral dose of 50mg glucose by means of a gavage needle and allowed 
to move freely, but larger volume of tail vain blood were collected at 3, 15 and 30 
minutes following administration. Samples from each animal at their respective time 
points were collected in EDTA-coated tubes and centrifuged at 1300g for 10 minutes 
to separate blood serum. Serum was collected and immediately stored at -80OC for 
Time 
      -4hours   0 15min 30min 45min  90min  
Fasting 
Glucose Measurements  
INSULIN  
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processing. On completion of the experiment and upon inspection, animals were 
supplied with food according to their diet.  
Figure 2.8: Schematic Representation of Oral Glucose Stimulated Insulin Secretion 
 
Food Intake Evaluation 
Animals participating in the phenotyping study plan were separated from their normal 
cage-mates at the start of experimental day, and placed into individual cages for the 
subsequent 24hours, whereby food intake was evaluated at 4, 8 and 24hours (W9). 
Following completion of the protocol animals were returned to their normal cages.  
 
Tissue Harvest 
Following the end of the study plan and subsequent examination using CLAMS 
(described below); experimental animals (on SC or HFD) were fasted for 4 hours 
prior to being euthanized. Frontal Cortex, Hippocampal, Hypothalamic and Cerebellar 
regions were isolated by anatomical identification using an appropriate mouse brain 
atlas (Paxinos G & Franklin KBJ 2001). Heart, kidney, lung, liver, muscle, pancreas, 
spleen, white- and brown adipose tissue was isolated in accordance with the anatomy 
of the laboratory mouse. Harvested tissue was snap-frozen using liquid nitrogen and 
stored in -80OC. Trunk blood (approx. 30µl) was collected in tubes containing 
appropriate anti-coagulant (EDTA) for isolation of plasma and examination of 
hormone levels by ELISA. Samples were collected and centrifuged at 1300g for 10 
minutes to separate blood plasma. Plasma was collected and immediately stored at -
80OC for processing. 
  
Time 
-4hours            0  3min 15min 30min 
Fasting 
Glucose Measurements  
GLUCOSE  
Blood Sampling  
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Metabolic phenotyping using the CLAMS® Activity Monitor 
The activity monitoring system was started and appropriate measurements and 
equilibration was allowed, according to the manufacturer’s specifications (Columbus 
Instruments®). Following the end of the 20-week study plan, experimental animals 
were weighted briefly before being examined using the CLAMS® Animal 
Monitoring System. KD and control animals were provided a 12:12 dark: light cycle, 
and their respective diets (SC or HFD) and water ad libitum. Measurements were 
taken over 48hours, following an initial 24hour acclimatization period. The well-
being and the availability and accessibility to food and water of the animals was 
checked regularly during this period. Similarly, care was taken to ensure that software 
output parameters concerning the functionality of the animal monitoring system 
remained within suggested specifications. Output files produced allowed for 
monitoring and comparison of metabolic parameters (mean total food intake, mean 
activity and mean respiratory exchange ratio) during the 2 phases of the daily light 
cycle.  
Figure 2.9: Representative Photograph from the CLAMS/Oxymax® System 
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In vivo Leptin (50µg/kg) sensitivity assessment  
As examination of the effects of leptin without accounting for the stress of intra-
peritoneal injections on body weight and food intake was not possible within the 
context of the 20-week study plan, a separate experiment was set up. A small cohort 
(n=6) of female adult (>8weeks) age-matched animals on SC was used. KD, CRE and 
WT SC animals were injected were kept on standard chow on a 12:12 night to dark 
cycle were used. Animals were separated from their cage mates and housed 
individually for a total of 3 weeks. An IP injection of saline was administered every 
day at dusk for the first 2 weeks of the protocol. Body weight and general health of 
the animals was recorded daily. 
Body weight and additionally, daily food intake was recorded over a 5-day period 
during the 3rd week. All animals received an IP injection of saline on the first day. On 
the second day, an IP injection of 50µg/kg leptin was administered to half the 
experimental animals from each genotype and the rest received an IP injection of 
saline (control group). On the 3rd day, the control group received IP leptin, while the 
previously leptin-treated animals received IP saline. In this way, we were able to 
maintain an internal control for the effects of leptin on body mass and food intake. IP 
Saline was administered to all animals for the 4th and 5th day.   
Table 3: Schematic Outline of the Leptin Sensitivity Assessment Protocol 
PROCEDURE SYMBOL 
IP Saline 
 
IP Leptin 
 
IP Leptin/Saline & Tissue Harvest 
 
Food Intake and Body Weight Assessment 
 
 
 
Animals were allowed to recover over the weekend. At the start of the 4th week, 
animals were fasted for 4 hours and schedule 1 was carried out by cervical dislocation 
1 hour following a 3rd round of IP leptin injections to half the animals for each 
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
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genotype (n=3), while the rest (n=3) received saline. Central and peripheral tissue was 
harvested and snap-frozen using liquid nitrogen and stored at -80OC. Tissue was 
processed for western blotting as described in previous sections.   
 
Ex vivo pancreatic β cell Isolation and Stimulation 
Collagenase Solution: A 10ml aliquot of Hank’s Buffered Salt Solution (Life 
technologies HBSS 14025092) was supplemented with 100µl of 25mg/ml 
Collagenase (Liberase TL – Roche 5401020001) was prepared per animal. 0.75ml 
was then dispensed in a separate falcon tube to collect pancreatic tissue upon 
dissection. 
Quenching Buffer: 500ml of HBSS was supplemented with 50 ml of 10% foetal calf 
serum and 5ml of penicillin/streptomycin and stored at 4oC. 
Overnight Solution: Dulbecco’s Modified Eagle Medium (DMEM) was supplemented 
with 1000mg of glucose, 50 ml of 10% foetal calf serum and 5ml of 
penicillin/streptomycin and stored at 4oC. 
Tissue Isolation: KD, CRE and WT adult female mice (>8weeks, n=8) were sacrificed 
using an appropriate CO2 chamber. The bile duct was identified and carefully cleared 
of connective tissue. By following the physiological direction of the duct, ventrally 
from the liver, its route to the pancreas can be identified. The small intestine was 
clamped proximally to the point of contact of bile duct and pancreas. The bile duct 
was carefully incised using spring scissors and a micro-renethane cannula attached to 
a needle was inserted and held in place by suturing. The pancreas was subsequently 
inflated using approx. 5ml of collagenase solution per animal and carefully dissected 
out to be collected in 0.75ml of ice cold Collagenase solution. Pancreatic tissue was 
then incubated at 37oC for 15 minutes. Tissue was subsequently exposed to 10ml of 
Quenching buffer and shaken vigorously for 15sec. An appropriate 500µm net was 
fitted over a 50ml falcon tube and pancreatic tissue in Quenching buffer was poured 
through. The tube and net were washed with an additional 10ml of Quenching buffer 
and centrifuged for 1 minute at 12,000rpm. Quenching buffer was aspirated and 
replaced by fresh 20ml to re-suspend the pellet formed. Following 3 washes, the pellet 
was suspended in 5ml of Quenching buffer and placed on ice. 
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Islet Identification: Pancreatic tissue was transferred to a 90mm Petri dish. Islets were 
identified under a light microscope and picked out by using head-polished glass 
Pasteur pipettes and a rubber tip. They were quickly transferred to Calcium and 
Magnesium-free HBSS and incubated in Overnight Solution at 37oC (95% O2, 
5%CO2).  24 hours late, islets were incubated in 20mM DMEM solution (5% FBS) at 
37oC (95% O2, 5%CO2) for one hour, before media was quickly frozen at -80oC to 
subsequently examined in terms of insulin and glucagon content by ELISA. 
 
Pancreatic Immunohistochemistry 
Tissue Isolation: KD and CRE adult female (>8weeks, n=4) were sacrificed using an 
appropriate CO2 chamber and pancreas was dissected and fixed in 4% 
paraformaldehyde in phosphate buffer solution (PBS) for 24 hours at 4°C. Tissue was 
embedded in paraffin and cut into 5µm sections using a microtome provided by the 
University of Dundee Tissue bank. Sections were collected and coated on glass 
microscope slides.  
Pancreatic Slice Staining: Slides were incubated at 60°C for 45 minutes and then 
immersed in Histoclear for 30 minutes to remove wax. They were quickly immersed 
in an appropriate rack containing 100% ethanol for 10 minutes followed by fresh 
100% ethanol for five minutes and a final wash in running water for 10 minutes. 
Slides were incubated in 10mM citric acid pH6.0 at 100°C for 30minutes. Upon 
cooling to room temperature in the citric acid, sections were permeabilised in PBST 
(PBS + 0.5% Triton X-100) for one hour. Following this antigen retrieval step, wells 
were drawn around tissue sections on the slide, using a PAP pen. 
Sections were then blocked using 5% BSA (blocking solution) in PBST and then 
incubated with primary antibody in blocking solution (insulin (Abcam®) 1:100 and 
glucagon 1:100(Sigma-Aldrich ®) in a humidified chamber overnight at 4°C. 
Following a 30minute wash in in PBST (3x10min) sections were incubated in 
appropriate secondary antibodies in PBST (Cy™3 (Jackson ImmunoResearch®) 
1:250 and Alexa Fluor® 488 (Life Technologies®) 1:500) for 1 hour at room 
temperature. Secondary antibody was removed and sections were washed in PBS (3x 
10minutes) and water (1x 10 minutes).  
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Sections were successively dehydrated in 70% ethanol for 2 minutes, 90% ethanol for 
2 minutes and 100% ethanol (2x 5 minutes) and allowed 30 minutes to dry at room 
temperature. Coverslips were placed over sections along with Vectashield anti-fade 
mounting medium with DAPI (Vector Laboratories®) that were sealed with nail 
varnish and allowed to dry. Stained sections were stored at 4°C in the dark until 
image acquisition. Fluorescent images were acquired using a confocal laser scanning 
microscope (Leica® TCS SP5 II) with x40 oil-objective lens.  
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Chapter 3: Validation of NesCre-mediated IL-6Rα Knockdown in 
Mice 
The main aim of my studies was to generate and validate the brain-specific down-
regulation of the IL-6Rα mice as to interrogate the role of central cytokine signaling 
in DIO and T2D. Cre/lox technology has been widely used in science to generate 
tissue specific genetic mutants, aimed at the investigation of specific gene functions in 
everyday physiology and disease (Utomo & al., 1999). It utilized the 34kb-long P1 
bacteriophage loxP   sequence (a sequence that is normally absent in mammalian 
tissue) and the activity of the cre gene that codes for a protein that mediates DNA 
recombinase activity when locating loxP sequences. As a consequence of these 
properties, where loxP sites are successfully inserted into the genome of organisms 
expressing Cre, the Cre protein leaps into action, causing recombination at the locus 
flanked by loxP (Utomo & al., 1999; Pechisker, 2004).  
Figure 3.1: Schematic Representation of Cre Technology -mediated Gene Disruption 
 
 
 
 
 
A variety of Cre models are commercially available, that allow for tissue specific 
targeting of Cre activity. Crossing such mice with mouse strains that bear a target 
gene flanked by 2 loxP sites in direct orientation, would result in offspring that 
experience inactivation of the target gene in cells expressing Cre recombinase activity 
(Kuhn & Torres, 2002; Le & Sauer, 2000). Nestin Cre mice have been previously 
used in a number of studies investigating the effects of brain-specific disruption of 
target proteins in metabolism (Zhang, et al., 2008; Loh, et al., 2012; Pedroso, et al., 
2014). Nestin Cre mice (B6Cg-Tg (Nes-cre) 1 Kln/J) were thus crossed with 
homozygous IL-6Rα floxed mice, towards the generation of a mice where the 
cytokine receptor system was disrupted in the brain, specifically. 
Adapted from Pechisker, 2004 
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Identification and Verification of B6.Cg-Tg (Nes-cre) 1Kln/J mice by PCR 
NesCre mice (Graus-Porta, et al., 2001) were generously donated by Dr Simon 
Arthur’s lab (MRC Protein Phosphorylation Unit, the University of Dundee) and 
samples were obtained for genotyping purposes. Initial verification of NesCre mice 
was carried out following the standard PCR (Jackson Laboratories®), using the 
GoTaq® Polymerase system (Promega®). DNA extracted from colony founders was 
used as a positive control.  As shown in Figure 3.2, using a 1% Agarose gel, a band at 
600 base pairs was evident in Nes-Cre-positive animals, as predicted by the sequence 
of the Cre primers used. The appearance of band at 200bp was incorporated in the 
protocol, by using primers for a non-coding region in mouse DNA as described in 
Methods. This acted as control for the success of PCR reactions. 
Figure 3.2:  Identification of animals bearing Cre activity by Standard PCR 
 
 
 
 
 
 
 
 
Figure 3.2: Image taken from a random set of animals from our NesCre X WT crosses. In lanes 1 & 2 
DNA extracted from the colony founders examined for the presence of CRE activity. As predicted by 
our primer-set, CRE activity was confirmed by the appearance of a band at 600bp. The success of PCR 
reactions was assessed by the appearance of a band at 200bp, coded from a ubiquitously expressed 
DNA fragment in the mouse genome. 
1     2 
1    2 
600bp 
200bp 
600bp 
200bp 
Lanes 1, 2 = Cre + Control 
88 
 
Identification and Verification of B6; SJL-Il6ratm1.1Drew/J mice 
In a similar fashion, incorporation of the loxP sites in IL-6Rαflox/flox mice was 
confirmed by standard PCR in accordance to the Jackson Laboratories® directions, 
using the KOD Hot Start Polymerase ® system. As shown in Figure 3.3, using a 1% 
Agarose gel, a band at 671 base pairs was evident in transgenic animals.  As 
mentioned above, primers for non-coding regions of the mouse genotype allowed 
assessing the success of PCR reactions by the appearance of band at 200bp. 
Figure 3.3: Identification IL-6Rαflox/flox animals by PCR 
 
 
 
 
 
Figure 3.3: The image was taken using DNA extracted from a random set of animals from our IL-
6Rαflox/flox colony. DNA extracted from the colony founders was used as a positive control, whereby the 
incorporation of the loxP sites flanking the IL-6Rα gene results in the appearance of a band at 671bp. 
Guidelines provided by the Jackson Laboratory®, suggested the appearance of a single band at 530bp 
to indicate WT animals, while a doublet at 530 and 671bp indicates that animals are heterozygotes for 
the loxP site. Homozygous IL-6Rαflox/flox mice were bread and naturally no heterozygote or WT 
offspring were identified. Positive control band can be observed at 200bp, confirming sample 
amplification. 
Crossing the CRE positive heterozygote animals with homozygote IL-6Rαflox/flox mice 
was expected to yield IL-6Rα knock-down in at least 1 in 4 of their resulting 
offspring. The incorporation of at least one loxP site in the genome from the 
homozygote IL-6Rαflox/flox parent should result in down-regulation of the IL-6Rα 
system in tissue where the Nestin promoter is active. Subsequently, in tissue where 
the Nestin promoter is expressed, Cre activity will be promoted and disruption of the 
gene was expected to take place. Since the offspring of heterozygote Nes-Cre and 
homozygote IL-6Rαflox/flox mice are guaranteed to have at least one copy of the flox 
gene, genotyping for the presence of CRE activity, allowed us to distinguish between 
Nestin-Cre IL-6Rα KD and wild-type litter-mates of the cross.  
671bp 
200bp 
Lane 1 = Flox 
Control 
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Examination of Brain IL-6Rα Gene Expression by Real Time-PCR 
To validate the effects of the breeding strategy, Real Time-PCR was used to assess 
IL-6Rα mRNA expression in the brain of animals previously classified as WT, 
NesCre+ and NesCreIL-6Rα KD by standard PCR. IL-6ra mRNA abundance in the 
frontal cortex, hippocampus, hypothalamus and cerebellum of adult (>8weeks) WT, 
CRE and KD mice (n=7-8) was calculated using the 2-∆CT method and normalized to 
similarly calculated Cyclophillin A abundance.  Statistical analysis of normalized data 
was carried out using the Mann Whitney U-test. This allowed for non-parametric 
examination of the null hypothesis that Il-6ra mRNA expression was similar in the 
brain of KD and control animals, against the alternative hypothesis that control 
animals exhibit increased receptor mRNA compared to the KDs.  
Figure 3.4.1: Comparison of IL-6ra mRNA between NesCre IL-6Rα WT and 
Nes-Cre+ mice 
 
Figure 3.4.1: Adult (>8weeks old) male mice (WT n= 7; NesCre+ n=7) were used from each genotype. 
Error bars indicate +/-SEM. Relative IL-6ra mRNA expression was compared using the 2-∆CT 
method, in cortical (p=0.06), hippocampal (p=0.14), hypothalamic (p=0.22) and cerebellar (p=0.049) 
brain tissue.  
Cerebellar IL-6ra mRNA was significantly (55%) decreased in CRE compared to WT 
animals (p=0.049), but not in the frontal cortex (p=0.06), hippocampus (p=0.14) or 
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hypothalamus (p=0.22) even though an overall trend of reduced IL-6ra mRNA was 
observed (Figure 3.4.1). In the frontal cortex, IL-6 receptor mRNA in NesCre+ mice 
was just over 50% the receptor mRNA expression of WT animals. Similarly, in the 
hippocampus a 40% reduction in IL-6Rα mRNA was observed, while in the 
hypothalamus a 35% reduction was noted. Since we have chosen to target the IL-6Rα 
system and evaluate its role in metabolism, the comparative between WT and 
NesCreIL-6Rα KD animals would not be appropriate. Since KD animals are NesCre+ 
themselves, the down-regulation would only be relevant in comparison to CRE 
animals.  
Figure 3.4.2:  Comparison of IL-6ra mRNA between NesCreIL-6Rα KD and 
NesCre+ mice 
 
Figure 3.4.2: Comparison of Il-6ra mRNA between NesCreIL-6Rα KD and NesCre+ mice 
Adult (>8weeks old) male mice (KD n= 6; NesCre+ n=7) were used from each genotype. Error bars 
indicate +/-SEM. Relative IL-6ra mRNA expression was compared using the 2-∆CT method, in frontal 
cortex (p=0.56), hippocampus (p=0.0183), hypothalamus (p=0.128) and cerebellum (p=0.68).   
Despite this, the Nes-Cre promoter system does however induce to brain-targeted 
disruption of Il-6ra mRNA when comparing in CRE and KD brains. Significant 
down-regulation of receptor mRNA was observed in the hippocampus (p=0.0183) and 
hypothalamus (p=0.0128) of KD compared to CRE controls, but not in the Frontal 
Cortex (p=0.56) or Cerebellum (p=0.68) (Figure 3.4.2). In the hippocampus a 32% 
reduction in IL-6Rα mRNA was observed, while a 50% down-regulation in receptor 
mRNA (47.80% +/-6.4%, p=0.0128) was observed in the hypothalamus. In the frontal 
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cortex (84.7+/-22.8%, p=0.56) and cerebellum (89.5+/-9.3%, p=0.68), KD animals 
exhibited modest reductions in receptor mRNA expression compared to control 
animals.  
Il-6ra mRNA in the 3 genotypes was fairly ubiquitous, even though the hippocampus 
and hypothalamus exhibited the highest expression (Figure 3.4.3). Significant 
differences were observed in WT animals only when comparing hippocampal to 
cerebellar Il-6ra mRNA expression (p=0.005). In NesCre+ mice both hippocampal 
(p=0.02) and hypothalamic (p=0.05) Il-6ra mRNA was significantly elevated 
compared to the cerebellum, but not the frontal cortex (p=0.34 and p=0.54). On the 
other hand, differences in receptor expression among the different brain regions failed 
to reach significance in NesCreIL-6Rα KD mice. 
Figure 3.4.3: Comparison of Il-6ra mRNA between Brain Regions in KD and 
control mice 
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Figure 3.4.3: Comparison of Il-6ra mRNA between Brain Regions in KD and control mice 
Adult (>8weeks old) male mice (PURPLE: KD n= 6; RED: NesCre+ n=7; GREEN: WT n=7) were 
used from each genotype. Error bars indicate +/-SEM. Relative IL-6ra mRNA expression was 
compared using the 2-∆CT method normalized to Cyclophillin A. WT: Frontal Cortex vs. 
Hippocampus, p=0.65; Frontal Cortex vs. Hypothalamus, p>0.99; Frontal Cortex vs. Cerebellum, 
p=0.09; Hippocampus vs Hypothalamus, p=0.78; Hippocampus vs Cerebellum, p=0.05; Hypothalamus 
vs Cerebellum, p=0.07. NesCre+: Frontal Cortex vs. Hippocampus, p=0.39; Frontal Cortex vs. 
Hypothalamus, p=0.54; Frontal Cortex vs. Cerebellum, p=0.56; Hippocampus vs Hypothalamus, 
p=0.99; Hippocampus vs Cerebellum, p=0.02; Hypothalamus vs Cerebellum, p=0.05. KD: Frontal 
Cortex vs. Hippocampus, p=0.96; Frontal Cortex vs. Hypothalamus, p=0.93; Frontal Cortex vs. 
Cerebellum, p=0.79; Hippocampus vs Hypothalamus, p=0.71; Hippocampus vs Cerebellum, p=0.51; 
Hypothalamus vs Cerebellum, p=0.99.  
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Examination of the pSTAT3 Response to IL-6 in Brain Tissue 
To functionally assess the effects of Nes-Cre-mediated down-regulation of the IL-6 
receptor gene in transgenic and control animals, a standard dose of IP IL-6 (50µg/kg) 
in animals previously genotyped by standard PCR. Responses were not quantified as 
the cost associated with treating a number of animals from each genotype with IL-6 
was a limitation (n=2).  
Figure 3.5.1: Hypothalamic pSTAT3Responses to IP IL-6 (50µg/kg) injection 
 
 
 
 
 
Figure 3.5.1: Adult male mice (>8weeks) from each genotype were used. Loading Order: (1) WT; (2) 
WT + IL-6; (3) CRE; (4) CRE + IL-6; (5) KD; (6) KD + IL-6. Representative blot, n=2 from each 
genotype. pSTAT3 – 79/88 kDa; Loading Control: GAPDH – 37 kDa (Cell Signaling®). 
Despite our attempts to confirm our initial findings at mRNA level using an antibody 
against the IL-6Rα, we were unable to secure an antibody that was sensitive and 
specific enough for the validation of such subtle effects in such a complex organ such 
as the brain. Targeting of the receptor using IL-6Rαflox/flox
 
mice leads to disruption of 
the cytokine-binding domain. Since most commercial antibodies available are 
targeted to the terminal domains of the receptor, quantification of differences at 
protein level was not possible. We thus examined the pSTAT3 response to a standard 
dose of peripheral IL-6 in KD, CRE and WT brain (hippocampus, hypothalamus and 
cerebellum). Despite our attempts to assay and illustrate the pSTAT3 response to IL-6 
in the frontal cortex, we were unsuccessful in a number of attempts. 
 
 
  
IL-6   -       +       -      +       -       +         
GAPDH 
pSTAT3 
WT CRE KD 
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Figure 3.5.2: Hippocampal pSTAT3 Responses to IP IL-6 (50µg/kg) injection 
 
 
 
 
 
 
 
Figure 3.5.2: Adult male mice (>8weeks) from each genotype were used. Loading Order from left to 
right: (1) WT; (2) WT + IL-6; (3) CRE; (4) CRE + IL-6; (5) KD; (6) KD + IL-6. Representative blot, 
n=2 from each genotype. pSTAT3 – 79/88 kDa; Loading Control: GAPDH – 37 kDa (Cell 
Signaling®). 
As mentioned in the introduction, circulating interleukin-6 is able to pass the blood 
brain barrier and mediate its associate signaling cascades in the brain. Figures in this 
section demonstrate IP IL-6 treatment to induce increases in phosphorylated STAT3 
protein in all brain regions examined. The hypothalamus was our main region of 
interest and encouragingly, hypothalamic pSTAT3 response to IP IL-6 was negligible 
to baseline in KD animals (Figure 3.5.1). This was in stark contrast to the clear up-
regulation in pSTAT3 observed in WT and CRE animals (n=2), albeit differences in 
the magnitude of the response were apparent.  
Figure 3.5.3: Cerebellar pSTAT3 Responses to IP IL-6 (50µg/kg) injection 
 
 
 
 
 
 
Figure 3.5.3: Adult male mice (>8weeks) from each genotype were used. Loading Order from left to 
right: (1) WT; (2) WT + IL-6; (3) CRE; (4) CRE + IL-6; (5) KD; (6) KD + IL-6. Representative blot, 
n=2 from each genotype. pSTAT3 – 79/88 kDa; Loading Control: GAPDH – 37 kDa (Cell 
Signaling®). 
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Examination of the pSTAT3 Response to IL-6 in the Peripheral Tissue 
Isolation of peripheral tissue from control and KD animals that were IP IL-6-treated 
prior to harvesting served to confirm that the effects of the transgenic were confined 
to the central nervous tissue. As mentioned, quantifying and comparing differences in 
receptor protein expression using a cytokine-binding-site-specific IL-6R antibody was 
not possible. Consequently this experiment allowed us on the one hand to test the 
ability of KD animals to respond to the cytokine peripherally and to compare those 
responses to control animals.  
Figure 3.6.1: Liver Tissue pSTAT3 Responses to IP IL-6 (50µg/kg) 
 
 
 
 
 
Figure 3.6.1: Adult male mice (>8weeks) from each genotype were used. Loading Order from left to 
right: (1) WT; (2) WT + IL-6; (3) CRE; (4) CRE + IL-6; (5) KD; (6) KD + IL-6. Representative blot, 
n=2 from each genotype. pSTAT3 – 79/88 kDa; Loading Control: GAPDH – 37 kDa (Cell 
Signaling®). 
Our studies were aimed at elucidating the role of IL-6 signaling in the brain 
specifically in the whole body metabolic responses to chronic HFD. IL-6 has 
important roles in the hematopoietic system as well as in tissues involved in glucose 
uptake and utilization (fat, muscle, liver). The pivotal role played by the periphery in 
the long and short-term regulation of homeostasis and the influence of IL-6 in multi-
organ cross talk involved, were highlighted in the Introduction. It was therefore 
important to confirm that any phenotype observed was not subject to non-specific 
recombination events in the periphery but was the consequence of disruption of 
central IL-6 signaling specifically.  
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pSTAT3 
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Figure 3.6.2: Muscle pSTAT3 Responses to IP IL-6 (50µg/kg) injection 
 
 
 
 
Figure 3.6.2: Adult male mice (>8weeks) from each genotype were used. Loading Order from left to 
right: (1) WT; (2) WT + IL-6; (3) CRE + IL-6; (4) CRE; (5) KD; (6) KD + IL-6. Representative blot, 
n=2 from each genotype. pSTAT3 – 79/88 kDa; Loading Control: GAPDH – 37 kDa (Cell 
Signaling®). 
No differences were observed in the IL-6-induced induction of pSTAT3 in liver 
(Figure 3.6.1), muscle (Figure 3.6.2) or white adipose tissue (Figure 3.6.3) which is 
particularly important when considering the response to glucose as well as the short 
and long-term regulation of metabolism. KD animals examined were also found to 
respond similarly to control animals to IP IL-6 in the thermogenic brown adipose 
tissue (Figures 3.6.4).  
Figure 3.6.4: White Adipose Tissue pSTAT3 Responses to IP IL-6 (50µg/kg) 
 
 
 
 
Figure 3.6.4: Adult male mice (>8weeks) from each genotype were used. Loading Order from left to 
right: (1) WT; (2) WT + IL-6; (3) CRE; (4) CRE + IL-6; (5) KD; (6) KD + IL-6. Representative blot, 
n=2 from each genotype. pSTAT3 – 79/88 kDa; Loading Control: GAPDH – 37 kDa (Cell 
Signaling®). 
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Figure 3.6.5: Brown Adipose Tissue pSTAT3 Responses to IP IL-6(50µg/kg) 
 
 
 
 
Figure 3.6.5: Adult male mice (>8weeks) from each genotype were used. Loading Order from left to 
right: (1) WT + IL-6; (2) WT; (3) CRE; (4) CRE + IL-6; (5) KD; (6) KD + IL-6. Representative blot, 
n=2 from each genotype. pSTAT3 – 79/88 kDa; Loading Control: GAPDH – 37 kDa (Cell 
Signaling®). 
Another important aspect to be considered was the heart, as previous studies 
suggested scattered CRE recombination in the vasculature, ventricles and atria of the 
heart in some NesCre models (The Jackson Laboratory, 2014). However, as 
previously reported by Dubois et al. (2006) this expression is not sufficient for 
effective targeting of genes at cardiac tissue, which would match the minimal effects 
in the ability of cardiac tissue to respond to IP IL-6 in our transgenic (Figure 3.6.6). 
Figure 3.6.6: Cardiac Tissue pSTAT3 Responses to IP IL-6(50µg/kg) 
 
 
 
 
Figure 3.6.6: Adult male mice (>8weeks) from each genotype were used. Loading Order from left to 
right: (1) WT; (2) WT + IL-6; (3) CRE; (4) CRE + IL-6; (5) KD; (6) KD + IL-6. Representative blot, 
n=2 from each genotype. pSTAT3 – 79/88 kDa; Loading Control: GAPDH – 37 kDa (Cell 
Signaling®).  
Nes-Cre mice were also previously suggested to exhibit some recombination at the 
level of the cytokine-producing spleen and some scattered expression in lung tissue 
(Dubois, et al., 2006). KD animals however can be seen to respond robustly to IP IL-6 
in these tissues (Figures 3.6.7-8), by comparable induction of pSTAT3 to WT and 
CRE controls.  
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Figure 3.6.7: Spleen pSTAT3 Responses to intra-peritoneal IL-6 (50µg/kg) 
injection 
 
 
 
 
Figure 3.6.7: Adult male mice (>8weeks) from each genotype were used. Loading Order from left to 
right: (1) WT; (2) WT + IL-6; (3) CRE; (4) CRE + IL-6; (5) KD; (6) KD + IL-6. Representative blot, 
n=2 from each genotype. pSTAT3 – 79/88 kDa; Loading Control: GAPDH – 37 kDa (Cell 
Signaling®). 
Scattered expression of CRE activity in the cortex, medulla and renal pelvis of some 
NesCre mice in studies carried by the Jackson laboratory (The Jackson Laboratory, 
2014). Similar findings were reported by Dubois et al. (2006) using 3 different 
reporter genes. In our experiments we observed differences in the kidney pSTAT3 
response to IP IL-6 between WT and NesCre-positive mice (CRE & KD). Despite 
being diminished compared to the responses observed in WT animals, CRE and KD 
responses appeared to be similar (Figure 3.6.9). This finding further underlined the 
requirement for the use of CRE animals as an appropriate control for the KD.  
Figure 3.6.8: Lung Tissue pSTAT3 Responses to IP IL-6 (50µg/kg) 
 
 
 
 
 
 
Figure 3.6.8: Adult male mice (>8weeks) from each genotype were used. Loading Order from left to 
right: (1) WT; (2) WT + IL-6; (3) CRE; (4) CRE + IL-6; (5) KD; (6) KD + IL-6. Representative blot, 
n=2 from each genotype. pSTAT3 – 79/88 kDa; Loading Control: GAPDH – 37 kDa (Cell 
Signaling®). 
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This section demonstrates that NesCreIL-6Rα KD animals respond to IP IL-6 by up-
regulation of pSTAT3 in peripheral organs examined. Unlike results shown in regions 
of the brain, WT, CRE and KD animals examined remained sensitive to the effects of 
IL-6 in peripheral tissues (Figures 3.6.1-9). Even though this does not exclude the 
possibility of down-regulation of the receptor in innervated peripheral tissue, it was 
beyond our means to examine any such effects. 
Figure 3.6.9: Kidney pSTAT3 Responses to IP IL-6 (50µg/kg) injection 
 
 
 
 
 
Figure 3.6.9: Adult male mice (>8weeks) from each genotype were used. Loading Order from left to 
right: (1) WT; (2) WT + IL-6; (3) CRE; (4) CRE + IL-6; (5) KD; (6) KD + IL-6. Representative blot, 
n=2 from each genotype. pSTAT3 – 79/88 kDa; Loading Control: GAPDH – 37 kDa (Cell 
Signaling®).  
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Examination of the ex vivo Hypothalamic Brain slice Response to IL-6 
Examination of the effects of NesCre-mediated targeting of the IL-6Rα at mRNA 
level by RT-PCR and at protein level by IP IL-6 administration suggested significant 
effects at the level of the hypothalamus. To further assess whether the attempted 
transgenic approach was of functional consequence to the ability of hypothalamic 
tissue to respond to IL-6, an ex vivo approach was utilized. Ex vivo hypothalamic 
brain slice treatment, is a technique previously established in the Ashford laboratory 
to examine the acute responses of the mediobasal hypothalamus tissue to external 
stimuli. In preliminary studies carried out, tissue obtained and treated using this 
method was found to respond to an array of important stimuli such as glucose 
deprivation (0.1mM) in the presence of insulin (10µΜ). In this model glucoprivation 
was found to predictably induce AMPK, PKB and STAT3 phosphorylation (data not 
shown).  
We thus proceeded to characterize the IL-6 response in the metabolically crucial 
mediobasal hypothalamus by examination of the change in phosphorylated STAT3 in 
ex vivo brain slices from control and KD animals. Brain slice tissue was processed 
and the magnitude of the IL-6 induced response was examined in terms of pSTAT3 
by western blotting. Using the induction of STAT3 phosphorylation as an output 
measure, we were able to assess the ability of IL-6 signaling to influence 
metabolically active hypothalamus in control and KD animals. GAPDH protein was 
used as a control and statistical analysis of normalized control and IL-6 treated 
responses from each genotype (n=7) was carried out by using the Mann Whitney U-
test. This allowed for non-parametric examination of the null hypothesis that brain 
slices from control and KD mice respond similarly to IL-6, against the alternative 
hypothesis that brain slices from control animals exhibit increased phosphorylation of 
STAT3 compared to KD slices.  
Acute treatment (30min) of hypothalamic brain slices with 20ng/ml IL-6 in WT 
animals resulted in a significant up-regulation of pSTAT3 protein. By normalizing 
pSTAT3 to GAPDH we were able to semi-quantitatively assess this response in WT, 
CRE and KD IL-6 treated brain slices by comparing to suitable GAPDH-normalized 
genotype controls (unstimulated). IL-6 was found to induce a much more robust 
response in WT animals compared to both CRE and KD animals. IL-6 induced a 
significant (p=0.0006; n=7), induction in pSTAT3 in WT animals. Similarly, yet in 
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support of mRNA data suggesting diminished IL-6Rα expression in CRE animals; IL-
6 treatment induced a significant (p=0.011; n=7), but more moderate induction in 
pSTAT3. On the other hand, in KD animals, this response failed to reach significance. 
In previous sections we were able to show down-regulation of hypothalamic IL-6Rα 
mRNA in KD animals compared to controls and similarly, decreases in the magnitude 
of the pSTAT3 response to IP IL-6 in a small number of animals examined.  This 
section confirms the ability of IL-6 to influence metabolically active neurons and 
astrocytes in the arcuate hypothalamus of WT and CRE animals, and more 
importantly the disruption of this response in our NesCre-IL-6R KD.  
Figure 3.7: Comparison of the effects of IL-6 (30min 20ng/ml) treatment to the 
induction of pSTAT3 protein in mouse hypothalamic ex vivo brain slices 
 
 
 
 
Figure 3.7: GREY: WT (n=7); BLUE: KD n=7; GREEN: CRE (n=7). Adult female mice (>8weeks) 
from each genotype were used. The expression of phosphorylated STAT3 protein was examined in 
WT, CRE and KD hypothalamic brain slices, under control conditions and following treatment with 
20ng/ml IL-6. Representative western blotting bands for pSTAT3 and GAPDH under control 
conditions and following IL-6 treatment. Loading Order from left to right: (1) WT (2) WT +IL-6 (3) 
KD; (4) KD + IL-6; (5) CRE; (6) CRE + IL-6.  Phospho-STAT3 expression was assayed by western 
blotting and quantified by densitometry with GAPDH as a loading control (Licor® Odyssey®). 
Statistical analysis of normalized data was carried out using the Mann Whitney U-test. IL-6 treatment 
promoted significant increases in pSTAT3 in relation to genotype controls in both WT (p=0.0006) and 
CRE (p=0.11) slices. This was not the case in KD mice, where pSTAT3 expression was largely 
unaffected by the treatment (p=0.6072).  
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Examination of Brain IL-6Rα Localization by Immunohistochemistry 
IL-6Rα immunoreactivity and co-localization with neuronal and astrocytic markers 
was examined in frontal, hippocampal and hypothalamic brain slices from KD and 
control animals. Images shown in this section were captured using a Leica® TCS SP5 
II microscope and subsequently analysed using the Volocity® Cellular Imaging and 
Analysis software (Perkin Elmer®) by Mrs. Alison Milne (Light Microscopy Facility 
School of Medicine, University of Dundee).  
Figure 3.8.1: IL-6Rα Expression and co-localization with NeuN & GFAP in the 
Frontal Cortex 
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C      D 
NeuN+ Cells Frontal Cortex
N
eu
N
+
 
c
e
lls
 
(%
)
0
20
40
60
80
100
CRE
KD
IL-6Ra+ NeuN+ Frontal Cortex
IL
-
6R
+
 
N
e
u
N
 
c
el
ls
 
(%
)
0
20
40
60
80
100
CRE
KD
 
Figure 3.8.1: Adult (>8weeks) mice were used. Representative images from CRE and KD frontal 
cortex brain slices (Figure 3.8.1A, B; n=2). Similar numbers of NeuN+ nuclei were observed in area-
matched slice from the CRE and KD frontal cortex (Figure 3.8.1C; CRE SC 63.7+/-9.5%, 466 cells; 
KD SC 67.6+/-4.7%, 383 cells). The percentage of IL-6 receptor-positive NeuN cells was not different 
between the 2 genotypes in examination using the Mann Whitney U-test (Figure 3.8.1D; CRE SC 
77.9+/-5.7%; KD SC 78.0+/-2.9%; p>0.99). 
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Region-matched brain slices from KD and CRE mice were co-stained with antibodies 
for neuronal (NeuN) and astrocytic (GFAP) biomarkers, as well as IL-6Rα protein. 
Receptor expression was observed in both NeuN- and GFAP-positive cells in both 
control and KD brains (Figure 3.8.1-3). However, co-localization was primarily 
detected in neuronal populations in both genotypes. Using manual cell counting we 
were able to calculate the percentage of IL-6 receptor-positive neurons in region-
matched brain slices in KD and CRE mice (Bologna-Molina, et al., 2011).  
Figure 3.8.2: IL-6Rα Expression and co-localization with NeuN & GFAP in the 
Hippocampus 
A - CRE      B – KD 
Blue: DAPI; Green: IL-6Rα; Pink: NeuN; Red: GFAP 
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Figure 3.8.2: Adult (>8weeks) mice were used. Representative images from CRE and KD 
hippocampal brain slices (Figure 3.8.2A, B; n=2). The percentage of NeuN+ nuclei in area- and 
region-matched hippocampal slices was similar in KD and control animals (Figure 3.8.2C; CRE SC 
74.5+/-16.2%, 616 cells; KD SC 78.6+/-0.8%%, 985 cells). The percentage of IL-6 receptor-positive 
NeuN cells was decreased by more than 60% in the KD compared to control mice (Figure 3.8.2D; 
CRE SC 98.1+/-0.4%; KD SC 28.0+/-0.8%; p=0.0002). 
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Figure 3.8.3: IL-6Rα Expression and co-localization with NeuN & GFAP in the 
Hypothalamus 
A - CRE     B - KD  
Blue: DAPI; Green: IL-6Rα; Pink: NeuN; Red: GFAP 
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Figure 3.8.3: Adult (>8weeks) mice were used. Representative images from CRE and KD 
hippocampal brain slices (Figure 3.8.3A, B; =2). The percentage of NeuN+ nuclei in hypothalamic 
slices from KD and control animals was similar (Figure 3.8.3C; CRE SC 67.0+/-1.2%, 376 cells; KD 
SC 72.0+/-6.2%%, 386 cells). Approximately 60% of NeuN+ cells identified were also IL-6Rα-
positive in control slices. Significant decreases were observed in KD mice, were less than 30% of 
NeuN cells were IL-6Rα-positive (Figure 3.8.3D; CRE SC 59.5+/-1.0%; KD SC 22.5+/-8.2%; 
p=0.0046). 
Statistical analysis of cell counting data was carried out using the Mann Whitney U-
test. This allowed for non-parametric examination of the null hypothesis that IL-6Rα 
protein expression in neuronal cells (stained using NeuN) was similar in the brain of 
KD and control animals, against the alternative hypothesis that control animals 
exhibit increased receptor protein in neurons compared to the KDs. The percentage of 
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IL-6Rα positive neurons was decreased in the KD hippocampus (p=0.0002) and 
hypothalamus (p=0.0046), but not the frontal cortex. This matched previous findings 
obtained by real-time PCR (Figure 3.4.2).  
To further examine the effects of NesCre-mediated IL-6Rα down-regulation in 
neurons and astrocytes, and to resolve any possible doubt regarding the quality of 
staining intensity and co-localization imaging data were analysed using the Volocity® 
Imaging and Analysis software (Barlow, et al., 2010). This allowed for quantification 
of the co-localization of the receptor with neuronal (NeuN) and astrocytic (GFAP) 
markers (Figure 3.8.4).  
Figure 3.8.4: Pearson’s Correlation Coefficient for Brain IL-6Rα co-localization with 
NeuN and GFAP 
Figure 3.8.4: Adult female mice (>8weeks) from each genotype were used (n=2). Pearson’s 
Correlation Co-efficient (PCC) was calculated for the IL-6Rα with neuronal NeuN and astrocytic 
GFAP from region-matched images from each genotype. PCC IL-6Rα/NeuN: Frontal Cortex: CRE 
0.421, KD 0.275; Hippocampus: CRE 0.36, KD 0.232; Hypothalamus: CRE 0.409, KD 0.197. PCC 
IL-6Rα/GFAP: Frontal Cortex: CRE -0.018, KD -0.047; Hippocampus: CRE -0.016, KD -0.068; 
Hypothalamus: CRE 0.103, KD -0.053. 
Recent studies suggest that calculation of a thresholded Pearson's correlation 
coefficient (PCC) using only intensity values over a determined threshold in relevant 
channels produces numerical values that more accurately describe biological protein 
expression relationships. PCC is a statistical analysis designed to measure the strength 
of a linear relationship between 2 variables, such as fluorescent intensities from 
images. The Volocity ® software subtracts the mean pixel intensity of an image from 
the intensity of each pixel within the image, generating a product of the difference 
from the mean that is summed for the entire dataset and divided by the maximum 
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possible sum of the product of the differences from the mean (Alder, et al., 2008). 
PCC generates a range of values, with +1 representing a perfect positive correlation, 
to -1, representing a perfect negative correlation, while 0 represents a random 
distribution. This method was used to further probe the validity of the receptor down-
regulation achieved in neuronal and astrocytic cells through computerized assessment 
of co-localization intensities of the IL-6Rα signal in relation to NeuN and GFAP 
while avoiding observer bias and variability often associated with cell counting 
methods (Matos, et al., 2006; Barlow, et al., 2010). 
A weak positive correlation was observed between NeuN and IL-6Rα in control 
animals, which was decreased the KD brain across all regions examined. There was 
no correlation between astrocytic GFAP and the IL-6Rα in Frontal Cortex and 
Hippocampus of control and KD animals. However in the hypothalamus, a weak 
positive correlation reported in CRE animals was contrasted by a weak negative 
correlation in the KD.  The small number of animals used in these experiments was a 
limitation. It was however beyond our current means to further elaborate our studies. 
Results in this section are consistent with previous reports suggesting NesCre floxed 
mice to exhibit primarily neuronal but also astrocytic Cre recombinase activity. 
Further studies would be required to outline the precise contributions of astrocytes 
and metabolically active neuronal populations to the phenotype.   
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Summary 
Chapter 3 served to confirm the brain specific down-regulation of the IL-6Rα in 
NesCreIL-6Rα KD compared to control animals. The expression of CRE recombinase 
and the incorporation of loxP sites for the receptor were initially confirmed by PCR 
(Figures 3.2-3). Brain-specific disruption of the IL-6Rα system in the brain was 
demonstrated using in vivo (Figures 3.5, 3.6) and ex vivo (Figures 3.7) approaches, 
as well as using real-time PCR (Figure 3.4) and immunohistochemistry (Figures 
3.8). Furthermore, results in this section indicated CRE and not WT mice to be the 
appropriate control group for the NesCreIL-6Rα KD mouse. Importantly, down-
regulation of the receptor system was confirmed in the metabolically-sensing 
hypothalamus, even though further studies would be required to outline the effects on 
individual neuronal and glial populations. Research over past years has consistently 
shown chronic high-fat feeding to activate pro-inflammatory pathways and related 
stress signaling in the rodent hypothalamus, promoting DIO and metabolic disease 
(Zhang, et al., 2008; Purkayastha, et al., 2011; Cai & Liu, 2011). To assess the role of 
central IL-6 signaling in the development of DIO and Type 2 Diabetes, KD and CRE 
mice were metabolically characterized over a period of 20 weeks on standard chow 
and high-fat-diet (Chapter 4). 
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Table 4: NesCreIL-6Rα KD Characterization 
METHOD OUTCOME 
Real Time PCR ↓Il-6ra mRNA compared to CRE 
controls 
• 35% in the hippocampus 
• 50% in the hypothalamus 
In vivo IP IL-6 (50µg/kg) Administration No effect in IL-6 induced increase in 
STAT3 phosphorylation in: 
• Heart 
• Kidney 
• Liver 
• Lung 
• Muscle 
• Spleen 
• Brown Adipose Tissue 
• White Adipose Tissue 
Disruption of IL-6 induced increase in 
STAT3 phosphorylation in: 
• Hypothalamus 
• Hippocampus 
Ex vivo treatment of mediobasal 
hypothalamic slice tissue with IL-6 
(20ng/ml) 
Unlike hypothalamic brain slices from 
control animals; IL-6 failed to induce a 
significant increase in STAT3 
phosphorylation in KD slices. 
Brain Immunohistochemistry ↓IL-6Rα protein expression in NeuN+ 
cells compared to CRE controls in: 
• Hippocampus 
• Hypothalamus 
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Chapter 4: Metabolic Phenotyping of NesCre-IL-6Rα KD mice 
As shown in Chapter 3 the novel NesCreIL-6Rαflox/flox (KD) mouse exhibits CNS-
specific disruption of the cytokine receptor in relation to control animals. In order to 
evaluate the role of central IL-6 signaling in the development of diet-induced obesity 
diabetes, a small cohort of age (8-10weeks old) - and male KD animals on SC and 
HFD for a total period of 20 weeks, during which they were subject to an array of 
metabolic phenotyping tests as outlined below. Multivariate analysis of variance was 
carried out to assess hypotheses regarding the effect of one or more independent 
variables such as diet and genotype on the parameter under examination at single time 
points or over time (IBM SPSS 21®). Additionally metabolic parameters governing 
energy expenditure were examined using the CLAMS® Animal Monitoring System 
prior to tissue harvest. CRE animals were used as the control group for both the SC 
and HFD study. Results from WT animals examined are presented in Appendix A.  
Table 5: Schematic Outline of 20-Week Study Plan 
PROCEDURE SYMBOL 
Weighting 
 
EchoMRI Body Composition Evaluation 
 
Oral Glucose Tolerance Test 
 
Intra-peritoneal Insulin Tolerance Test 
 
Food Intake 
 
Oral Glucose Stimulated Insulin Secretion 
 
      
 
 
 
 
 
  
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
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Body Weight Progression 
CRE and KD on SC mice exhibited minimal weight gain over the 20-week study 
period (Figure 4.1). HF-fed animals, experienced dramatic increases in weight gain 
compared to SC controls (p<0.0001), gaining 2g of body weight/week during the first 
6 weeks. Body weight gain was subsequently reduced and maintained to 1g/week 
until the end of the study. Brain-specific down-regulation of the IL-6 receptor failed 
to exert an effect on weight gain progression observed in both SC and HF-fed KDs 
compared to control animals (p=0.272).  
Figure 4.1: Mean Weight Gain during the 20-week Study Plan 
Figure 4.1: GREEN: CRE SC (n=9); BLUE: KD SC (n=9); RED: CRE HFD (n=7); 
PURPLE: KD HFD (n=11). Mean weight gain in CRE (1.9+/-0.2g; n=8) and KD SC (1.9+/-
0.2g; n=9) animals was closely matched over the course of the study. Diet predictably 
induced significant increases in mean body weight gain in both KD (13.0+/-1.4g; n=11) and 
CRE (13.3+/-1.1g; n=7) HF-fed mice compared to SC controls (p<0.0001). No differences 
were apparent between the 2 genotypes in this response, and multivariate analysis (IBM SPSS 
21®) indicated no significant effect of genotype (p=0.272) or the interaction between diet and 
genotype (p=0.454) on the body weight gain observed during the study.  
 
0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20
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Body Composition 
The body composition of experimental animals was periodically examined during the 
course of the study by means of the Echo MRI™ system in accordance with the study 
plan described (Table 4). This allowed for investigation of differences in percentage 
lean and fat body mass of CRE and KD animals on SC and HFD. Body composition 
data obtained through the course of the study (Study Weeks 3, 7, 15 and 20) were 
analysed by MANOVA (IBM SPSS® 21). Comparison of body composition at 
individual time points was carried out by 1-way ANOVA.  
Figure 4.2.1: Body Composition at Week 3 of the Study 
 
Figure 4.2.1: GREEN: CRE SC (n=9); BLUE: KD SC (n=9); RED: CRE HFD (n=7); PURPLE: KD 
HFD (n=11). KD SC mice exhibited decreased percentage body fat mass compared to CRE controls 
(Figure 4.2.1C; CRE SC 19.22+/-0.80%, n=9; KD SC 15.51+/-0.34%, n=9; p=0.001), even though no 
significant differences in percentage lean body were apparent between the 2 groups (Figure 4.2.1A; 
CRE 76.46+/-1.9%, n=9; KD SC 78.44+/-0.90%, n=9; p>0.99). A 10% increase in mean percentage 
body fat was evident across both groups following 3 weeks of HFD. No significant differences were 
observed between KD and control HF-fed animals in percentage lean (Figure 4.2.1B; CRE 65.73+/-
0.99%, n=8; KD HFD 66.9922 +/-1.5214%, n=11; p=0.2052) or fat body mass at this point of the study 
(Figure 4.2.1D; CRE 29.51 +/-1.22%, n=8; KD HFD 28.62+/-1.1791%, n=11; p>0.99).  
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Analysis of between-subject factors indicated a significant effect of diet in the 
variance observed in lean (p<0.0001, F=828.53) and fat (p<0.0001, F=1670.84) 
composition recorded over the course of the study. Furthermore, significant 
differences in the percentage lean (p<0.0001, F=16.32) and fat (p<0.0001, F=30.56) 
body mass of the two genotypes. The interaction of genotype and diet also exerted a 
significant effect in the variance observed in lean (p=0.001, F=15.00) and fat 
(p<0.0001, F=38.77) body composition of experimental animals.   
Figure 4.2.2: Body Composition at Week 7 of the Study 
 
Figure 4.2.2: GREEN: CRE SC (n=9); BLUE: KD SC (n=9); RED: CRE HFD (n=7); PURPLE: KD 
HFD (n=11). KD SC mice continued to exhibit a leaner phenotype compared to control animals, and 
significant differences in both percentage lean (Figure 4.2.2A; CRE 71.41+/-1.18%; n=8; KD 76.77+/-
0.65%, n=9; p=0.0293) and fat (Figure 4.2.2C; CRE 23.98+/-0.84%; n=8; KD 16.36+/-0.80%, n=9; 
p=0.007) body mass were observed at week 7 of the study. A 20% increase in body adiposity was 
observed in both HF-fed groups compared to SC mice at Week 7. This represented a further 10% 
increase since Week 3, however percentage lean (Figure 4.2.2B; CRE HFD 55.07% +/-0.87, n=7; KD 
HFD 56.98 +/-1.25 %, n=11; p=0.6572) and fat (Figure 4.2.2D; CRE HFD 41.56 +/-1.19%, n=7; KD 
HFD 38.89 +/-1.05%, n=11; p=0.31) body mass was not significantly different between the 2 groups. 
KD SC mice displayed a significantly leaner phenotype compared to control animals 
at the beginning of the study (Week 3 - Figure 4.2.1). Despite the lack of differences 
in terms of body weight, this effect that was maintained throughout the course of the 
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20-week study plan (Figure 4.1). Percentage body fat was stable in SC animals 
during the study, and negligible fluctuations were observed at weeks 7, 12, 15 and 20. 
KD SC percentage body fat was around 18% for the remainder of the study, by 
contrast to a 25% observed in CRE SC mice (Figure 4.2).  
Figure 4.2.3: Body Composition at Week 12 of the Study 
 
Figure 4.2.3: GREEN: CRE SC (n=9); BLUE: KD SC (n=9); RED: CRE HFD (n=7); PURPLE: KD 
HFD (n=11). The leaner phenotype observed in KD SC compared to CRE SC at Weeks 3 and 7 were 
preserved at Week 12 of the study. KD SC mice continued to exhibit decreased percentage body fat 
mass (Figure 4.2.3C; CRE SC 25.74+/-0.79%, n=9; KD SC 17.78 +/-1.10%, n=9; p=0.0074) and 
increased percentage lean body mass (Figure 4.2.3A; CRE SC 68.98+/-0.64%, n=9; KD SC 75.14+/-
1.22%, n=9; p=0.014) compared to their controls. HF-mice mice on the other hand, exhibited a 5% 
increase in percentage body fat between Weeks 7 and 12, reaching 45%. CRE and KD HFD animals 
were nearly identical in terms of both percentage lean (Figure 4.2.3B; CRE HFD 49.61+/-0.75%, n=7; 
KD HFD 48.98+/-0.87%, n=11; p>0.99) and fat (Figure 4.2.3D; CRE HFD 47.48+/-0.69%, n=7; KD 
HFD 46.14+/-0.82%, n=7; p>0.99) body mass following 12 weeks of diet.  
Three weeks of HFD induced a 10% increase in percentage body fat in both control 
and KD animals compared to SC animals. CRE and KD HFD percentage body fat 
increased to approx. 30% and significant differences in body composition observed in 
KD SC animals were not observed (Figure 4.2.1B, D). KD HFD mice closely 
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matched CRE HFD animals in body composition following 3 and 7 weeks of diet 
(Figure 4.2.2B, D), where body adiposity further increased to nearly 40% of total 
body mass.  
Figure 4.2.4: Body Composition at Week 15 of the Study 
 
Figure 4.2.4: GREEN: CRE SC (n=9); BLUE: KD SC (n=9); RED: CRE HFD (n=7); PURPLE: KD 
HFD (n=11). Significant differences observed between KD SC and control animals in terms of 
percentage fat (Figure 4.2.4C; CRE SC 25.74+/-0.79%, n=9; KD SC 17.78+/-1.10%, n=9; p=0.002) 
and lean (Figure 4.2.4A; CRE SC 64.40+/-2.60%, n=9; KD SC 72.67+/-0.76%, n=9; p=0.001) body 
mass were still evident at Week 15. Similarly matching results from Week 12, KD and CRE HFD mice 
were identical in terms of both lean (Figure 4.2.4B; CRE HFD 46.93+/-0.64%, n=7; KD HFD 47.11+/-
0.77%, n=11; p>0.99) and fat (Figure 4.2.4D; CRE HFD 47.75+/-0.81%, n=7; KD HFD 48.31+/-0.78, 
n=11; p>0.99) body composition. Body fat accounted for approximately 47% of total body mass in HF-
fed mice following 15 weeks of diet.  
Body adiposity continued to increase in HF-fed mice between Weeks 7 and 12, albeit 
at a slower rate. Body fat accounted for approximately 45% of total body mass in KD 
and CRE HFD mice, a further 5% increase from Week 7 (Figure 4.2.2-3). KD HFD 
and control mice were nearly identical in body composition and no significant 
differences were observed between the 2 groups in percentage lean or fat body mass 
at Week 12 of the Study (Figure 4.2.3).  
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Figure 4.2.5: Body Composition at Week 20 of the Study 
 
Figure 4.2.5: GREEN: CRE SC (n=9); BLUE: KD SC (n=9); RED: CRE HFD (n=7); PURPLE: KD 
HFD (n=11). Increases in mean percentage body fat mass were observed in KD SC mice at Week 20 
compared to Week 15 of the Study. Despite this, percentage body fat (Figure 4.2.5C; CRE SC 
25.03+/-0.52%, n=9; KD SC 20.35+/-1.02%, n=9; p=0.03) remained decreased and percentage lean 
body mass (Figure 4.2.5A; CRE SC 68.24+/-0.45%, n=9; KD SC 72.99+/-0.95%; p=0.002) still 
increased compared to CRE SC mice. By stark contrast, percentage body fat mass in CRE HFD was 
significantly decreased compared to KD HFD mice after 20 weeks of diet (Figure 4.2.5D; CRE HFD 
46.78+/-0.75%, n=9; KD HFD 50.91+/-0.64%, n=11; p=0.04). Differences observed in percentage lean 
body mass failed to reach significance (Figure 4.2.5B; CRE HFD (48.00 +/-0.64%, n=7; KD HFD 45. 
75 +/-0.80%, n=11; p=0.36).  
Between Weeks 12 and 15 of the study, body composition in CRE and KD HFD was 
largely unchanged (Figure 4.2.3-4). CRE HFD percentage body fat was around 47% 
at Week 12 and marginal fluctuations were observed on examination at Weeks 15 and 
20 of the study (Figures 4.2.3-5). KD HFD percentage body fat mass increased to 
approx. 51% between Weeks 15 and 20, and significant differences were observed in 
between the 2 groups at the end of the study (Figure 4.2.5B, D).   
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Daily Food Intake  
The daily food intake of experimental animals was evaluated on Week 9 of the study 
plan. Mice on SC and HFD were housed individually overnight, and food intake 
measurements were taken on the subsequent day at 4, 8 and 24 hours. Statistical 
analysis was conducted using a 1-way ANOVA (SPSS®).    
Figure 4.3: Examination of Daily Food Intake at Week 9 of the Study 
 
Figure 4.3: GREEN: CRE SC (n=9); BLUE: KD SC (n=9); RED: CRE HFD (n=7); PURPLE: KD 
HFD (n=11). Consistent with the anorexic effects of central IL-6 signaling, total food intake was 
significantly increased in KD compared to CRE SC mice (Figure 4.3A; CRE SC 2.5+/-0.1g, n=9; KD 
SC 3.3+/-0.2g, n=9; p=0.03). Increased food intake was also observed in KD mice at 4hours (Figure 
4.3C; CRE SC 0.0g; KD SC 0.5+/-0.1g; p<0.0001) and 8hours (Figure 4.3C; CRE SC 0.0g; KD SC 
0.7+/-0.1g; p<0.0001). Matching the trend observed in SC groups, the total food intake of KD HFD 
animals was nearly double compared to control animals and significant differences were observed 
(Figure 4.3B, CRE HFD 1.8+/-0.1g, n=7; KD HFD 3.6+/-0.3g, n=11; p<0.001). Correspondingly 
statistical analysis confirmed a significant effect of genotype on the food intake of mice on HFD at 
4hours (Figure 4.3D; CRE HFD 0.1+/0.1g; KD HFD 0.8+/-0.2g; p=0.019) and 8hours (Figure 4.3D; 
CRE HFD 0.2+/-0.1g; KD HFD 1.3+/-0.3g; p=0.004).  
 
Mice are nocturnal animals and thus the large majority of activity and food intake 
takes place at night. Indeed, more than 90% of food intake in CRE mice on SC and 
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HFD was recorded over the latter part of the protocol (8-24hours).  This relationship 
was disrupted in KD mice, even though the greater part of food intake was still 
observed overnight. Significant increases were detected in the KD SC food intake at 
4hours (p<0.0001) and 8hours (p<0.0001) of the protocol, where eating was 
negligible in control animals (Figures 4.3C, D). This effect was accentuated in KD 
HFD mice (n=11) where 40% of the food intake was recorded within the first third of 
the protocol. Similarly significant differences were observed in the food intake of KD 
and CRE HFD mice at 4 (p=0.019) and 8 hours (p=0.004). Total food intake through 
the 24hour period was also significantly increased in both the SC (p=0.003) and HF-
fed (p<0.0001) KD mice compared to their respective controls (Figure 4.3A, B).  
 
Intra-Peritoneal Insulin Tolerance Test 
The responsiveness of experimental animals to the effects of intra-peritoneal injection 
of insulin (1U/kg body mass) was examined at 6, 9 and 15 weeks of the experimental 
study, following a 4 hours fast. Exogenous administration of insulin via this route is 
known to acutely reduce circulating blood glucose levels in mammals. Statistical 
analysis of Insulin Tolerance Tests (ITT) was carried out by MANOVA (IBM SPSS 
21®). Blood glucose responses from experimental animals were tabulated as a 
function of time from administration of insulin, while genotype (CRE or KD) and diet 
(SC or HFD) were set as between-subject variables. Additionally, baseline glycaemia 
was assessed in experimental animals on SC and HFD, and statistical analysis was 
carried out using a 2-way ANOVA. 
The ability of SC animals to respond to IP insulin was unaffected by the course of the 
study, and blood glucose in KD and control mice was indeed reduced following 
insulin administration at 3 different time points during the study (Figures 4.4.1-3). 
Down-regulation of the IL-6Rα in the CNS of KD animals was of little consequence 
to the ability of the transgenic to respond to insulin.  Blood glucose responses to 
insulin in KD SC and HFD mice were indistinguishable compared to control animals 
at Week 6 of the study (Figure 4.4.1A, B– ITT1). Statistical analysis of the blood 
glucose response to ITT1 in KD and CRE mice over the course of 90minutes, 
revealed no significant effect of genotype (p=0.11). Furthermore, blood glucose 
during ITT1 in KD and CRE HFD mice was similar to SC controls and statistical 
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analysis indicated no significant effect of diet (p=0.16) or the interaction of diet and 
genotype (p=0.06) in the response.  
Figure 4.4.1: ITT1 at Week 6 of the Study 
 
Figure 4.4.1: GREEN: CRE SC (n=9); BLUE: KD SC (n=9); RED: CRE HFD (n=7); PURPLE: KD 
HFD (n=11). Results were plotted as means +/-SEM. Statistical analysis of between-subject factors, 
indicated no significant effect of genotype (p=0.11, F=2.73) in the variance observed. KD and CRE SC 
blood glucose responses during ITT1 were nearly identical (Figure 4.4.1A). Diet failed to exert a 
significant effect on the blood glucose response to ITT following 6 weeks of HF-feeding, despite 
differences between SC and HFD mice (Figure 4.4.1B; p=0.16, F=2.05). The interaction of genotype 
and diet was not statistically significant (p=0.06, F=3.8), even though marginal differences were 
observed between the KD and CRE HFD response. On the other hand, diet (p=0.0035, F=4.84), 
genotype (p<0.001, F=20.28) and their interaction (p=0.04, F=4.54) exerted a significant effect on 
baseline glycaemia as indicated by 2-way ANOVA. Blood glucose at rest was similar in KD and CRE 
SC mice (Figure 4.4.1C CRE SC 6.4 +/-0.3 mM Glucose, n=8; KD SC 7.2 +/-0.2 mM Glucose, n=9; 
p=0.15). KD HFD mice exhibited significant increases compared to SC groups following 6 weeks of 
diet (p=0.002), but this was not the case for the CRE HFD (p>0.99) and significant differences were 
observed between the 2 HF-fed groups (Figure 2.4.1D; CRE HFD 6.4 +/-0.4 mM Glucose; n=7; KD 
HFD 8.5545 +/-0.3123 mM Glucose, n=11; p=0.002).  
Comparison of baseline glycaemia in control and KD animals at Week 6 (Figure 
4.4.1C, D) indicated a significant effect of genotype (p<0.001, F=20.28), diet 
(p=0.0035, F=4.84), and their interaction in the variance observed (p=0.04, F=4.54). 
KD and CRE SC blood glucose levels were nearly identical and no significant 
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differences were identified at this point (p=0.37). Blood glucose at rest in CRE HFD 
mice was not statistically different to CRE SC mice (p>0.99), by contrast to KD HFD 
animals where significant increases were observed compared to both KD SC (p=0.02) 
and CRE HFD mice (p=0.002).  
Figure 4.4.2: ITT2 at Week 9 of the Study 
 
Figure 4.4.2: GREEN: CRE SC (n=9); BLUE: KD SC (n=9); RED: CRE HFD (n=7); PURPLE: KD 
HFD (n=11). Results were plotted as means +/-SEM. No significant effect of genotype (p=0.5, F=0.47) 
was reported in statistical analysis of variance observed in the blood glucose response of KD and CRE 
mice to ITT2. Blood glucose responses to ITT2 at Week 9 in KD SC mice mirrored results in control 
mice (Figure 4.4.2A). Nine weeks of high fat feeding failed to exert a significant effect on the blood 
glucose response to ITT2, despite differences between SC and HFD mice (Figure 4.4.2B; p=0.11, 
F=2.76). There was no significant interaction of genotype and diet (p=0.57, F=0.33), reflected in the 
closely matched blood glucose profiles of KD and CRE HFD mice. Statistical examination of resting 
glycaemia at week 9 indicated a significant effect of diet (p<0.001, F=20.20), but not of genotype 
(p=0.15, F=2.22) or their interaction (p=0.75, F=0.09) in the variance observed. Blood glucose at rest 
was similar in SC mice (Figure 4.4.2C CRE SC 7.1+/-0.2 mM Glucose, n=9; KD SC 7.0+/-0.2 mM 
Glucose, n=9; p=0.96) and comparable increases were recorded KD (p=0.02) and CRE HFD (p0.007) 
mice in response to diet (Figure 4.4.2D CRE HFD 8.5+/-0.4 mM Glucose, n=7; KD HFD 8.0+/-0.2 
mM Glucose, n=9; p=0.72).  
Baseline glycaemia in KD mice at Study Week 9 paralleled levels observed in SC and 
HFD controls (Figure 4.4.2C, D; p=0.15, F=2.22). Significant increases were 
observed in HF-fed mice compared to SC groups (p<0.001, F=20.20), but there was 
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no significant interaction of genotype and diet (p=0.75, F=0.09) in the variance 
observed. Likewise, there was no significant differences between KD and control 
mice during ITT2 (p=0.5, F=0.47), while blood glucose responses were largely 
unaffected by diet (Figure 4.4.2A, B; p=0.5, F=0.47).  
Figure 4.4.3: ITT3 at Week 15 of the Study 
 
Figure 4.4.3: GREEN: CRE SC (n=9); BLUE: KD SC (n=9); RED: CRE HFD (n=7); PURPLE: KD 
HFD (n=11). Results were plotted as means +/-SEM. Significant differences were observed between 
SC and HF-fed mice in the blood glucose response to ITT at Study Week 15 (p=0.03, F=5.38). 
However, blood glucose responses to ITT3 in KD mice on SC (Figure 4.4.3A) and HFD (Figure 
4.4.3B) were similar to their respective controls. Matching results in ITT1&2 statistical analysis of 
ITT3 indicated no significant differences between KD and CRE mice (p=0.41, F=0.72), and no 
significant interaction between genotype and diet (p=0.71, F=0.14). Resting blood glucose levels 
observed in KD mice at week 15 were not different to their CRE controls (p=0.23, F=1.151). 
Significant differences in resting blood glucose were maintained between SC (Figure 4.4.3C; CRE SC 
5.6+/0.4mM Glucose; KD SC 6.8+/-0.4mM Glucose) and HF-fed (Figure 4.4.3D; CRE HFD 8.7+/-
0.6mM Glucose; KD HFD 8.6+/-0.3mM Glucose) mice at week 15 of the study (p<0.0001, F=33.62). 
There was no significant interaction of diet and genotype in the variation observed (p=0.13, F=2.39).   
Increases observed in the resting blood glucose of HF-fed compared to SC mice were 
maintained on examination at Study week 15 (Figure 4.4.3C, D; p<0.0001, F=33.62). 
Furthermore, significant differences were reported in the blood glucose response of 
SC and HF-fed mice to ITT3 (Figure 4.4.3A, B; p=0.03, F=5.38). However, 
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differences observed at baseline and during ITT3 in KD and CRE mice failed to reach 
significance.  
Collectively, KD blood glucose responses to ITT1-3 were not different to control 
mice on SC or HFD during the course of the study. Differences observed between SC 
and HFD groups only reached significance at Study week 15. Importantly even 
though CRE HFD baseline glycaemia was similar to SC groups at week 6, KD HFD 
exhibited hyperglycaemia compared to all 3 groups. Hyperglycaemia was observed in 
both CRE and KD HFD compared to SC animals on subsequent examination at weeks 
9 and 15.  
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Oral Glucose Tolerance Test and Glucose-Stimulated Insulin Secretion  
To further assess the ability of experimental animals to regulate glycaemic levels, 
glycaemic levels in response to oral administration of a standard dose of 100µl of a 
50% glucose solution (oGTT) was examined at weeks 10 and 14. Resting and 
glucose-stimulated blood glucose responses were recorded over 120min. A modified 
protocol was used at Study week 19 to examine changes in circulating blood 
hormones. Results were analyzed using repeated measures MANOVA (IBM SPSS 
21®). Blood glucose levels recorded during oGTT were tabulated as a function of 
time from administration of glucose with genotype (CRE or KD) and diet (SC or 
HFD) set as between-subject variables. Additionally, baseline glycaemic levels 
recorded prior to the challenge were analyzed separately by 2-way ANOVA.  
The ability of the body to regulate glycaemic levels is an important component of 
current diabetic therapy, and good glycaemic management is understood to reduce 
associated complications and morbidity (Voiqt, et al., 2015; Healy & Dungan, 2015; 
Aronoff, et al., 2004). Significant differences were observed in the ability of KD and 
CRE mice to clear glucose on examination at Study Week 10 (p=0.005, F=9.98). 
Blood glucose in response to the challenge was significantly elevated in KD mice 
compared to controls on both SC and HFD. Additionally, analysis of the influence of 
between-subject factors in the variance observed, revealed a significant effect of diet 
(p<0.0001, F=40.33), but no significant interaction of genotype and diet (p=0.17, 
F=1.996). On the other hand, significant differences observed in baseline glycaemia 
between SC and HF-fed mice at Study Week 10, were not accompanied by 
differences between KD and CRE animals.  
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Figure 4.5.1: oGTT1 at Week 10 of the Study  
Figure 4.5.1: GREEN: CRE SC (n=9); BLUE: KD SC (n=9); RED: CRE HFD (n=7); PURPLE: KD 
HFD (n=11). Results were plotted as means +/-SEM. Statistical analysis of oGTT1 at Study Week 10 
revealed significant differences between KD and CRE responses (p=0.005, F=9.98), while a significant 
differences were also observed between SC and HF-fed (p<0.0001, F=40.33). However, the interaction 
between the two did not reach significance at this point (p=0.17, F=1.996). Significant increases were 
observed in the baseline glycaemia of HF-fed mice compared to SC (p=0.0003, F=17.22), however 
there was no significant effect of genotype (p=0.2, F=1.74), or the interaction of diet and genotype 
(p=0.48, F=0.51) in the variance observed. Baseline glucose levels were similar in KD and CRE SC 
animals (Figure 4.5.1C; CRE SC 5.8+/-0.2mM; KD SC 6.5 +/-0.3mM; p=0.73), however the mean 
acute (15min) response to oGTT1, revealed a deficit in glucose clearance in the KD SC compared to 
CRE controls (Figure 4.5.1A; CRE SC 11.9+/-0.8mM; 14.3+/-0.5Mm; p=0.0003). Similarly, despite 
the lack of differences at baseline (Figure 4.5.1D; CRE HFD 7.5+/-0.5mM; KD HFD 7.7+/-0.4Mm; 
p>0.99), KD HFD exhibited marginal differences in glucose clearance compared to CRE HFD mice at 
15minutes of oGTT1 (Figure 4.5.1B; CRE HFD 14.4875 +/-0.9054mM Glucose;  KD HFD 19.1+/-
1.4mM Glucose). 
Significant differences observed in the blood glucose response to oGTT1 of KD and 
CRE mice were not maintained when re-examined at Study Week 15 (Figure 4.5.2; 
p=0.08, F=0.09). In contrast, significant differences observed in the glucose clearance 
of HF-fed and SC mice in oGTT1 were still evident at Study Week15 (Figure 4.5.2A, 
B; p>0.0001, F=30.99). Mean resting blood glucose levels at Study week 14 
paralleled results obtained at week 10. Baseline glycaemia prior to oGTT2 was not 
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different between KD and CRE mice (Figure 4.5.2C, D; p=0.11, F=2.68), while 
significant increases were observed in both HF-fed groups compared to SC animals 
(p<0.0001, F=31.06).  
Figure 4.5.2: oGTT2 at Week 14 of the Study  
Figure 4.5.2: GREEN: CRE SC (n=9); BLUE: KD SC (n=9); RED: CRE HFD (n=7); PURPLE: KD 
HFD (n=11). Results were plotted as means +/-SEM. Figure 4.5.2A, B: Differences observed between 
KD and control animals in the failed to reach significance by MANOVA (p=0.08, F=3.23).Glucose 
clearance in HFD groups was disrupted compared to SC mice (p<0.0001, F=30.99). No significant 
effect of the interaction of genotype and diet in the variance observed (p=0.94, F=0.005). Figure 
2.5.2C, D: Glucose levels recorded were significantly elevated (p<0.0001, F=31.06) in HFD (Figure 
4.5.2D; CRE HFD 8.1+/-0.5mM Glucose; KD HFD 8.3+/-0.4mM Glucose) compared to SC (Figure 
4.5.2C; CRE SC 5.7+/-0.3mM Glucose; KD SC 6.7+/-0.3mM Glucose) mice, but differences observed 
between the two genotypes failed to reach significance (p=0.11, F=2.68).   
During the modified oGTT protocol used at week 19, larger blood volume was 
collected from experimental animals at smaller intervals over 30minutes. This 
allowed for examination of changes in circulating plasma insulin (GSIS) and 
glucagon levels in response to an oral glucose challenge in experimental animals.  
Correspondingly to results from Study Weeks 10 and 14, there was no significant 
effect of genotype (p=0.91; F=0.01) or its interaction with diet (p=0.37, F=0.84) in the 
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variance observed in resting blood glucose levels at Week 19 (Figure 4.5.3C, D). 
Baseline glycaemia was significantly increased in both groups on HFD compared to 
SC mice, and statistical analysis confirmed a significant effect of diet (p<0.0001, 
F=32.97).  Conversely, glycaemia during oGTT3 was significantly increased in KD 
mice compared to diet-matched controls (Figure 4.5.3A, B; p<0.0001, F=25.97), 
while aggravated hyperglycaemia in HF-fed mice underscored the influence of diet in 
the response (p<0.0001; F=23.58). Hyperglycaemia compared to diet-matched 
controls was maintained throughout oGTT3 in KD mice.  Blood glucose responses to 
oGTT3 peaked at 15min in CRE mice, but this was not the case in the KD where 
further increases were observed at 30min. 
Examination of plasma insulin levels during oGTT3 (oGSIS), revealed a substantial 
deficit in the ability of SC and HFD KDs to release insulin in response to glucose 
loading (Figure 4.5.4). Analysis of the variance observed in GSIS confirmed 
significant differences between KD and CRE mice KD animals (p=0.049; F=4.40). 
Chronic HF-feeding induced increases in baseline and GSIS compared to SC mice, 
indicative of the significant effect of diet in the response (p=0.009, F=8.44). Increases 
observed in plasma insulin levels in control mice during GSIS were suppressed in KD 
animals. KD SC mice exhibited severe disruption of basal as well as glucose-
stimulated insulin secretion throughout the protocol (Figure 4.5.4A). Baseline plasma 
insulin levels were similar in KD and CRE HFD; however administration of glucose 
failed to promote increases in plasma insulin in KD mice (Figure 4.5.4B). 
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Figure 4.5.3: Modified oGTT3 at Week 19 of the Study 
Figure 4.5.3: GREEN: CRE SC (n=9); BLUE: KD SC (n=9); RED: CRE HFD (n=7); PURPLE: KD 
HFD (n=11). Results were plotted as means +/-SEM. A significant effect of genotype (p<0.0001, 
F=25.97), diet (p<0.0001, F=23.58) was identified by MANOVA. Blood glucose levels rose acutely 
following glucose administration in both groups of animals on SC. The KD SC response was 
significantly elevated at 3min (Figure 4.5.3A; CRE SC 8.8+/-0.7mM Glucose; KD SC 12.3+/-0.7mM 
Glucose; p=0.02) and 30min (Figure 4.53A; CRE SC 12.6+/-1.5mM Glucose; KD SC 21.5+/-0.9mM 
Glucose; p<0.0001). Pronounced increases were observed in the acute blood glucose of CRE and KD 
HFD animals compared to SC mice (Figure 4.5.3A, B; CRE HFD 12.9+/-0.6Mm Glucose; KD HFD 
15.5+/-1.0). Glycaemic levels were elevated in KD HFD compared to CRE HFD throughout oGTT3. 
This effect was of significance at 15min (Figure 4.5.3B; CRE HFD 19.6+/-1.0mM Glucose; KD HFD 
24.2+/-1.1mM Glucose; p=) and 30min (Figure 4.5.3B; CRE HFD 17.9+/-1.8mM Glucose; KD HFD 
26.5+/-1.2mM Glucose; p<0.0001) following the challenge. Figure 4.5.3C, D: Increases observed in 
the resting blood glucose of HF-fed (CRE HFD 8.8+/-0.3mM Glucose; KD HFD 9.1+/-0.2mM 
Glucose) compared to SC mice (CRE SC 6.9+/-0.5mM Glucose; KD SC 6.5+/-0.4mM Glucose) 
highlighted the significant effect of diet in the variance observed at Study week 19 (p<0.0001, 
F=32.97). There were no significant differences between the 2 groups on HFD (p=0.37, F=0.84). 
The dramatic effects observed in terms of plasma insulin (Figure 4.5.4A, B) as well 
as the inhibitory role IL-6 is known to exert on gluconeogenesis (Metzger, et al., 
1997; Moh, et al., 2008; Wunderlich, et al., 2010), encouraged us to examine plasma 
glucagon levels in experimental animals. Glucagon levels are kept low under 
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normoglycaemic conditions, while as mentioned, hyperglucagonaemia is observed in 
DIO and long-term diabetes, arising from the establishment of insulin resistance and 
dyslipidaemia. As plasma volume became a limiting factor, it was only possible to 
assess plasma glucagon levels using a small number of samples from each group at 
baseline and following 30min of glucose administration (Figure 4.5.4D). 
Figure 4.5.4: oGSIS at Week 19 of the Study 
Figure 4.5.4A-C: GREEN: CRE SC (n=6); BLUE: KD SC (n=6); RED: CRE HFD (n=7); PURPLE: 
KD HFD (n=7). Results plotted as means +/-SEM. MANOVA indicated a significant effect of 
genotype (p=0.049, F=4.40) and diet (p=0.009), but no significant interaction between the 2 factors 
(p=0.33, F=1.01) in the variance observed. Figure 4.5.4A: Decreases in baseline insulin levels were 
evident in KD SC animals compared to CRE controls (CRE SC 1.13+/-0.26pg/ml; KD SC, 0.45+/-
0.03pg/ml; p<0.001). This effect persisted through the 3, 15 and 30min time points (all p<0.01). Figure 
4.5.4B: Resting plasma insulin levels were similar in CRE and KD HFD mice (CRE HFD 3.94+/-
0.27pg/ml; KD HFD 2.37+/-0.27pg/ml; p=0.13). Significant increases to baseline were observed in 
CRE HFD at the 15min time point (7.059+/-2.128pg/ml; n=6, p=0.0062). Plasma insulin was 
significantly different in KD HFD compared to CRE HFD at 15 (p<0.0001) and 30 min (p<0.0004).   
Figure 4.5.4D: GREEN: CRE SC (n=4); BLUE: KD SC (n=4); RED: CRE HFD (n=3); PURPLE: 
KD HFD (n=3). Results plotted as means +/-SEM. MANOVA of plasma glucagon levels at during 
GSIS indicated a significant effect of genotype (p=0.04, F=5.51), but not of diet (p=0.25, F=6397.78) 
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or their interaction (p=0.15, F=2.50) in the variation observed. Figure 4.5.4D; 0min: CRE SC 
142.47+/-51.97pg/ml Glucagon; KD SC 95.95+/-24.63pg/ml Glucagon; p>0.9; 30min: CRE SC 
145.49+/-98.42pg/ml Glucagon; KD SC 79.81+/-31.23pg/ml Glucagon; p>0.9. Marginal differences 
between the HF-fed groups failed to reach significance in pair-wise comparison. Figure 4.5.4D; 0min: 
CRE HFD 311.87+/-183.67pg/ml Glucagon; KD HFD 105.67+/-42.60pg/ml Glucagon; p=0.92; 
30min: CRE HFD 471.99+/-197.35pg/ml Glucagon; KD HFD 71.32+/-19.91pg/ml Glucagon; 
p=0.1366. 
Mean plasma glucagon in SC mice were similar, yet increases observed in CRE HFD 
mice were suppressed in KD HFD. A significant effect of genotype was reported in 
statistical analysis of variance (p=0.04, F=5.51), however differences observed in 
pair-wise comparison of KD and diet-matched controls were not significant (Figure 
4.5.4D). Data in this section clearly indicate a deficit GSIS in KD mice, and possibly 
a disruption in the physiological antagonistic relationship to glucagon. Significant 
differences were correspondingly observed in the ability of KD and CRE mice to 
clear glucose at 2 different points during the study (Week10 & 19, but not 14). 
Regardless, KD mice were still able to clear glucose during GTT, and insulin was 
detectable in blood plasma during GSIS. To further examine the origin of this defect 
in the KD, ex vivo GSIS and insulin glucagon staining, was examined in isolated 
pancreatic islet cells. 
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Metabolic Phenotyping using the CLAMS/Oxymax® Activity Monitor 
Following the completion of the Study Plan (Table 4) protocol animals were 
examined using the CLAMS/Oxymax® Activity monitoring system. Mice were 
housed individually in specialized activity monitoring cages and allowed 24 hours to 
familiarize with the new environment. A 12:12 dark: light cycle was maintained, and 
their access to water and respective diet in powder were provided ad libitum. Food 
intake, activity, heat and respiratory exchange ratio were recorded over the 
subsequent 48-hour period. Comparison of metabolic parameters within each phase of 
the cycle as well as differences between the 2 phases, and the associated influence of 
genotype and diet was assessed by MANOVA (IBM SPSS®). 
Figure 4.6.1: Mean Food Intake in CLAMS over 48 hours 
Figure 4.6.1: GREEN: CRE SC (n=9); BLUE: KD SC (n=9); RED: CRE HFD (n=7); PURPLE: KD 
HFD (n=11). Results plotted as means +/-SEM. Food intake was significantly increased during the 
dark compared to the light phase in both SC (Figure 4.6.1A; p<0.0001, F=117.21) and HFD (Figure 
4.6.1B; p<0.0001, F=33.58). Differences observed in the total food intake of KD and control mice on 
SC (p=0.18, F=1.91) and HFD (p=0.21, F=1.64) were not statistically significant. Dark Phase: CRE 
SC 6.1+/-0.3g; KD SC 7.1+/-0.2g; CRE HFD 4.7+/-0.6g; KD HFD 5.8+/-0.6g. Light Phase: CRE SC 
2.5+/-0.3g; KD SC 2.3+/-0.2; CRE HFD 2.2+/-0.2; KD HFD 2.5+/-0.2g.  
Food intake in experimental animals was significantly elevated during the dark phase 
of the light cycle (Figure 4.6.1). Approx. 75% of total food intake took place during 
the dark phase in both SC and HF-fed mice. However there was no significant effect 
of genotype, despite marginal differences observed in the food intake of KD and diet-
matched controls (Figure 4.6.1; SC: p=0.40, F=0.93; HFD: p=0.31, F=1.18). 
Significant differences observed at Study week 9 were not maintained on examination 
using the CLAMS/Oxymax®, which could relate to differences in the environment 
and food access in the metabolic phenotyping cages. 
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Figure 4.6.2: Mean Activity during CLAMS 
Figure 4.6.2: GREEN: CRE SC (n=9); BLUE: KD SC (n=9); RED: CRE HFD (n=7); PURPLE: KD 
HFD (n=11). Results plotted as means +/-SEM. Mean activity in SC (p<0.0001, F=214.0) and HFD 
(p<0.0001; F=199.4) mice was significantly influenced by the phase of the light cycle (Figure 4.6.2A, 
B). CRE SC and KD were significantly more active during the dark phase (p<0.0001). Figure 4.6.2A; 
Dark Phase: CRE SC 508.5+/-23.6AU; KD SC 347.5+/-12.06AU; p<0.001. Activity was equally 
suppressed in CRE and KD SC mice during the light phase (Figure 4.6.2A; CRE 181.6+/-12.55AU; 
KD 198.5+/-12.01AU; p=0.82). Figure 4.6.2B; Dark Phase: CRE HFD 276.3+/-15.07AU; KD HFD 
252.1+/-8.44AU p=0.68; Light Phase: CRE HFD 130.3+/-7.55AU; KD HFD 142.1+/-5.47AU; p=0.85. 
Activity was similarly decreased compared to SC mice in both CRE and KD HFD. Significant 
differences to SC mice during the dark (p<0.0001, F=110.6), but not the light phase of the cycle 
(p=0.11, F=2.61).  
As mentioned in previous sections, activity, food intake and thermogenesis are 
stereotypically elevated in the dark phase of the cycle of nocturnal animals. Chronic 
HF-feeding has been shown to induce increases in thermogenesis through changes in 
adiposity and decreased activity.  Mean locomotor activity of experimental animals 
on SC and HFD recorded by the CLAMS/Oxymax® Animal Monitoring system was 
consistent with this notion. Down-regulation of the IL-6Rα in SC mice was associated 
with significant decreases in activity (Figure 4.6.2A; p<0.0001) and thermogenesis 
compared to control mice (Figure 4.6.3A; p<0.0001). Activity was decreased in HF-
fed mice in the dark phase, however there was no significant effect of diet on activity 
in the light phase (Figure 4.6.2B; p=0.11, F=2.61). On the other hand significant 
increases in thermogenesis were observed in HFD compared to SC mice during both 
phases of the cycle (Figure 4.6.3B; Dark: p<0.0001, F=599.4; Light: p<0.0001, 
F=475.1). KD and CRE HFD mice were identical in terms of activity (Figure 4.6.2B; 
Dark: p=0.68; Light: p=0.85). Significant differences in thermogenesis were only 
observed during the light phase (Figure 4.6.3B; Dark: p=0.007; Light: p>0.0001). 
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Figure 4.6.3: Mean Heat Generated during CLAMS 
Figure 4.6.3: GREEN: CRE SC (n=9); BLUE: KD SC (n=9); RED: CRE HFD (n=7); PURPLE: KD 
HFD (n=11). Results plotted as means +/-SEM. Matching data recorded in terms of activity, heat 
generated was significantly influenced by the light cycle (p<0.0001, F=440.7) and thermogenesis was 
increased in KD (p<0.0001) and control SC (p<0.0001) mice during the dark phase. In further accord, 
thermogenesis was significantly influenced by genotype differences in both the dark (p<0.0001, 
F=44.03) and light phase (p<0.0001, F=119.5). Figure 4.6.3A; Dark Phase: CRE SC 0.92+/-0.007 
kcal/L O2; KD SC 0.84+/-0.005kcal/L O2; p<0.0001. Light Phase: CRE SC 0.81+/-0.006kcal/L O2; 
KD SC 0.73+/-0.008kcal/L O2. Figure 4.6.3B; Dark Phase: CRE HFD 1.08+/-0.008kcal/L O2; KD 
HFD 1.06+/-0.009kcal/L O2; p=0.007. Thermogenesis was significantly influenced by diet during both 
the dark (p<0.0001, F=599.4) and light phases (p<0.0001, F=199.5). Heat generated in KD (p<0.0001) 
and CRE HFD (p<0.0001) mice was significantly elevated compared to SC mice. Figure 4.6.3B; 
Light Phase CRE HFD 0.99+/-0.005kcal/L O2; KD HFD 0.90+/-0.01kcal/L O2; p<0.0001. Increased 
thermogenesis was observed in both KD (p<0.0001) and CRE HFD (p<0.0001) mice compared to SC. 
KD animals exhibited significantly decreased heat generation compared to CRE HFD  during the light 
phase. 
Respiratory exchange ratio (RER) can be used to indirectly assess the metabolic 
substrate being consumed by the body towards energy production. RER values close 
to 1.0 are indicative of metabolism relying predominantly on carbohydrate as a fuel 
source, 0.85 suggests a mix of fat and carbohydrate, while 0.70 indicates that fat is the 
predominant fuel source (Christiansen & Hansen, 1939). Typically RER is close to 
1.0 in SC mice during the feeding dark phase of the light cycle, and closer to 0.7 in 
HF-fed animals. Consequently during the light phase where food intake is naturally 
restricted, increased reliance on stored fat as metabolic fuel, RER is also around 0.7.  
 
Figure 4.6.4: Mean RER during CLAMS 
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Figure 4.6.4: GREEN: CRE SC (n=9); BLUE: KD SC (n=9); RED: CRE HFD (n=7); PURPLE: KD 
HFD (n=11). The variance observed in RER was significantly influenced by the light phase as expected 
(Figure 4.6.4A, B; p<0.0001, F=73.40). Genotype differences also exerted a significant effect on the 
variance observed in both the SC and HF-fed groups. KD SC displayed significantly increased RER 
compared to CRE controls suggesting increased reliance on carbohydrate during the dark phase 
(Figure 4.6.4A; CRE SC 0.92+/-0.004; KD SC 0.99+/-0.003; p<0.0001, F=344). By contrast to the 
dark phase, CRE SCs were observed to rely on mixed fuel during the light phase. KD SC animals 
continued to rely on carbohydrate during the non-feeding light phase by stark contrast to control 
animals (Figure 4.6.4A; CRE SC 0.88+/-0.03; KD SC 0.94+/-0.003; p<0.0001, F=3406). HFD 
induced significant disruption of the mean RER of animals during both phases of the light cycle in 
comparison to SC animals (Figures 4.6.4A, B; Dark: p<0.0001, F=409.1; Light: p<0.001, F=891.4). 
Consistent with the high fat content of the diet and their increased body fat, CRE HFD in particular 
exhibited increased reliance rely on fat metabolism during both phases of the  light cycle (Figure 
4.6.4B; CRE HFD Dark:0.74+/-0.001; Light: 0.76+/-0.001). This effect was disrupted in KD HFD 
animals that were seen to rely on a mixture of carbohydrate and fat in both the dark (0.82+/-0.0007, 
p<0.0001) and light (0.81+/-0.0008, p<0.0001) phases of the light cycle (Figure 4.6.4B).  
Unsurprisingly the light cycle exerted a significant effect on the variance observed in 
the RER of both SC (p<0.0001, F=183.3) and HF-fed mice (p<0.0001, F=433.1). 
Additionally, significant differences were observed between the HFD and SC groups 
in both phases (Dark: p<0.0001, F=409.1; Light: p<0.0001, F=891.4), as expected. 
Intriguingly increased reliance on carbohydrate oxidation compared to diet-matched 
controls was maintained through both phases of the cycle in both SC and HF-fed KDs 
(Figure 4.6.4A, B; p<0.001, F=73.4). Results obtained using the animal monitoring 
system suggested the brain-specific disruption of the IL-6 receptor to induce 
decreased activity and thermogenesis as well as a deficit in the ability of KD mice to 
utilize fat as a fuel. No significant differences were observed in terms of food intake. 
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Plasma Leptin and IL-6 at the End of the Study 
Increases in IL-6 (Kalofoutis, et al., 2006) and leptin (Friedman & Halaas, 1988) 
plasma levels have been associated with the development of diabetic disease. 
Circulating leptin levels have been known to correlate with adiposity and increase 
dramatically in response to DIO (Maffei, et al., 1995), while appetite and body weight 
are acutely suppressed in response to central leptin.  
Figure 4.7.1: Plasma Leptin at the End of the Study 
Figure 4.7.1: GREEN: CRE SC (n=5); BLUE: KD SC (n=5); RED: CRE HFD (n=5); PURPLE: KD 
HFD (n=5). Results plotted as means +/-SEM. Plasma leptin levels were significantly influenced by 
diet, and 10-fold increases were observed in HF-fed mice compared to age- and genotype-matched SC 
(p<0.0001, F=395). 2-way ANOVA also indicated a significant effect of genotype (p=0.04, F=5.027), 
but no effect of the interaction of genotype and diet in the variance observed (p=0.05, F=4.36). 
Circulating leptin levels in KD SC were analogous to levels observed in control mice (CRE SC 
14919+/-34.02pg/ml; KD SC 15683+/-3006pg/ml; p<0.99). Increases observed in response to chronic 
HF-feeding were significantly augmented in KD HFD mice compared to CRE HF-fed mice (CRE HFD 
103578+/-7991pg/ml; KD HFD 125164+/-2881pg/ml; p=0.03).  
Inflammatory signaling in the central nervous system has been suggested to 
participate in neuroendocrine signaling networks dedicated to regulation of body 
weight, body composition and satiety levels (Zhang, et al., 2008). Brain-specific 
down-regulation of the IL-6 receptor was demonstrated in NesCreIL-6Rα KD mice in 
Chapter 3. Differences observed in the body composition (Figures 4.2) and food 
intake (Figures 4.3) of KD mice during the study encouraged me to examine 
circulating plasma leptin & IL-6 levels. The influence of genotype and diet in the 
differences observed in plasma IL-6 and leptin were assessed separately by 2-way 
ANOVA. 
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Figure 4.7.2: Plasma IL-6 levels at the End of the Study 
Figure 4.7.2: GREEN: CRE SC (n=5); BLUE: KD SC (n=5); RED: CRE HFD (n=5); PURPLE: KD 
HFD (n=5). Results plotted as means+/-SEM. Statistical analysis circulating IL-6 levels indicated a 
significant effect of the interaction of genotype and diet (p=0.008, F=9.27) in the variance observed but 
no significant effect of genotype (p=0.076, F=3.6), or diet alone (p=0.095, F=3.15). A two-fold 
increase in plasma IL-6 was observed in KD SC mice compared to age-matched control mice (CRE SC 
58.82+/-13.03pg/ml; KD SC 138.9+/-15.41pg/ml; p=0.014). Chronic HF-feeding promoted significant 
increases in plasma IL-6 in control mice (p=0.017), but no differences were observed between SC and 
HF-fed KDs (p=0.81). Equivalent plasma IL-6 levels detected in KD and CRE HFD mice (CRE HFD 
175.8+/-14.22; KD HFD 199.2+/-20.95pg/ml; p=0.85). 
Despite differences in food intake (Figure 4.3) and body composition (Figure 4.2), 
there was no significant difference between KD and CRE SC mice in terms of 
circulating plasma leptin (Figure 4.7.2; p<0.99). On the other hand, chronic HF-
feeding was associated with 10-fold increases in plasma leptin levels in both KD and 
control mice compared to age-matched SCs (Figure 4.7.1; p<0.0001, F=395). The 
effect of genotype in the variance observed related to differences between KD and 
control mice on HFD (Figure 4.7.1; p=0.04, F=5.027). Plasma leptin was 
significantly elevated in KD HFD mice compared to controls, reflecting differences 
observed in body composition at the end of the study (Figure 4.2.5).  Previous studies 
have suggested regulate leptin sensitivity through central effects (Fukuda, et al., 2005; 
Ropelle, et al., 2010). To further interrogate the contribution of leptin to the 
phenotype, the sensitivity of KD and control mice to the anorexigenic and weight-
reducing effects of leptin was assessed in separate experiments.  
Consistent with previous studies (Kern, et al., 2001), a 2-fold induction of IL-6 was 
observed in response to HFD in CRE HFD compared to SC mice (Figure 4.7.2, 
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p=0.0007). This effect was not observed in KD mice, as plasma IL-6 was significantly 
increased in the KD compared to SC controls (Figure 4.7.2, p=0.0014), and no 
further increases were observed in response to chronic HF-feeding (p=0.81). Mean 
plasma IL-6 in KD mice was comparable to levels recorded in HF-fed controls, 
independently of diet (p=0.09, F=3.15). 
 
Pancreatic Insulin and Glucagon  
Examination of the effects of the insulin response to oral glucose in KD and control 
animals (on SC & HFD) in vivo revealed a significant deficit in basal and glucose-
stimulated insulin release (Figure 4.5.4). To interrogate the origin of this defect, 
pancreatic cell morphology was examined by immunohistochemistry, as well as the 
ability of ex vivo pancreatic cells to respond to glucose. 
Figure 4.8.1: Pancreatic Islet Immunohistochemistry in SC mice 
Index: Blue: DAPI; Red: Insulin; Green: Glucagon 
A – WT SC     B - CRE SC    
 
 
 
 
 
 
 
 
 
 
 
 
C – KD SC 
 
 
 
 
 
 
 
 
 
Figure 4.8.1: Adult (>8 weeks old) mice 
were used.  A – WT SC (n=4); B – CRE SC 
(n=4); C- KD SC (n=4). Pancreatic Insulin 
and Glucagon was examined in control 
and NesCreIL-6Rα KD animals by 
immunohistochemistry. Islets identified 
under x40 magnification (Leica® TCS SP5 
II). Images obtained from KD mice 
confirmed the expression of insulin and 
glucagon in pancreatic tissue.  Similar 
pattern of Insulin/glucagon staining 
observed in KD and control islets.  
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Immunohistochemical examination of pancreatic tissue indicated NesCre-mediated 
down-regulation of the IL-6Rα to have no direct effect in the expression of insulin 
and glucagon protein at the pancreas. Glucagon and insulin staining are commonly 
used to confirm the expression of pancreatic α and β cells respectively. Our transgenic 
approach did not induce any effects on insulin/glucagon staining in KD SC compared 
to both CRE and WT animals (Figure 4.8.1A-C). Changes in islet morphology as a 
consequence of the pathophysiological effects of DIO in control animals were not 
different in the KD (Figure 4.8.2A, B). The deficit observed in KD mice in during 
GSIS (Figure 4.5.4) was thus not associated with differences in islet morphology 
compared to control animals, or the ability of KD islets to express insulin and 
glucagon. 
Figure 4.8.2: Pancreatic Islet Immunohistochemistry in HF-fed mice 
Index: Blue: DAPI; Red: Insulin; Green: Glucagon 
A – WT HFD     B - KD HFD    
 
Pancreas from age-matched WT, CRE and KD SC animals was collected with the 
help of Mrs Jennifer Gallagher and Dr Alison D. McNeilly. Pancreatic islet cells from 
Figure 4.8.2: Adult (>8 weeks old) mice were used following chronic HF-feeding.  A – WT HFD 
(n=2); B – KD SC (n=2). Insulin and Glucagon protein staining was examined in control and 
NesCreIL-6Rα KD animals by immunohistochemistry. Islets identified under x40 magnification 
(Leica® TCS SP5 II). Pancreatic islets identified in slides from HF-fed animals (n=2) displayed 
increases in size compared to SC islets. Insulin staining was pronounced, while glucagon staining 
was markedly decreased compared to images obtained from SC mice. This effect was observed in 
both KD and control islets identified. 
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WT, CRE and KD SC animals were isolated ex vivo to assess the ability of endocrine 
tissue within islets to release insulin and glucagon. Islets were incubated in high 
glucose (20mM glucose) for 1 hour (Carter, et al., 2009) and Insulin and Glucagon 
levels secreted in media were measured by ELISA (Figure 4.8.3). Results were 
analysed by 1-way ANOVA. No significant differences were reported between KD 
and CRE islets in terms of ex vivo glucose-stimulated insulin (p=0.110, F=2.91) or 
glucagon release (p=0.52, F=0.43). Even though examination of the glucose-
stimulated insulin secretion of KD animals in vivo revealed a clear deficit in insulin 
release (Figure 4.5.4), no significant differences were observed when islets were 
isolated ex vivo. 
Figure 4.8.3: Insulin and Glucagon secretion from ex vivo Pancreatic Islets in 
Response to High Glucose (20mM) 
Islet Ex vivo Insulin Release
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Figure 4.8.3: Pancreatic islets from adult (>8weeks) mice on standard chow were isolated ex vivo and 
stimulated with 20mM Glucose. GREY: WT SC (n=8); CRE SC (n=8); KD SC (n=8). Results 
represent mean hormone levels detected in islet media +/-SEM. Glucose-stimulated insulin release 
from ex vivo KD islets was comparable to levels observed in CRE islets (Figure 4.8.3A; CRE SC 
0.74+/-0.08pg/ml Insulin; KD SC 1.01+/-0.11pg/ml Insulin; p=0.11; F=2.91). Similarly, glucagon 
secretion from ex vivo islets was not statistically different between CRE and KD mice (Figure 4.8.3B; 
CRE SC 68.73+/-17.87pg/ml Glucagon; KD SC 93.06+/-9.36pg/ml Glucagon; p=0.52, F=0.43). WT 
animals were examined as an additional control group. Insulin (Figure 4.8.3A; WT SC 0.72+/-
0.07pg/ml) and glucagon (Figure 4.8.3B; WT SC 84.64+/-28.21pg/ml) secretion from WT islets 
resembled levels detected in CRE and KD islets.  
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Examination of the Response to Intra-Peritoneal Leptin 
Circulating leptin levels correlate with body weight and adiposity, and increases are 
known to promote energy expenditure and satiety through central effects (Friedman & 
Halaas, 1988; Cohen, et al., 2001). Hyperleptinaemia and leptin resistance have been 
consistently reported in obese humans and animal models of obesity (Maffei, et al., 
1995; Frederich, et al., 1995). More recently, persistent increases in circulating 
cytokines such as IL-6 in response to chronic HF-feeding have been suggested to 
promote leptin resistance at the hypothalamus. The accumulation of shared negative 
feedback regulators (e.g. SOCS-3, EPAC-1), have been suggested to impair the ability 
of leptin to induce increases in STAT3 phosphorylation (Fukuda, et al., 2005; Mori, et 
al., 2004).  
Figure 4.9.1: Examination of the effects of IP Leptin on Food Intake and Change 
in Body Weight in mice 
Figure 4.9.1: GREEN: CRE SC (n=6); BLUE: KD SC (n=6). Adult (>8weeks) female mice were 
used. Leptin treatment exerted a significant effect on body weight in both genotypes (Figure 4.9.1A; 
CRE SC -0.3+/-0.1g; KD SC -0.5+/-0.1g; p<0.0001, F=48.18). Body weight responses to leptin 
treatment and control conditions were nearly identical in KD and CRE SC mice (Figure 4.9.1A; 
p=0.43, F=0.62). Similarly the interaction between genotype and treatment was not statistically 
significant (Figure 4.9.1A; p=0.12, F=2.49). Food intake decreased in response to leptin treatment in 
both CRE and KD mice (Figure 4.9.1B; p=0.03, F=9.58). Statistical analysis indicated a significant 
effect of genotype on the variance observed in food intake (Figure 4.9.1B; p=0.01; F=7.09). This 
related to differences observed under control conditions prior (CRE SC 2.5+/-0.3g; KD 4.0+/-0.2g; 
p=0.03), but not in response to leptin treatment (CRE SC 1.8g+/-0.3g; KD SC 2.9+/-0.4g; p=0.19). 
Compensatory increases were observed in both genotypes during the 2 days following leptin treatment. 
CRE and KD food intake was not statistically different on Day 3 (CRE SC 3.7+/-0.4g; KD SC 3.2+/-
0.3g; p= 0.74) or Day 4 (CRE SC 2.7+/-0.4g; KD SC 3.3+/-0.3g; p=0.74). 
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Statistical analysis of the response to the leptin sensitivity assessment protocol was 
carried out with regards to changes food intake and body weight over 4 days. Results 
were analyzed using 2-way ANOVA (IBM SPSS 21®). Leptin treatment was 
associated with decreases in body weight and food intake in both CRE and KD SC 
mice (Figure 4.9.1). Changes observed in body weight were independent of genotype 
(p=0.43, F=0.62). The effect of genotype on food intake (p=0.01, F=2.09), related to 
increased food intake in the KD prior to leptin treatment (p=0.03) corroborating 
previous findings (Figure 4.3). Food intake following IP leptin was not significantly 
different between KD and control mice (p=0.19). Furthermore, the induction of 
STAT3 phosphorylation in response to IP leptin was intact in NesCreIL-6Rα KD 
mice (Figure 4.9.2).  
Figure 4.9.2: Examination of the effects of IP Leptin (50µg/kg) on STAT3 
phosphorylation in hypothalamic tissue 
 
 
 
 
 
 
 
 
Figure 4.9.2: Adult (>8 weeks) mice were used. Half of the KD and CRE SC animals (n=6) 
participating in this experiment received an IP injection of Leptin (50µg/kg) (+) and the rest Saline (-), 
as indicated. Hypothalamic tissue was collected 1hour following leptin or saline injection. Leptin 
administration consistently induced up-regulation of phosphorylated STAT3 protein in the 
hypothalamus. pSTAT3 – 79/88 kDa; Loading Control: GAPDH – 37 kDa (Cell Signaling®) 
  
Leptin 
pSTAT3 
GAPDH 
-     +     -     +     -     +         -      +     -     +     -     + 
CRE KD 
140 
 
Summary 
The metabolic phenotype of the novel NesCreIL-6Rα KD on SC and HFD was 
examined over a period of 20 weeks, and compared to control animals (Diagram 3). 
Body weight gain through the course of the study was closely matched between the 
two genotypes, both on SC and HFD (Figure 4.1). Paradoxically, KD SC mice 
exhibited hyperphagia (Figure 4.3), while body adiposity was significantly decreased 
compared to age-matched controls throughout the course of the study (Figures 4.2.1-
5). KD HFD mice were also hyperphagic compared to diet-matched controls; 
however following 20 weeks of HF-feeding, increased adiposity was recorded. The 
phenotype was not the consequence of differences in leptin sensitivity, as indicated by 
additional studies using a separate group of KD and CRE SC mice. The hyperphagic 
phenotype of the KD was not associated with differences in baseline glycaemia or 
insulin sensitivity during the study. Sensitivity to the hypoglycaemic effects of 
exogenous insulin was similar in KD and control mice on SC at Study weeks 6, 9 and 
15 (Figures 4.4.1-3). Evidence of insulin resistance was only apparent in KD and 
control HF-fed mice after 15 weeks of diet, and no differences were observed 
between the 2 genotypes in this response. However, glucose clearance was 
significantly suppressed in KD mice at Study Weeks 10 and 19 (but not 14), while 
basal and glucose-stimulated insulin secretion was dramatically disrupted (Figures 
4.5.1-4).  Additional studies conducted using ex vivo islets from KD SC and control 
mice, indicated that the disruption of GSIS in KD mice in vivo was not due to 
differences in the ability of islets to produce and secrete insulin and glucagon 
(Figures 4.8.1-3). Collectively our studies suggest central IL-6 signaling to 
participate in the integration of satiety signals, at least in part through the regulation 
of insulin release in response to changes in glucose loading.  
Finally, at the end of the study, KD and control mice were examined using the 
CLAMS/Oxymax® system. Consistent with central IL-6 signaling promoting 
pyrogenesis (Rothwell, et al., 1991) and fat oxidation (Wallenius, et al., 2002); KD 
mice exhibited decreased activity and thermogenesis at different stages of the light 
cycle (Figures 4.6.2-3). Furthermore, differences in RER between KD and diet-
matched control mice indicated increased reliance on carbohydrate fuel in the KD 
even in response to HFD (Figure 4.6.4).  
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Table 6: Summary of the NesCreIL-6Rα KD Metabolic Phenotype 
Metabolic Phenotype Parameter 
Examined 
Differences Compared to Control Mice 
SC HFD 
Body Weight - - 
Body Fat Composition ↓ ↑After 20 weeks 
24-Hour Food Intake ↑ ↑ 
Plasma Leptin - ↑ 
IP Leptin Sensitivity - N/A 
Baseline Glycaemia - - 
IP Insulin Tolerance Test - - 
Oral Glucose Tolerance Test ↓Glucose 
Clearance 
↓Glucose 
Clearance 
In vivo GSIS ↓ ↓ 
Ex vivo GSIS - N/A 
Pancreatic Islet Insulin/Glucagon 
Immunohistochemistry 
- - 
Food Intake in CLAMS  ↑ (ns) ↑ (ns) 
Activity in CLAMS ↓ Dark Phase - 
RER in CLAMS ↑Both Phases ↑Both Phases 
Thermogenesis in CLAMS ↓ Both Phases ↓ Light Phase 
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Chapter 5: Discussion 
Generation and Characterization NesCreIL-6Rα KD mice 
By crossing NesCre and IL-6Rαflox/flox mice, we were able to generate and validate a 
novel transgenic where the IL-6Rα gene was disrupted in the brain specifically 
(NesCre-IL-6Rα KD).  Wild-type (WT), NesCre+ (CRE) and KD mice were 
identified by standard PCR (Figures 3.2, 3.3). Receptor mRNA expression in KD and 
control brains was initially assayed using real-time PCR and significant differences 
were observed between age- and sex-matched CRE and WT IL-6ra mRNA expression 
(Figure 3.4.1). This finding as well as other recent published work suggesting 
differences in the metabolic phenotype of CRE and WT/C57Bl6 mice, indicated CRE 
mice to be the appropriate control group for the KD (Harno, et al., 2013). IL-6ra 
mRNA was significantly decreased in the hippocampus and the hypothalamus, but not 
the frontal cortex or the cerebellum of KD mice compared to CRE controls (Figure 
3.4.2). Brain IL-6Rα protein expression was also examined using 
immunohistochemistry. In region-matched slices from the hippocampus and 
hypothalamus of CRE and KD mice, the percentage of IL-6 receptor-positive NeuN 
cells was decreased in the KD group (Figure 3.8.2-3). Matching mRNA expression 
data, IL-6Rα immunoreactivity was similar in the KD and CRE frontal cortex (Figure 
3.8.1). Analysis of imaging data using Volocity® (PerkinElmer®) indicated the 
NesCre-mediated disruption of the IL-6Ra to be primarily affect receptor co-
localization with neurons, even though decreases in receptor co-localization with 
astrocytic biomarkers were also observed (Figure 3.8.4). 
To functionally assess the effects of the KD, the ability of IL-6 to activate STAT3 in 
ex vivo brain slices from the mediobasal hypothalamus was examined by western 
blotting. IL-6 treatment in control slices promoted significant increases in pSTAT3 in 
this metabolically active brain region, contrasting KD responses that failed to reach 
significance (Figure 3.7). Furthermore, KD and control mice were administered a 
weight-adjusted dose of intra-peritoneal (IP) IL-6 in vivo. IP IL-6 treatment in CRE 
mice induced STAT3 phosphorylation in peripheral (heart, kidney, liver, lung, muscle, 
spleen, brown- & white-adipose tissue) and central tissue examined (hippocampus, 
hypothalamus and cerebellum).  Peripheral tissue from KD mice responded to IL-6 
treatment in a similar fashion to control animals, confirming that peripheral receptor 
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expression was not disturbed (Figures 3.6.1-9). However, phosphorylation/activation 
of STAT3 in response to IL-6 was disrupted in the KD brain across all regions 
examined, in further support of the brain-specific disruption of the IL-6 receptor 
system (Figures 3.5.1-3). Consistent with previous studies using NesCre mice, results 
shown in Chapter 3 confirmed brain-specific disruption of the IL-6Rα system in 
NesCreIL-6Rα KD mice. To examine the role of central IL-6 signaling in the 
development of DIO and diabetes, KD and control mice on SC and HFD were 
examined over a 20-week period. 
 
Metabolic Phenotype of the NesCreIL-6Rα KD 
Brain-specific IL-6Rα down-regulation in NesCreIL-6Rα KDs was associated with a 
dramatic suppression of in vivo GSIS (Figure 4.5.4), but was of little consequence to 
the blood glucose response to insulin (Figures 4.4.1-3) and the body weight and food 
intake response to leptin (Figure 4.9.1-2). Body weight was closely matched between 
KD and control animals on SC diet, while dramatic increases observed in control 
animals on HFD were mirrored in HF-fed KDs (Figure 4.1). Paradoxically, KD SC 
mice were significantly leaner than control mice, despite being hyperphagic (Figures 
4.2.1-5, 4.3, 4.9.1), hypoactive and less thermogenic (Figure 4.6.2-4). Hyperphagia 
and suppression of energy expenditure was also observed in the HF-fed KDs, and the 
leaner phenotype was progressively reversed through the course of 20weeks of diet 
(Figures 4.2.1-5, 4.6.2-4). The complex phenotype observed in the KD can be 
explained by the combined disruption of (a) the anorexigenic effects of central insulin 
and IL-6 signaling (Woods, et al., 1979; Wallenius, et al., 2002); (b) the lipogenic 
effects of GSIS in the periphery (Kahn & Flier, 2000); and (c) the thermogenic and 
lipolytic effects of central IL-6 signaling (Rothwell, et al., 1991; Van Hall, et al., 
2003; Carey, et al., 2006). Consistent with previous findings, studies using the 
NesCreIL-6Rα KD additionally implicate central IL-6 signaling in the coordination of 
insulin secretion in response to changes in nutrient availability; and to be 
consequently required for the induction of the anabolic and anorexic effects of the 
hormone. 
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Figure 5.1: Schematic representation of the NesCreIL-6Rα KD metabolic 
phenotype 
 
In response to glucose loading, insulin acts to inhibit liver gluconeogenesis and 
activates glucose up-take  (Hardwick, et al., 1959; Caygill & Stein, 1972; Mohan & 
Bessman, 1985) lipogenesis (Kim, et al., 1998; Griffin & Sul, 2004; Seo, et al., 2004), 
while by passing the blood-brain barrier insulin acts in the mediobasal hypothalamus 
to inhibit food intake  (Woods & Seeley, 2000; Schwartz, et al., 2000). The brain 
modulates autonomic output to the periphery, driving changes in energy expenditure 
in muscle and fat, as well as regulating endocrine secretions from the pancreas. The 
suppression of GSIS observed the KD in vivo was not maintained in isolated ex vivo 
islets, implicating central effects to underlie the defect (Figures 4.8.1-3). Insulin 
secretion from the pancreatic β cell is stimulated by parasympathetic inputs  (Kaneto, 
et al., 1975; Berthoud, et al., 1980; Lundquist, 1982; N'Guyen, et al., 1994) and 
inhibited by sympathetic innervation that promotes the expression of counter-
regulatory hormones (Ahren, 2000; Gilon & Henquin, 2001). This is coordinated by 
specialised neuronal populations of the hypothalamus  (Guillod-Maximin, et al., 2004; 
Jansen, et al., 1997) and the brainstem (Ionescu, et al., 1983; Jansen, et al., 1995; 
Dallaporta, et al., 1999).  Glucose-dependent changes in the activity of POMC and 
NPY/AgRP neurons in the hypothalamus in particular, are likely implicated in the 
GSIS phenotype observed in the NesCreIL-6Rα KD (Claret, et al., 2007; Ersnt, et al., 
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2009; Belgardt, et al., 2009). Given the GSIS defect observed in the KD, in 
conjunction with hyperphagia, it is possible that brain-specific disruption of the IL-6 
receptor induced increases in orexigenic NPY and decreased anorexigenic POMC 
activity in the hypothalamus (Senaris, et al., 2011; Schele, et al., 2013); that would 
suppress pancreatic β cell secretions, inhibiting both the anorexic and anabolic effects 
of the insulin (Woods, et al., 2006; Palou, et al., 2009). 
Pharmacological or diet-induced increases in circulating IL-6 have been suggested to 
promote enhanced GSIS in mice (Carey, et al., 2006; Franckhauser, et al., 2008). This 
was not the case in the NesCreIL-6Rα KD, suggesting central IL-6 to be involved in 
the physiological enhancement of GSIS in response to insulin resistance (Figures 
4.5.4, 4.7.2). Furthermore, recent studies have suggested central IL-6 signaling to be 
required for the induction of the anorexic effects of exendin-4, a drug that decreases 
NPY expression in the brain and increases sympathetic output (Perez-Tilve, et al., 
2010; Dalvi, et al., 2012; Shirazi, et al., 2013; Yang, et al., 2014). The increased 
reliance on carbohydrate fuel, decreased thermogenesis and increased lipogenic 
capacity observed in HF-fed NesCreIL-6R KD mice would be consistent with this 
(Figure 4.2.1-5, 4.6.2-4). Further studies would be required to determine the effect of 
the KD on the balance of anorexigenic/orexigenic neuropeptides at the brain and the 
expression of thermogenic and lipolytic enzymes in the periphery.  
Despite suppression of GSIS, KD animals avoided overt hyperglycaemia in response 
to oral glucose, suggesting that compensatory events might have accounted for the 
defect (Figures 4.5.1-3). The first phase of insulin secretion ensues within the first 2 
minutes of a glucose challenge and peaks by approx. 10 min, followed by longer more 
prolonged phase that plateaus at 2-3hours (Gerich, 2002; Del Prato, et al., 2002). 
Hyperinsulinaemia is commonly observed in chronically HF-fed mice (Winzell & 
Ahren, 2004), and disruption of the pulsatility of insulin secretion into the portal vein 
has been suggested to directly contribute to the development of insulin resistance at 
the level of the liver  (Schofield & Sutherland, 2012; Song, et al., 2000; Porksen, et 
al., 1996; Butler, et al., 2003). Indeed, chronic high fat feeding was associated with 
the disruption of the 1st and the enhancement of the 2nd phase of GSIS control animals 
(Figure 4.5.4), indicative of the establishment of insulin resistance (Del Prato & 
Tiengo, 2001; Cheng, et al., 2013). This was contrasted by marginal increases in 
plasma insulin in the KD HFD mice that were sufficient to maintain comparable 
glycaemia to controls. It is thus likely that the chronic suppression of insulin secretion 
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observed in KD animals, promoted increased insulin sensitivity at the liver. Further 
studies would be required to confirm whether KD mice experienced differences in the 
expression of factors regulating insulin sensitivity at the liver during GSIS, such as 
G6Pase (Franckhauser, et al., 2008; Mauer, et al., 2014).  
 
Conclusions 
The expression of adipostatic (e.g. insulin and leptin) and inflammatory mediators 
(e.g. IL-6) is increased during the development of DIO (Bastard, et al., 2006), and 
circulating levels have been shown to correlate with diabetic disease severity 
(Mohamed-Ali, et al., 1997; Kroqu-Madsen, et al., 2004; Daniele, et al., 2014). 
Cytokine release from adipose tissue increases in response to stimuli such as 
oxidative stress (Pereda, et al., 2006) and hyperglycaemia (Kroqu-Madsen, et al., 
2004), commonly observed in obesity and type 2 diabetes (Wellen & Hotamisligil, 
2005; Tsiotra & Tsigos, 2006; Boden, 2009). More recently, sustained activation of 
inflammatory cascades at level of the hypothalamus has been suggested to be central 
to the development of DIO and the establishment of metabolic dysfunction leading to 
diabetic pathology (Zhang, et al., 2008; Wang, et al., 2010).  
The role of IL-6 in metabolic regulation was previously highlighted in studies 
involving IL-6 null mice that exhibited glucose intolerance, insulin insensitivity and 
developed mature onset obesity (Wallenius, et al., 2002; Matthews, et al., 2010). 
Since then, IL-6 has been demonstrated to drive glucose uptake from muscle 
(Petersen & Pedersen, 2006) as well as pancreatic β cell glucose-stimulated insulin 
secretion (GSIS) in vivo and ex vivo (Choi, et al., 2004; Ellingsgaard, et al., 2011); 
and to promote liver insulin sensitivity during GSIS (Wunderlich, et al., 2010). 
Infusion of peripheral or central IL-6 itself, inhibits food intake through the induction 
of anorexigenic POMC in the hypothalamus  (Rummel, et al., 2006; Senaris, et al., 
2011), but is also associated with increases in white adipose tissue (WAT) lipolysis 
and sympathetic stimulation of brown adipose tissue (BAT) thermogenesis (Rothwell, 
et al., 1991; Plata-Salaman, 1996; Wallenius, et al., 2002). More recently, IL-6 has 
been suggested to promote the action of insulin through central effects (Flores, et al., 
2006; Shirazi, et al., 2013; Mauer, et al., 2014), however prolonged engagement of 
the cytokine signaling cascade is associated with pathology (Campbell, et al., 2014) 
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The suppression of baseline and glucose-stimulated insulin and glucagon levels 
observed in NesCreIL-6Rα KD animals indicate the cytokine to be prominently 
involved in the regulation of the brain-pancreas axis. Furthermore, persistent 
hyperphagia and inhibition of fat oxidation in the novel transgenic, implicate the 
cytokine in the integration of meal-related factors (e.g. glucose) at the brain and the 
modulation of acute- and long-term autonomic output that drive changes in 
metabolism in the periphery (Mauer, et al., 2014). IL-6 would appear to act centrally 
to regulate pancreatic insulin secretion, and perhaps increases observed in response to 
HF-feeding in both mice and humans represent a protective response to augment 
insulin secretion in the face of persistent increases in circulating nutrients.  
In addition to the pyrogenic and anorexigenic effects of cytokines in the context of 
infection, our data suggest increases in circulating IL-6 to act at the brain to intercept 
prolonged exposure to hyperphagia, at least in part through enhancing insulin 
secretion. SC KDs exhibited hyperphagia that was accompanied by significant 
increases plasma IL-6, that unlike control animals were not further increased in 
response to HFD. Given the leaner phenotype observed in KD SC mice, it is possible 
that increases in circulating IL-6 act in the brain to indirectly promote increases in 
adipose tissue expansion through insulin. On the other hand, IL-6 acts centrally to 
promote thermogenesis through fat oxidation, an effect that was disrupted in KD 
mice, but was of no consequence on SC. However, in HF-fed KDs, the combined 
suppression of GSIS and reduced glucose clearance, as well as hyperphagia and 
inhibition of fat oxidation resulted in increased adiposity. Collectively, this composite 
phenotype observed in our mouse model would suggest IL-6 to be a component of the 
acute protective response to nutrient excess in mammals, whose prolonged 
engagement in DIO and type 2 diabetic humans experiences resistance, further 
promoting metabolic dysfunction. KD mice exhibited a form of metabolic inflexibility 
in terms of fuel utilization and decreased thermogenesis that likely contributed to the 
increased body fat observed in response to HFD. This scenario would match the 
phenotype observed in a number of chronic DIO and T2D patients, where the ability 
of the body to regulate food intake and utilize fuel is compromised (Larson, et al., 
1995; Labayen, et al., 2004). Despite the dramatic inhibition of GSIS, KD mice were 
still able to clear glucose, through marginal fluctuations in plasma insulin levels. This 
might suggest central IL-6 signaling to be indirectly involved in the regulation of 
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insulin sensitivity at liver (Inoue, et al., 2006) or muscle tissue (Pedersen, et al., 
2001). 
In summary, the NesCreIL-6Rα KD exhibited brain-specific down-regulation of the 
IL-6Rα system with prominent effects in metabolically active mediobasal 
hypothalamus, which was associated with a significant effect on insulin secretion and 
energy expenditure. However, further studies would be required to outline the precise 
contribution of individual neuronal populations and compensatory changes in the 
expression of circulating and tissue-specific biological markers to the phenotype. 
 
Diabetic Treatment and Interleukin-targeted therapies 
Glycated haemoglobin (HbA1c) is the current recommended method of assessment of 
long term glycaemia in diabetic patients (Nielsen, et al., 2014). Glycated haemoglobin 
is formed by reversible glycation at the N-terminus and is known to increase 
proportionally to glucose intolerance. The practice is followed as HbA1c levels reflect 
the fluctuation in glucose levels over a period of 2-3 months, the typical lifespan of 
erythrocytes (Jeffcoate, 2004; Tahara & Shima, 1993). This provides an obvious 
advantage to assessment of fasted blood glucose alone, even though diet or treatment 
can alter HbA1c values within 6 weeks. HbA1c in health is below 42mmol/mol 
(<6%), ranges between 42 and 47mmol/mol (6.0-6.4%) in pre-diabetic patients and 
exceeds 48mmol/mol (>6.5%) in diabetes (International Expert Committee, 2009). 
Current regiments suffer from an array of side-effects such as weight gain, 
hypoglycaemia, gastrointestinal infections and bone fragility (Barnett, 2013).  An 
over-reliance on insulin therapy should also be noted; that albeit effective in the 
management of hyperglycaemia and dyslipidaemia, is not subject to physiological 
regulation and is accompanied with other long term complications (Lavernia, 2008; 
Shogbon & Levy, 2000; Moghissi, 2010; Reider, et al., 2009).  
Metformin is currently the first line of pharmacological treatment, although the 
precise mechanisms by which the biguanide is able to induce its potent anti-
hyperglycaemic effects are not clear (Rena, et al., 2013). Activation of AMPK via 
metformin has been suggested to involve biguanide metal-binding properties (Logie, 
et al., 2012), which would be consistent with the metallic taste reported by patients. 
Metformin + insulin dual therapy is most effective at regulating glycaemia and body 
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weight, even compared to insulin monotherapy (Strowig, et al., 2002). Despite being 
particularly effective at HbA1c regulation, this choice of dual therapy increases both 
the incidence of hypoglycaemia while still posing the thread of cardiovascular 
complications associated with increased body weight (Anon., 2015; Anon., 2014).  
Sulfonylureas have now been used for a number of decades (Mirsky, et al., 1956) in 
diabetic care and are known to lower HbA1c in monotherapy (Anon., 1985). Their 
action involves glucose independent inhibition of potassium flux through KATP 
channels at the β cell (Ashcroft & Rorsman, 1989; Smith, et al., 1990). This allows 
for depolarization and opening of voltage-gated Ca2+ channels, stimulating insulin 
secretion (Panten, et al., 1996). The use of sulfonylureas (Wheeler, et al., 2013) and 
their combination with metformin in particular, is of questionable long-term efficacy, 
as it has been associated with dose-related hypoglycaemia, cardiovascular 
complications and morbidity (Roumie, et al., 2014; Li, et al., 2014; Mogensen, et al., 
2015).  
Thiazolidinediones, on the other hand, target the PPARγ signaling cascade (de Douza, 
et al., 2001; Spiegelman, 1998), inducing an expansion of adipose tissue, which 
ameliorates inflammation and insulin resistance (Saraf, et al., 2011; Ikeda & 
Sugiyama, 2011). Unfortunately, data suggest that unwanted side effects include 
increases in body weight (Boden & Zhang, 2006; Hermansen & Mortensen, 2007), 
increased incidence of bone fractures (Riche & King, 2010; Zhu, et al., 2014), and 
alarmingly increased incidence of bladder cancer (Turner, et al., 2014; Tseng, 2014) 
and cardiovascular events  (Della-Morte, et al., 2014). 
When considering the aging population of the world today as well as the increasing 
incidence of DIO and T2D, it would appear that new pharmacotherapies are required 
that are associated with fewer side effects and the risk of further cardiovascular events 
through their use over extended periods of time. In line with other recent work 
(Maeder, et al., 2011; Kraakman, et al., 2013; Emamaullee, et al., 2009), studies using 
the NesCreIL-6Rα KD provide evidence that cytokine signaling could provide a 
means of manipulation of insulin secretions that would not rely on previously 
established pharmacotherapies or insulin replacement therapy in itself. Central and 
peripheral cytokine signaling are increasingly understood to participate in the 
beneficial effects of exercise, that is still the most common means of management of 
long term metabolic stress (Pi-Sunyer, 2012; Danesh, et al., 2008; Petersen & 
Pedersen, 2006). Possible pitfalls of interleukin-signaling based therapies were 
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previously exposed, in phase I studies using recombinant human CNTF in ALS 
patients, as some subjects developed auto-antibodies for the drug (Anon., 1995). 
However, advancements since then, have allowed for drugs like the highly efficacious 
Tocilizumab to be approved by the FDA towards the treatment for rheumatoid 
arthritis and Castleman Disease patients  (Nishimoto, 2005; Nishimoto, et al., 2004; 
Maini, et al., 2006). The drug acts by blocking both modes of IL-6 signaling, but was 
interestingly found to been associated with hyperlipidaemia and weight gain. 
Similarly, recent translational has indicated the treatment of hypercholesterolaemic 
mice with the natural blocker of IL-6 trans-signaling, sgp130Fc fusion protein, 
ameliorated atherosclerosis, but had no effect on weight gain and serum lipid levels in 
response to HF-feeding in mice (Rabe, et al., 2008; Schuett, et al., 2012).  
The selective pharmacological blockade of IL-6 trans-signaling would appear to be 
good strategy for targeting the accumulation of aberrant inflammatory signaling and 
atherosclerosis observed in DIO, however as indicated by our studies, the inhibition 
of the insulin-sensitizing effects of classical signaling, is highly unwelcome in the 
context of diabetic disease. Similarly studies selectively targeting activation this 
aspect of IL-6 cytokine family signaling in muscle and brain have been particularly 
promising in terms of insulin and leptin resistance (Watt, et al., 2006; Steinberg, et al., 
2006). Administration of IL-6 in healthy humans was previously shown to have no 
direct effects on glucose utilization (Steenber, et al., 2003), despite promoting 
increased fat oxidation (Van Hall, et al., 2003). Perhaps in conjunction with necessary 
lifestyle changes and other compatible therapies, a pharmacological agent that would 
block trans-signaling and yet drive the selective activation of cytokine signaling 
through the membrane-bound receptor would be of therapeutic benefit.  
GLP-1 is an incretin secreted by the small intestine to stimulate glucose-dependent 
insulin secretion, inhibits glucagon secretion, delays gastric emptying and promote 
satiety (Nauck, et al., 1993; Enc, et al., 2001; Lee, et al., 2002). GLP-1 analogues 
have shown tremendous potential, with a reported single dose glucose-lowering 
potency similar to one or two daily insulin injections (Drucker & Nauck, 2006). 
Synthetic inhibitors of DPP-4, the enzyme responsible for degradation of GLP-1 are 
currently used in T2D therapy (DeFronzo, et al., 2012; Vilsboll, et al., 2010). These 
drugs display high potency in HbA1c regulation and confer the advantage of inducing 
weight loss, which is not accompanied by the risk of hypoglycaemia (White, 2009; 
Neumiller, 2009). Common side effects in combination drug therapy include nausea 
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and gastrointestinal effects (Anon., 2011; Liu, et al., 2014), however most alarmingly 
and despite their recent introduction a link to the development of pancreatitis and 
pancreatic cancer has been reported in patients (Tella & Rendell, 2015; Gokhale, et 
al., 2014; Monami, et al., 2014; Filippatos, et al., 2014; Raz, et al., 2014). Results 
using the NesCreIL-6Rα, in agreement with studies published by the Donath group 
(Ellingsgaard, et al., 2008; Shirazi, et al., 2013), indicate central IL-6 signaling as a 
potential enhancer of the ability of GLP-1 agonists to promote the action of insulin. 
GLP-1 agonists and IL-6 action itself unlike metformin, SURs and glitazones, are not 
associated with increases in body weight and are of no direct consequence to blood 
glucose levels or the incidence of cardiovascular events. Perhaps a pharmacological 
agent targeting specific enhancement of the IL-6 classical signaling over trans-
signaling in the hypothalamus could provide a means to limit some of the unwanted 
risks associated with GLP-1 agonists through decreasing the required dose. Further 
studies in the safety, effectiveness and compatibility of such drug combinations would 
be required.  
 
 
Future Work 
Changes in energy expenditure and the anabolic utilization of fat have been 
previously shown to involve interaction of hindbrain catecholamine neurons 
regulating corticotropin-releasing hormone neurons of the paraventricular 
hypothalamic nucleus that promote changes in the autonomic output of the brain 
(Ritter, et al., 2006; Hudson & Ritter, 2004; Li, et al., 2013). The phenotype observed 
in the NesCreIL-6Rα KD would be consistent with disruption of this axis, in 
agreement with recent studies implicating IL-6 signaling in the response to GLP-1 
analogues. Towards the specific targeting of neuronal populations, a particularly good 
option would be the use of Sf1 CRE (Jackson Laboratories®) mice; that induces 
recombination in GABAergic and Glutamatergic neurons of the glucose-sensing 
ventromedial hypothalamus involved in the regulation of autonomic responses to 
changes in energy homeostasis. This model was successfully used for mapping of the 
ventromedial hypothalamus in the developing mouse brain (Cheung, et al., 2013), 
while previous studies indicated the action of leptin at this site to be required for 
regulation of body weight homeostasis (Dhillon, et al., 2006). Another particularly 
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good candidate when considering the food intake phenotype observed would be the 
Pomc Cre (Jackson Laboratories®) mouse that was previously used to study the 
action of leptin in the brain (Balthasar, et al., 2004). 
Importantly, the use of CRE mice is known to be accompanied with an array of off-
target effects; and the Sf1 CRE mouse itself is known to also induce recombination in 
the cerebral cortex and caudal brainstem, while scattered recombination in the 
adrenal, gonads and pituitary that might interfere with the phenotype (Pihlajoki, et al., 
2013; The Jackson Laboratory, 2011; Harris, et al., 2014). Intracerebroventricular 
administration of adenoviral vectors (Xue, et al., 2008; Xue, et al., 2012) that mediate 
the disruption of the IL-6 receptor would confine disruption of the receptor under the 
regulation of region-specific promoters (e.g. AAV2/8-Cre in the VMH) would 
minimize non-specific effects (Unger, et al., 2007). Designer receptors exclusively 
activated by designer drugs (DREADD) have been shown to be of particular efficacy 
and specificity, and recent studies have demonstrated the specific contribution of 
neuronal populations of the hypothalamus and not the hindbrain to modulate satiety 
and energy expenditure (Zhan, et al., 2014). Additional selectivity, specificity in gene 
targeting has been reported for the novel CRISPR-Cas system (Sander & Joung, 2014; 
Ma, et al., 2014) that could also be utilized in this fashion.   
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Limitations 
My studies began with a particular focus on the role of hypothalamic inflammation in 
diabetic disease. It was not however possible to acquire a transgenic model that would 
limit the recombination events to the hypothalamus specifically using our current 
means. Nes-Cre mediated down-regulation of the IL-6 receptor, albeit successful at 
inducing recombination centrally as well as indicating the importance of IL-6 
signaling in diabetic disease development, lacked specificity.  
Verification of the transgenic was attempted by several different techniques, however 
since our Nes-Cre mediated approach did not ablate but down-regulated the receptor 
system; this proved particularly challenging. In addition, the IL-6Rαflox/flox mouse 
mediates its effects by disrupting the binding site of the receptor, which made 
verification at the protein level impossible. This prompted us to pursue functional 
approaches, such as the IP administration of IL-6 to transgenic animals. Having also 
demonstrated down-regulation of the receptor at mRNA by real time PCR (Figures 
3.4.2) and protein level by immunohistochemistry (Figures 3.8.1-3), as well 
disruption of the in vivo pSTAT3 response to IL-6 in the brain (Figures 3.5.1-3) as 
well as the ex vivo mediobasal hypothalamus (Figure 3.7), the phenotype observed in 
our in vivo studies is at large the consequence of central effects. In attempts to verify 
the down-regulation of the receptor by immunohistochemistry, we found the effects 
induced in NesCre-KDs to be variable, and even though primarily confined to 
neuronal populations some effects in astrocytic populations were observed (Figure 
3.8.4). However, due to the small number of animals we were able to use at this point 
(n=2), it was not possible to provide any meaningful quantification of the effects 
observed by immunohistochemistry.  
Finally, it would be important to address that differences observed in 2 separate 
occasions in KD animals (Figures 4.3, 4.9.1) were not observed in examination using 
the CLAMS/Oxymax® animal monitoring system (Figure 4.7.1). From closer 
examination of the feeding pattern of experimental animals during the procedure; we 
conclude the differences relate to the length of the study and the stress of the 
procedure, as a number of animals appeared to be having issues with food 
accessibility due to the novel environment. Shorter studies or intermittent exposure to 
the experimental set-up would account for these differences.  
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Appendix  
Metabolic Characterization of NesCre+ and NesCreIL-6Rα WT mice 
Figure 3.1: 
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Figure 3.2:  
 
Figure 3.2: 
Week3 – Mean Lean SC: CRE 76.462+/-1.8790%, n=8; WT 81.6713+/-0.9156%, n=8; p=0.0195. 
Mean Fat SC: CRE 19.22+/-0.8047%, n=8; WT 11.28+/-0.8662%, n=8; p<0.0001. Mean Lean HFD: 
CRE 65.7332+/-0.9901%, n=8; WT 70.7318+/-1.151%, n=8; p=0.2052. Mean Fat HFD: CRE 
29.5113+/-1.2201%, n=8; WT 22.5927+/-1.2731%, n=8; p=0.0168. 
Week7 – Mean Lean SC: CRE 71.4125+/-1.1801%, n=8; WT 78.4838+/-1.5456%, n=8; p=0.0032. 
Mean Fat SC: WT 13.7138+/-1.8790%, n=8; CRE 23.975+/-0.8448%, n=8; p=0.0003. Mean Lean 
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HFD: CRE 55.0714+/-0.8668%, n=7; WT 59.419+/-1.3802%; n=7; p=0.1033. Mean Fat HFD: CRE 
41.5571 +/-1.1912%, n=7; WT 35.4736+/-1.4073%, n=7; p=0.0124. 
Figure 3.3: 
 Figure 3.3: 
Total food intake SC: WT=3.5125+/-0.3744g, n=8; CRE = 2.5111+/-0.1172g, n=9; p=0.012. 
Total food intake HFD: WT=3.0857+/-0.1056g, n=7; CRE=1.8+/-0.1363g, n=8; p=0.0003. 
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Figure 3.4: 
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Figure 3.4: 
Week12 – Mean Lean SC: CRE 68.9788+/-0.6403%, n=8; WT 75.9386+/-1.7187%, n=7; p=0.0048. 
Mean Fat SC: CRE 25.7389+/-0.7927%, n=8; WT 16.5014+/-1.8050%, n=8; p=0.0009. Mean Lean 
HFD: CRE 48.7588+/-1.1444%, n=8; WT 53.6969+/-0.9837%, n=8; p=0.0269. Mean Fat HFD: CRE 
45.2050+/-2.3498%, n=8; WT 40.6984+/-1.0848%, n=8; p=0.00185. 
Week15 – Mean Lean SC: CRE 65.0467+/2.3804%, n=8; WT 75.085+/-1.8322%, n=8; p=0.0011. 
Mean Fat SC: CRE 25.6788 +/-0.7322%, n=8; WT 17.3063 +/-1.8549%, n=8; p=0.0013. Mean Lean 
HFD: CRE 48.3038+/-1.4830%, n=8; WT 52.9253+/-1.0368%, n=8; p=0.00501. Mean Fat HFD: 
CRE 46.35 +/-1.5674%, n=8; WT 41.7397 +/-1.1024%, n=8; p=0.1316. 
 
Figure 3.5: 
 Figure 3.5: 
Week20 – Mean Lean SC: CRE 68.2363+/-0.4456%, n=8; WT 75.2485+/-1.8228%, n=8; p=0.0020. 
Mean Fat SC: CRE 25.03+/-0.5203%, n=8; WT 16.5014+/-1.8050%, n=8; p=0.0057. Mean Lean 
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HFD: CRE 49.2463 +/-1.3617%, n=8; WT 53.6969+/-0.9837%, n=8; p=0.5270. Mean Fat HFD: CRE 
45.4963 +/-1.4328%, n=8; WT (42.0338 +/-1.7235%, n=8; p=0.6940. 
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Figure 3.6:
 
Figure 3.6: 
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ITT Week 6: SC Baseline: CRE 6.3889+/-0.3182mM Glucose, n=8; WT 7.0857+/-0.2890mM 
Glucose, n=8; p=0.5117. SC T15: CRE 3.6889+/-0.287926mM Glucose, n=8; WT 5.1571+/-
0.2935mM Glucose, n=8; p= 0.0071. HFD Baseline: CRE 6.411+/-0.415mM Glucose, n=9; WT 
9.75+/-0.571mM Glucose; p<0.0001. HFD T15: CRE 3.967+/-0.274mM, n=9; WT 6.262+/-0.526mM, 
n=8; p=0.0015. 
ITT Week 9: SC Baseline: CRE 7.133+/-0.176mM Glucose, n=9; WT 7.3+/-0.411mM Glucose, n=8; 
p=0.9989. SC T15: CRE 4.922+/-0.355mM Glucose, n=9; WT 5.075+/-0.276mM Glucose, n=8; 
p=0.9996. HFD Baseline: CRE 9.0+/-0.774mM Glucose, n-8; WT 8.475mM Glucose, n=8; p=0.9894. 
HFD T15: CRE 5.012+/-0.571mM Glucose, n=8; WT 6.787+/-0.514mM Glucose, n=8, p=0.2. 
ITT Week 15: SC Baseline: CRE 5.637+/-0.372mM, n=8; WT 6.463+/-0.477mM Glucose; p=0.4699. 
SC T15: CRE 4.425+/-0.446mM Glucose, n=8; WT 5.213+/-0.394mM Glucose, n=8; p=0.5245. HFD 
Baseline: CRE 8.425+/-0.588mM, n=8; WT 8.762+/-0.331, n=8; p=0.9973. HFD T15: CRE 
4.863+/0.31mM, n=8; WT 6.938+/-0.574mM, n=8; p=0.0213. 
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Figure 3.7: 
 
Figure 3.7: 
Week 10 oGTT: SC Baseline: CRE 5.789+/-0.206mM Glucose, n=8; WT 6.488+/-0.355, n=8; 
p=0.9317. SC T15: CRE 11.944+/-0.814mM Glucose, n=8; WT 13.163+/-0.611, n=8; p=0.4773. HFD 
Baseline:  CRE 7.512+/-0.456mM Glucose, n=8; WT 9.225+/-0.41mM Glucose, n=8; p=0.7291. HFD 
T15: CRE 14.488+/-0.905mM Glucose, n=8; WT 16.625+/1.383mM Glucose, n=8; p=0.4742. 
Week 14 oGTT: SC Baseline: CRE 5.678+/-0.268mM Glucose, n=9; WT 8.050+/-0.270, n=8; 
p=0.0188. SC T15: CRE 13.389+/-1.002mM Glucose, n=9; WT 15.613+/-0.708, n=8; p=0.0334. HFD 
Baseline:  CRE 8.113+/-0.509mM Glucose, n=8; WT 8.887+/-0.476mM Glucose, n=8; p=0.9993. 
HFD T15: CRE 17.475+/-1.71mM Glucose, n=8; WT 16.087+/0.960mM Glucose, n=8; p=0.9751. 
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Figure 3.8: 
Figure 3.8: 
Week 19 oGSIS: SC Baseline: CRE 1.13+/-0.257pg/ml Insulin, n=6; WT 0.711+/-0.078pg/ml Insulin, 
n=6; p=0.0855. SC T3: CRE 1.299+/-0.361pg/ml Insulin, n=6; WT 0.819+/-0.112pg/ml Insulin, n=6; 
p=0.0431. SC T15: CRE 1.878+/-0.268pg/ml Insulin, n=6; WT 1.654+/-0.17pg/ml Insulin, n=6; 
p=0.4745. SC T30: CRE 1.202+/-0.138pg/ml Insulin, n=6; WT 0.951+/-0.057pg/ml Insulin, n=6; 
p=0.3951.  
 
Week 19 oGSIS: HFD Baseline: CRE 3.943+/-1.814pg/ml Insulin, n=6, WT 5.244+/-1.86pg/ml 
Insulin, n=6; p=0.2454. HFD T3: CRE 3.49+/-1.109pg/ml Insulin, n=6; WT 3.701+/-1.394pg/ml 
Insulin, n=6; p=0.9619. HFD T15: CRE 7.059+/-2.128pg/ml Insulin, n=6; WT 5.974+/-2.325pg/ml, 
n=6; p=0.3702. HFD T30: CRE 5.31+/-1.986pg/ml Insulin, n=6; WT 4.239+/-1.607pg/ml Insulin, 
n=6; p=0.3798.
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